POKRENIMO TALAS ODRŽIVIH VREDNOSTI! Izveštaj o održivom razvoju Hemofarma za 2018 LET’S CREATE THE WAVE OF SUSTAINABLE VALUES! Sustainable Development Report for 2018 1 Izveštaj o održivom razvoju kompanije Hemofarm A.D. Sustainable Development Report Hemofarm a.d. priprema se sedmu godinu has been prepared for the seventh year in a row zaredom prema svetskim smernicama Global in accordance with the Global Reporting Initiative Reporting Initiative (GRI). Ove godine izveštaj (GRI) guidelines. This year, the Report has been je pripremljen u skladu sa smernicama GRI, u prepared in accordance with the GRI guidelines, in „Core“ verziji, uz predstavljanje 36 opštih i 83 Core version, with the presentation of 36 general specifična indikatora. and 83 specific indicators. Procenu usaglašenosti izveštaja za 2018. Independent auditing company Ernst & Young godinu sa navedenim smernicama, kao i d.o.o. Beograd has verified the compliance of the tačnost navedenih informacija, verifikovala je Report for 2018 with the indicated guidelines, as nezavisna revizorska kuća Ernst & Young d.o.o. well as the accuracy of the provided information. Beograd. Hemofarm A.D. Sustainable Development Report Izveštaj o održivom razvoju kompanija is published annually and the previous one was Hemofarm a.d. objavljuje godišnje i prethodni published for the year 2017. je izdat za 2017. godinu. Any questions, suggestions and dialogue on the Sva pitanja, sugestije i dijalog na temu topic of sustainable development can be addressed održivog razvoja moguće je adresirati putem by e-mail to svakodobro@hemofarm.com. mejla svakodobro@hemofarm.com. 2 Ilustracija/Illustration: Blaženka Jovanović 3 4 POKRENIMO TALAS ODRŽIVIH VREDNOSTI! Izveštaj o održivom razvoju Hemofarma za 2018 LET’S CREATE THE WAVE OF SUSTAINABLE VALUES! Hemofarm Sustainable Development Report for 2018 5 6 Sadržaj Table of contents 102-46 Naše nove vrednosti – svetionik na putu u još Our new values – the lighthouse to light our bolju budućnost ..................................................... 8 way to even better future ................................................8 Uvodna reč generalnog direktora ....................... 10 CEO Editorial .................................................................. 10 Agilnost kao „lozinka“ savremenog doba .......... 14 Agility as modern age “password“ ............................. 14 Dijalog sa zainteresovanim stranama ................ 18 Dialog with stakeholders .............................................. 18 Matrica materijalnosti i materijalne teme ............ 21 Materiality matrix and topics ....................................... 21 Profil kompanije u 2018. ....................................... 24 Company profile in 2018 .............................................. 24 Naše vrednosti i naši ciljevi održivog razvoja ........ 30 Our values and our sustainable development goals........................................................ 30 AGILITY ................................................................. 32 Šta je za nas agilnost ............................................ 33 AGILITY ............................................................................ 32 Agilna nabavka kao stub agilnog poslovanja ..... 34 What agility means to us .............................................. 33 Efikasna proizvodnja i snažne tehnološke Agile purchasing as a pillar of agile operations........ 34 kompetence uslov brzog reagovanja na Efficient production and strong technological dinamično tržište ................................................. 38 competencies – basics for fast responding to dynamic market ................................... 38 ENTREPRENEURSHIP ............................................ 46 Šta je za nas preduzimljivost ................................. 47 ENTREPRENEURSHIP .................................................... 46 Najznačajniji finansijski pokazatelji ...................... 48 What entrepreneurship means to us ......................... 47 Uticaj na okruženje .............................................. 50 The most important financial indicators .................... 48 Odgovorno upravljanje otpadom ......................... 55 Impact on environment ................................................ 50 Bezbednost i zaštita zdravlja na radu ................. 58 Responsible waste management................................ 55 Occupational health and safety................................... 58 INTEGRITY............................................................. 64 Šta je za nas integritet .......................................... 65 INTEGRITY....................................................................... 64 Odgovoran marketing i transparentne What integrity means to us.......................................... 65 i pouzdane komunikacije ..................................... 66 Responsible marketing and transparent and Upravljanje kvalitetom je garancija razvoja ....... 73 reliable communications .............................................. 66 Istraživanje i razvoj – stub unapređenja palete Quality management is the key enabler of proizvoda .............................................................. 76 development .................................................................. 73 Motivisani zaposleni kao formula uspeha .......... 83 Research and development – the pillar of product Usaglašenost poslovanja je ključ sigurnosti i portfolio improvement ................................................. 76 izvesne budućnosti .............................................. 86 Motivated employees are the formula for success .. 83 Compliance is the key to safety and certain future .. 86 ONE STADA............................................................ 90 Šta je za nas jedinstvena STADA .......................... 91 ONE STADA ..................................................................... 90 Briga o zdravlju ljudi kao suština društvene What ONE STADA means to us .................................... 91 odgovornosti ........................................................ 92 Caring for people’s health as the core of social responsibility .............................. 92 Komparativna analiza održivog razvoja i uticaja Hemofarma (2016-2018) ........................ 96 Comparative analysis of Hemofarm’s sustainable O izveštaju i principima izveštavanja .................. 99 development and impact (2016-2018)....................... 96 GRI Indeks .......................................................... 107 About report and reporting principles ....................... 99 GRI Index ...................................................................... 107 Mišljenje nezavisnog revizora ........................... 117 Independent auditor ̓s opinion ................................. 117 7 Naše nove vrednosti – svetionik na putu u još bolju budućnost Our new values – the lighthouse to light our way to even better future Budućnost se ne događa tek tako; poput istorije, The future does not happen just like that; similar ona se stvara. Mi u STADA Grupi zato smo uvereni to history, it is created. At STADA Group, we are da su, u ovom vremenu promena i tehnološkog therefore convinced that, in the era of changes razvoja, oni koji nisu otvoreni za kreativnost, koji and technological development, people who are nisu spremni da se preispituju i menjaju, već not open to creativity, and who are not willing danas zaglavljeni u prošlosti. Održivi razvoj za to examine and change themselves, are already nas je zato imperativ. stuck in the past. Sustainable development is therefore an imperative for us. Jedan od načina da kompanija i čitava Grupa dodatno rastu, pored egzaktnih biznis rezultata, Apart from exact business results, improving repjeste i unapređenje reputacije i imidža. Najbolja utation and image is one of the ways of boosting osnova za to su korporativne ključne vrednosti, the growth of the company and the entire Group. koje kontinuirano treba preispitivati i usaglaThe key corporate values, which should be conšavati sa nivoom razvoja i potreba kompanije. tinuously reviewed and aligned with the level of Istražujući kakva je naša STADA danas i u kom development and needs of the company, are the pravcu ide, u okviru brojnih radionica sa ključnim best grounds for it. Upon looking into the curinternim stajkholderima u čitavoj Grupi, došli rent status and future prospects of our STADA smo do novih korporativnih ključnih vrednosti. at numerous workshops with the key in-house Svi smo složni da one predstavljaju naš budući stakeholders across the Group, we have come stub rasta i razvoja. to the new key corporate values. We all agree that they are the future pillar of our growth and Zato je neophodno da budemo agilni i preduzidevelopment. mljivi i da se sa punim integritetom, svi zajedno, zalažemo za jedinstvenu STADA-u. AGILNI smo Therefore, all of us together should be agile, jer prilagođavanje promenama brže od konpromote entrepreneurship, while fostering ONE kurencije predstavlja najvažniji faktor uspeha. STADA with full integrity. We are AGILE because PREDUZIMLJIVI smo jer su ideje i postupci adapting to changes faster than competition is svakog od nas iskre koje podstiču budući the most important success factor. We promote rast. INTEGRITET i međusobno poštovanje su ENTREPRENEURSHIP, as the ideas and actions of nam na prvom mestu u primeni standarda i each one of us are the sparkles igniting the future razvoju kvaliteta. Kako bismo postupali u najgrowth. INTEGRITY and mutual respect are our boljem interesu kompanije, zalažemo se za top priority in terms of compliance with standkoncept JEDINSTVENE STADE. Dakle, naše nove ards and improvement of quality. In order to act korporativne ključne vrednosti su: AGILITY, in the best interest of the company, we support ENTREPRENEURSHIP, INTEGRITY i ONE STADA. the ONE STADA concept. Thus, our new key corSmatramo da ih danas ne treba prevoditi, budući porate values are: AGILITY, ENTREPRENEURSHIP, da je engleski svojevrsni esperanto novog doba, INTEGRITY and ONE STADA. We think that we a naš cilj da ove vrednosti, za svakog i svuda, should leave them untranslated, as the English 8 pa i u svim zemljama u kojima STADA posluje, language is a sort of Esperanto of the new age, prenesu isto značenje. and our goal is that these values have the same meaning for everyone and everywhere, in each Budućnost je u našim rukama! I zato vas već sad country where STADA operates. pozivam da zajedno pišemo novo poglavlje. The future is in our hands! That’s why I am inviting Na tom putu naše nove korporativne ključne you already now to write a new chapter together. vrednosti su naš svetionik, a Naša misija – Vaše zdravlje! Along that way, our new key corporate values are our lighthouse, and Our mission is Your health! Peter Goldschmidt Peter Goldschmidt CEO STADA Grupe CEO STADA Group 9 Uvodna reč generalnog direktora CEO Editorial 102-14 Brzina, tehnološke inovacije, promene i izazovi Fast pace, technological innovation, change and suštinske su karakteristike vremena u kome challenges are essential features of the time we live živimo. Zato danas značaj održivog razvoja in. The importance of sustainable development is razume mnogo više ljudi nego pre 7 godina, presently understood by much more people than kada smo predstavili Hemofarmov prvi Izveštaj seven years ago when we presented Hemofarm’s o održivom razvoju. Biti pionir u nekoj oblasti first Sustainable Development Report. Being a pionije lako, a mi smo to u ovoj oblasti bili ne samo neer in some area is not easy, and we were that in u Srbiji već i u regionu. Ono što smo, međutim, u this area not only in Serbia, but also region-wide. međuvremenu i sami shvatili, uprkos izuzetnim However, we have understood in the meantime ostvarenim rezultatima, jeste da smo i mi, kao that, in spite of the remarkable results achieved, we uostalom i čitavo čovečanstvo – zapravo tek na are, as a matter of fact, only at the beginning of an početku jednog civilizacijski važnog puta. important civilization journey, together with the rest of the mankind. Na tom putu, svet je definisao 17 ciljeva globalnog održivog razvoja, a kao jednu od najvećih On this journey, the world has defined 17 global pretnji prepoznao klimatske promene. Održivi Sustainable Development Goals, and identified razvoj, međutim, predstavlja daleko veći zadatak climate change as one of the biggest threats. od zaštite životne sredine. On znači bitku za Sustainable development, however, represents a far ekonomski napredak u kvalitetnijem životnom more comprehensive task than environmental prookruženju i humanijem društvu. Kao takav, tection. It entails a battle for economic progress in održivi razvoj je važan svima, a zavisi od svake a better quality environment and a more humane kompanije i svakog pojedinca. Odgovornost je, society. As such, sustainable development is impordakle, na svakom od nas. tant to everyone, and it depends on every company and each individual. Accordingly, the responsibility I kada već o tome razgovaramo, kao čovek lies with each one of us. koji ima privilegiju ali i odgovornost da vodi Hemofarm, sada sam u prilici da sa Vama Speaking of which, as a man who has the privilege, podelim i zadovoljstvo. Ono je zasnovano na nizu but also the responsibility to lead Hemofarm, I am podataka koji govore da je i u godini za nama now able to share with you the satisfaction, too. It naša kompanija, kao važan član STADA Grupe, is substantiated by a series of data indicating that na delu pokazala kako se bori za ciljeve održivog our company, as an important member of STADA razvoja. To činim s ponosom, ali i nadom da Group, has shown also in the year behind us how it ćete čitajući Izveštaj koji je pred Vama biti ohraadvocates for the goals of sustainable development breni da i sami, kao i u partnerstvu sa nama, u in practice. I’m doing it with pride, but also the hope narednom periodu učinite još više. I da ćete to, that by reading the Report which is before you, you baš kao i mi, otvoreno i u želji da inspirišete, will be encouraged to do even more in the future podeliti sa drugima. yourself, as well as in partnership with us, and that you, just like us, will openly and inspirationally share Hemofarm je u 2018. godini ostvario značajno it with others. povećanje ekonomske vrednosti, pre svega zahvaljujući rastu direktno generisane vrednoIn 2018, Hemofarm achieved a significant increase sti, a u odnosu na prethodnu godinu procenat in economic value, primarily due to the growth of rasta od prodaje povećan je za 14,36%. directly generated value, and recorded a 14.36% sales growth compared to the previous year. 10 Nastavili smo obaranje sopstvenih rekorda. We have continued breaking our own records. We Proizveli smo više od 5,5 milijardi proizvodproduced more than 5.5 billion technical producnih jedinica, odnosno ostvarili rast od 5%. tion units, and recorded a 5% growth. The output Proizvodnja je uvećana i po obimu za čitavih was also increased in terms of volume by as much 1%, što nas dovodi do rekordnih 245 miliona as 1%, resulting in the record score of 245 million pakovanja proizvoda u 2018. Postignuti rezulpacks of products in 2018. The achieved results tati dobijaju još veći značaj kada se vidi da smo gain even more in significance considering that we značajno smanjili utrošak električne energije i significantly reduced the consumption of electricity prirodnog gasa po jedinici gotovog proizvoda. and natural gas per finished product unit. We also Takođe, smanjili smo potrošnju vode i ostvareduced the consumption of water and achieved rili značajne finansijske uštede, istovremeno significant savings, while simultaneously raising the podižući nivo zaštite životne sredine. level of environmental protection. U protekloj godini za nas je poseban značaj imala The transformation undertaken by STADA last year, transformacija u koju je ušla STADA sa dolaskom after the new management headed by Mr Peter novog menadžmenta, predvođenog g. Piterom Goldschmidt took the helm, creating a state-of-theGoldšmitom, postajući moderna generička art group of generic companies focused on market grupacija, fokusirana na tržišni rast i razvoj growth and pharmaceutical portfolio development, farmaceutskog portfolija. Ujedno, Hemofarm is of a particular importance for Hemofarm. At the je delom pokazao zašto je jedan od najznačajsame time, Hemofarm has demonstrated by its nijih proizvodnih i ekspertskih stubova čitave actions why it is one of the most important producSTADA Grupe. To smo potvrdili i činjenicom da tion and expertise pillars of the entire STADA Group. se iz Srbije rukovodi regionalnom proizvodnjom, This has also been acknowledged by the fact that razvojem i kontrolom kvaliteta. regional production, development and quality control is managed from Serbia! 11 Veoma sam ponosan što Hemofarm sa razlogom I am very proud that Hemofarm can reasonably može da kaže da ne samo prati najsavremenije boast of not only keeping up with the cutting-edge tehnološke inovacije i procese već da ih kreira i technological innovations and processes, but also živi. Mi smo, tako, proaktivan deo četvrte inducreating and living them. We are, thus, a proactive strijske revolucije, sa razvijenim mehanizmima part of the fourth industrial revolution, with develi implementacijom informacije kao vodeće oped mechanisms and the implementation of informonete, posebno u digitalnom okruženju. mation as the leading asset, especially in the digital Agilnost i uređenost naše proizvodnje i centraenvironment. The agility and excellent organization lizovanog pogona za pakovanje takve su da ih of our production and centralized packaging plant je moguće uporediti sa funkcionisanjem najsloare such that they can be compared with the operženijih i najuređenijih aerodroma, što su tokom ation of the most complex and best-organized air2018. potvrdile čak 22 najeminentnije domaće i ports, which was confirmed by as many as 22 most međunarodne eksterne inspekcije. Zbog toga ne eminent national and international external audits iznenađuje da smo aplikaciju instaliranu u cilju in the course of 2018. It is therefore not surprising praćenja skladištenja i otpremanja naših proithat the application installed for monitoring of prodzvoda nazvali upravo „red letenja“. uct storage and shipment operations was named the ﬂight schedule . Pa ipak, za nas su najvažniji resurs – ljudi. Naša porodica od 3.100 članova u prošloj godini se Nevertheless, our most important resource is proširila. Broj zaposlenih povećao se za 7%, a people. Our family comprising 3,100 members žene su zadržale svoju dominaciju i sa 53% i dalje expanded last year. The headcount increased by čine većinu. Uz to, Hemofarm je u 2018. postao 7%, while women retained their dominance, still još bezbednije mesto za rad, i povrede na radu holding the majority share of 53%. In addition, su smanjene za čak 26,3%. Iako su svih 14 bile Hemofarm became an even safer place of work in „lake povrede“, odlučili smo da u 2019. intenzivi2018, as occupational injuries were reduced by as ramo edukaciju usmerenu ka povećanju svesti o much as 26.3%. Although each of 14 injuries were značaju odgovornog bezbednosnog ponašanja minor ones, we decided to intensify education u procesu rada i prevenciji povreda. aimed at raising awareness about the importance of responsible safety behaviour in the process of Mi znamo moć znanja i zato se neprework and injury prevention in 2019. stano usavršavamo, učeći od najboljih i podstičući inovativnost i inicijative naših zapoWe are aware of the power of knowledge and that slenih. Zahvaljujući stalnom ulaganju u njihovo is why we constantly develop professionally, by usavršavanje, mnogi procesi urađeni su brže i learning from the best and encouraging the innokvalitetnije uz ostvarenje značajnih ušteda, što vativeness and initiatives of our employees. Owing nas je motivisalo da sve svoje ekspertize dodatno to continuous investment in their upgrading, many usmerimo, kroz transfer znanja, ka drugima, processes were made faster and better, with considnaročito ka mladima. Svoj doprinos dali smo erable savings, which motivated us to further focus dualnom obrazovanju, nastavili uspešnu reaall our expertise by transferring knowledge to others, lizaciju Mentorskog programa i programa especially to young people. We have contributed to stipendiranja. To dodatno doprinosi kredibilidual education by continuing the successful impletetu naše Hemofarm fondacije, koja je nizom mentation of the Mentoring Programme and the uspešnih akcija i u 2018. godini dokazala zašto je Scholarship Programme. This additionally contribu javnosti prepoznata kao lider u oblasti zdravlja utes to the credibility of our Hemofarm Foundation, i društvene odgovornosti. which demonstrated through a number of successful actions carried out also in 2018, why it has been U duhu jedinstvene STADA-e i nove korporativne recognized in the public as a leader in the field of kulture, a u skladu sa savremenim trendovima, health and social responsibility. unapredili smo i kompanijski i vizuelni identitet medijskih kampanja i značajno povećali In the spirit of ONE STADA and the new corporate culture, and in line with the contemporary trends, 12 prisustvo u digitalnim medijima i na društvewe have also enhanced both corporate and media nim mrežama. Tako smo ojačali ključne kanale campaigns visual identity, and significantly increased komunikacije sa našim ciljnim grupama. I sve to, presence in digital media and on social networks. na liniji našeg novog globalnog korporativnog We have thus strengthened the key communication slogana: Naša misija – Vaše zdravlje, koji u fokus channels with our target groups, everything in tune stavlja prevenciju i razvoj zdravih životnih stilova. with our new global corporate slogan: Our mission Your health, which focuses on prevention and develUobičajeno je da matične korporacije izveštavaju opment of healthy lifestyles. o održivom razvoju, a da lokalne kompanije preuzimaju i lokalizuju te izveštaje. Kod nas je sasvim Parent corporations generally report on sustainaobrnuto – Hemofarm će u 2019. započeti proces ble development, and such reports are cascaded transfera znanja i iskustava iz domena održivog to local companies. In our case, it is the other way razvoja ka STADA Grupi, kako bi joj pomogao around Hemofarm will start the process of transu izradi prvog Izveštaja o održivom razvoju. ferring know-how and experience in the field of Upravo to će biti sjajna prilika da Hemofarm sustainable development to STADA Group in 2019, postavi vrlo konkretne i merljive KPI-jeve za in order to help it prepare its first sustainable develsve oblasti poslovanja kako pred svoj tim, tako i opment report. This will be a great opportunity for pred globalni STADA tim, u skladu sa globalnim Hemofarm to set up very specific and measurable ciljevima održivog razvoja UN. Tako ćemo dati KPIs for all areas of business, both before its own značajan doprinos dodatnom uvećanju ekonomteam and the global STADA team, in line with the ske vrednosti i reputacije STADA Grupe. global UN Sustainable Development Goals. In such a way, we will make a significant contribution to furUvereni smo da sve navedeno najbolje ilustruje ther increase in the economic value and reputation naše novopostavljene ključne korporativne of STADA Group. vrednosti – AGILITY, ENTREPRENEURSHIP, INTEGRITY i ONE STADA. Mi ih i ne prevodimo We are confident that everything mentioned best upravo zato što su agilnost, preduzetništvo, illustrates our newly-established key corporate integritet i zajedništvo vrednosti svuda iste za values AGILITY, ENTREPRENEURSHIP, INTEGRITY sve nas u celoj STADA-i, a koje ljudi širom sveta – and ONE STADA. We do not translate them from dobro razumeju. Kao naša vodilja, ove vrednosti the English language because agility, entrepreneurdirektno su povezane i sa našim ključnim ciljeship, integrity and unity are the values which are vima održivog razvoja. U to ćete imati priliku da the same for all of us across STADA, and which are se uverite i čitajući stranice koje su pred Vama. perfectly well understood by people all around the world. As our guiding light, these values are directly Nastojimo da naše delovanje, pa i ovaj Izveštaj, related to our key Sustainable Development Goals. i Vama budu motivacija za nove uzlete. Za nas You will have the opportunity to see it yourselves je to, bez ikakve sumnje – sigurni put da pokrealso by reading the pages in front of you. nemo talas održivih vrednosti. We have been striving to motivate you through our actions, and even through this Report, for new breakthroughs. It is for us, without any doubt, a straightforward way to run a wave of sustainable values. dr Ronald Seeliger Dr Ronald Seeliger generalni direktor Hemofarma i Chef Executive Officer of Hemofarm and potpredsednik STADA Grupe Vice President of STADA Group 13 Agilnost kao „lozinka“ savremenog doba Agility as modern age “password“ Odgovoriti na izazov, istrajati na ispravnom To respond to challenges, persevere on the right putu uz spremnost na preispitivanje i promenu, path while being open to reassessment and obezbediti jednakost mogućnosti, brinuti changes, ensure equal opportunities, care for o drugima i prirodi, usuditi se na iskorak iz others and nature, step out of the comfort zone poznatog ka boljem, imati hrabrosti da osloboand into the enhancement zone, have a courage diš sopstvenu kreativnost i uradiš nešto što je to free your own creativity and do something difdrugačije i bolje, dati najbolje od sebe za opšte ferent and better, give your best for the common dobro, učiniti to sa puno strasti i istinskim uvegood, do it with a lot of passion and true convicrenjem. Ovo su neki od odgovora koje smo tion were some of the answers my colleagues and moje kolege i ja davali, otkrivajući na jednom I gave, revealing in one test, first to ourselves, and testu najpre sebi, a onda i drugima, šta za nas then also to others, what sustainable developpredstavlja održivi razvoj. Ispostavilo se da ment actually means to us. It turned out that our je u našim različitim odgovorima bilo mnogo diﬀerent responses were pretty common. First zajedničkog. Pre svega, mi delimo osećanje da of all, we share the feeling that we contribute to doprinosimo izgradnji boljeg sveta. To osećanje building a better world. This feeling is supported podržano je svim onim što možemo i što činimo by everything that we can and that we do as a – kao deo Hemofarma i STADA Grupe. I to part of Hemofarm and STADA Group. And it makes nas čini ponosnim i spremnim da inspirišemo us proud and prepared to inspire others. That is druge. U tome je smisao i ovog, našeg sedmog the point of our seventh Sustainable Development Izveštaja o održivom razvoju. Report. Ako pročitate ovaj izveštaj, biće vam jasno zašto If you read this report, you will understand why a je jedna velika uspešna korporacija i farmaceutlarge, successful corporation and pharmaceutical ski lider, kakav je Hemofarm, izuzetno ponosna leader such as Hemofarm is exceptionally proud što je u godini za nama uspela da proizvodnju that, in the year behind us, it managed to increase podigne za 1%, a da poslovanje učini još odrproduction by 1% and make the business even živijim. Shvatićete da je to još jedno obaranje more sustainable. You will realize that this is yet rekorda, postignuto na nivou i u uslovima u another record, achieved at the level and under kojima su mnogi mislili da je biti još bolji gotovo the conditions in which many people thought that nemoguće. Razumećete da je taj procenat it was almost impossible to be even better. You will onaj jedan važan korak koji pomera granice understand that this one percent is the one impori dokazuje da je pomeranje granica baš uvek tant step that moves the boundaries and proves moguće. I da iza njega stoje neki drugi veći i još that moving boundaries is always possible, and važniji procenti. Oni govore o značajnim povećathat some other, higher and even more important njima proizvodnje lekova i OTC/CHC proizvoda, percentages are behind it. They reveal significant o broju inovacija, o novim znanjima i tehnoloincreases in production of medicines and OTC/ gijama, ubrzanju i efikasnosti proizvodnje, o CHC products, the number of innovations, new uštedama i impresivnom smanjenju otpada. A knowledge and technologies, speeding up and 14 ono što je važnije od svega – svi ovi rezultati su efficiency of production, savings and impressive delo ljudi, naših ljudi. I oni su dokaz nikad poziwaste reduction. Nevertheless, the most importivnijeg uticaja Hemofarma na okruženje! tant thing is that all these results are the work of people, our people. They bear witness to more Iza svih naših uspeha stoji 3.100 porodica koje positive impact of Hemofarm on the environment čine Hemofarm Grupu i jedan tim koji čini than ever before! jedinstvenu STADA Grupu. Taj tim pomaže da se mnogi ljudi ne razbole i da se hiljade njih Our entire success is based on 3,100 families that izleči. Da neki parkovi budu lepši i zeleniji jer make Hemofarm Group and one team that makes smo nastavili sađenje, ali i korišćenje ambalaža the ONE STADA Group. This team helps many od recikliranih materijala, da su neka deca people not to get sick, as well as in curing thousrećnija, jer smo im pomogli da prevaziđu sands of them. It helps making some parks more određene prepreke, da najbolji imaju stipendije beautiful and greener as we continued not only koje će im omogućiti da budu još bolji, da su planting trees but also using recycled materials, mnogi mladi uz znanje kroz dualno obrazovanje making some children happier as we help them stekli i veštine. Da je i zahvaljujući apelima svih to overcome certain obstacles by granting scholnas, neko dobio najvažniji poziv i bubreg, neko arships to the best ones, which will enable them to srce, a svi oni – život. I da od toga nema većeg be even better. Many young people also acquired bogatstva. skills along with the knowledge gained through dual education. And, owing to the appeals of all of Zato su rezultati na koje se osvrćemo u ovom us, some people got the most important call and a izveštaju zapravo manifest naše posvećenosti kidney, or a heart, and all of them got life. There is održivom razvoju i dokaz da iza svake naše reči nothing more precious than that. 15 stoje konkretna dela. I da je na kraju svih njih That’s why the results presented in this Report are jedan zajednički cilj – kvalitetniji i zdraviji život! actually a manifesto of our commitment to sustainable development and evidence that every single Razvijajući inovativnost i pobednički duh kod word is substantiated by concrete actions, all of mladih, izgradili smo farmaceutsku „čistu which have the same ultimate goal – a better qualsobu“ na Tehnološko-metalurškom fakultetu ity and healthier life! u Beogradu i inspirisali mnoge studente da budu još bolji na svojim studijama i biraju najAimed at developing innovativeness and winning savremenije predmete u koje je i Hemofarm mentality among young people, we have built utkao svoja bogata istraživačka i proizvodna a pharmaceutical clean room at the Faculty iskustva. Podstičući inovativnost najmlađih of Technology and Metallurgy in Belgrade and članova našeg tima, zaslužno smo ušli u finale inspired many students to be even better at za Evropu na jednom od najeminentniji globaltheir studies and choose the most contemporary nih takmičenja mladih inovatora u održivom courses to which Hemofarm has contributed its razvoju – „Ideje za akciju“, koje organizuju preextensive research and production related expestižna poslovna škola Vorton, sa Univerziteta rience. By encouraging the innovativeness of the Pensilvanije, i Svetska banka. youngest members of our team, we deservedly reached the European finals at Ideas for Action , Kada kažemo da brinemo o zaštiti životne one of the most eminent global competitions of sredine, mi to činimo suštinski, brinući o okruyoung innovators in sustainable development, ženju u svakom aspektu poslovanja. Zato ne organized by the prestigious Wharton School of iznenađuje da smo tokom prošle godine skoro Business at the University of Pennsylvania, and the 200 miliona pakovanja za naše proizvode obezWorld Bank. bedili upotrebom recikliranog kartona. Rast proizvodnje prati i rast upotrebe recikliranog When we say that we care about environmental kartona, koji se koristi za više od 80% svih protection, we do it for real, taking care of the envipakovanja u Hemofarmu. Na taj način naša ronment in every aspect of business. It is therefore kompanija je sačuvala preko 17.000 stabala, not surprising that almost 200 million packages uz uštedu električne energije koju bi inače were provided for our products by using recycled potrošili za 44 dana i vode za oko 37 dana rada cardboard during the past year. The production Hemofarma. growth is accompanied by the growth in consumption of recycled cardboard, which is used for more Kad mi kažemo da se svim srcem borimo za than 80% of all packs in Hemofarm. In this way, zdravlje, znanje, kulturu, aktivan život i zdravo our company has preserved over 17,000 trees, okruženje, to znači da smo kroz delovanje thus saving the electricity that would otherwise Hemofarm fondacije u 2018. godini realizovali be spent in 44 days and water in about 37 days of čak 86 aktivnosti i da smo uložili značajan rad, Hemofarm operation. materijalna sredstva ali i, iznad svega, ljubav prema ljudima. U tome nismo bili sami. Ostvarili When we say that we are wholeheartedly advocatsmo 173 partnerstva sa stejkholderima – instiing health, knowledge, culture, active lifestyles and tucijama sistema, međunarodnom zajednicom, healthy environment, this means that, through the civilnim sektorom, medijima i uglednim pojeoperation of Hemofarm Foundation in 2018, we dincima i na delu dokazali koliko su partnerstva carried out as many as 86 activities and invested sigi važna, i snažna. Naše kolege su posvetile 786 nificant eﬀort, funds, and above all, love for people. svojih volonterskih sati razvoju mladih i budućih We were not alone in doing it. We established 173 stručnjaka kroz Mentorski program. partnerships with stakeholders – system institutions, international community, civil sector, media Kampanjom „Ne dozvoli da pukne” osvojili smo and prominent individuals, and demonstrated in osam novih nagrada, ali pre svega podigli svest practice the significance and power of partnerships. o značaju preventivnih pregleda i kontrole Our colleagues devoted 786 volunteer hours to the krvnog pritiska. Podržali smo zdravstvene development of young, future experts through the institucije programima donacija i dali doprinos Mentoring Programme. 16 usavršavanju farmaceuta i lekara kroz kontinuiWe won eight new awards for Don’t Let It Burst ranu medicinsku edukaciju. Pokazali smo koliko campaign, but most importantly, we raised the cenimo, umemo da prepoznamo i nagradimo awareness about the importance of preventive izuzetnost i time što smo povodom 25 godina medical examinations and blood pressure screenuspešnog rada Hemofarm fondacije ustanoings. We supported healthcare institutions through vili „Nagradu za izuzetnost“. Visoke standarde donation programmes and contributed to profespostavili smo i izborom Vigora Majića, direktora sional development of pharmacists and physicians Naučno-istraživačke stanice Petnica, za prvog through continuous medical education. We showed laureata. how much we cherish, and are able to identify and reward excellence by establishing the Excellence Bićemo veoma srećni ako ovi rezultati o kojima Award on the occasion of marking 25 years of sucgovori i naš Izveštaj o održivom razvoju i za cessful work of Hemofarm Foundation. We also set vas budu inspiracija. Lično sam, inspirisana high standards by selecting Vigor Majić, Director of Valentinom Tereškovom, prvom ženom astroPetnica Science Centre, to be the first laureate. nautom, i sama zaključila da naša ograničenja najčešće ne proizilaze iz ograničenih mogućWe will be very happy if the results presented in our nosti, već iz limitirane vizije. Zato je važno Sustainable Development Report become inspiraohrabriti i sebe i druge, da istražujemo načine tion to you, too. Inspired by Valentina Tereshkova, kako postići boljitak. Na ličnom, poslovnom the first woman astronaut, I myself concluded that i društvenom planu. Lokalno i planetarno. U our constraints do not usually come from limited sadašnjosti koja će obezbediti budućnost. Jer possibilities, but rather from a limited vision. It is baš to je održivi razvoj. Kada se ka tim višim therefore important to encourage both ourselves ciljevima krećemo brže, veštije, lakše – to je and others to explore ways to achieve better results, agilnost. Zato smo mi saglasni da je agilnost in personal, professional and social life, locally and „lozinka“ savremenog doba, i zato je vidimo i globally, in the present that will provide a better kao sopstvenu vrednost. Ona nas, uz preduzetfuture. Because, it is what sustainable development ništvo, integritet i zajedništvo koje iskazujemo is all about. When we pursue those higher goals i kao jedinstvena STADA, uverava da stvaramo faster, more skilfully, easier – that is agility. That’s sigurnije danas i bolje sutra. why we are on the same page when thinking about agility as a modern age password , and consider it our own value. Together with entrepreneurship, integrity and unity that we demonstrate as ONE STADA, it makes us certain that we are creating a safer today and a better tomorrow. Sanda Savić Sanda Savić direktorka korporativnih poslova i Corporate Aﬀairs and komunikacija Hemofarma Communications Director Dijalog sa zainteresovanim stranama Dialog with stakeholders 102-40 102-42 102-43 102-44 Pravi napredak počiva na stalnom Real progress is based on constant reassessment preispitivanju da li je sve što kompanija whether all company activities meet the interests radi u skladu sa interesima i potrebama and needs of the community in which it operates. društva u kome obavlja svoju delatnost. Zato For that reason, Hemofarm pays a great deal Hemofarm veliku pažnju poklanja mišljenju of attention to the attitude of the stakeholders, zainteresovanih strana, jer se tako razvijaju because, in such a way, both the company and u pravom smeru i kompanija i njen portfolio. its portfolio are developed in the right direction. Kroz taj proces dijaloga, kontinuiranog Through the process of dialogue, continuous preispitivanja i posledičnih strategija za reassessment and resulting improvement stratunapređenja, podiže se nivo pozitivnog egies, the level of a positive impact on the enviuticaja na okruženje, a u slučaju Hemofarma, ronment is raised, and in case of Hemofarm, the portfolio farmaceutskih proizvoda biva u pharmaceutical product portfolio is harmonized najvećoj meri usklađen sa realnim potrebama to the maximum extent with the actual needs domaćeg zdravstvenog sistema i pacijenata. of the national healthcare system and patients. Mišljenje ključnih stejkholdera za Hemofarm Hemofarm cherishes the opinion of the key stakeje važno i kod unapređenja internih procedura, holders also in terms of improvement of in-house čime se razvijaju korporativna efikasnost procedures, thus upgrading corporate efficiency i transparentnost, ali i sama korporativna and transparency, as well as the corporate culture kultura. Ključni stejkholderi za Hemofarm itself. The key Hemofarm’s stakeholders include nisu samo oni koji su trenutno povezani not only those who are currently linked to corsa poslovanjem kompanije već i sve one porate operations, but also all the stakeholders zainteresovane strane koje u budućnosti mogu who might have an impact on the operations and imati uticaj na poslovanje i samu farmaceutsku pharmaceutical sector itself, or vice versa – those branšu, kao i povratno – važan je Hemofarmov on whose life or work Hemofarm might have an uticaj na njihov život ili rad. Zato top impact in the future as well. For that reason, commenadžment kompanije svake godine evaluira pany’s top management evaluates the lists of key liste ključnih stejkholdera, nastojeći da ih stakeholders every year, trying to properly rank adekvatno rangira i kontinuirano dopunjuje. and update them on an ongoing basis. Thus, Tako su 2017. godine studenti farmacije bili in 2017, the students of pharmacy were one of jedna od najvažnijih grupa stejkholdera koja je the most important groups of stakeholders, who iz vizure budućih stručnjaka dala svoje osvrte referred to Hemofarm’s operations from the point na poslovanje Hemofarma. Ove godine to su: of view of future experts. This year, they include: • top menadžment Hemofarma (13 • Hemofarm top management (13 anketiranih), respondents), • zaposleni Hemofarma (150 anketiranih), • Hemofarm employees (150 respondents), • poslovni partneri i dobavljači – domaći • business partners and suppliers – local and i strani (20 anketiranih; Represent international (20 respondents; Represent Communications, Kreativa Unlimited, Communications, Kreativa Unlimited, BioMimicry Norway, EY, Coca Cola, NIS i dr.), BioMimicry Norway, EY, Coca Cola, NIS, etc.), • farmaceuti i doktori (50 anketiranih; • pharmacists and doctors (50 respondents; različitih medicinskih specijalnosti), diﬀerent medical specialties), • zvanične državne institucije i mediji (18 • official state institutions and the media (18 anketiranih; Privredna komora Srbije, respondents; Chamber of Commerce and Adria Media Group i dr.), Industry of Serbia, Adria Media Group, etc.), • predstavnici nevladinog i akademskog • representatives of non-government and sektora (80 anketiranih; Mikser festival, academic organisations (80 respondents; NVO Moj lepi grad, Fakultet savremenih Mikser festival, NVO Moj lepi grad, Faculty umetnosti, studenti različitih specijalof Contemporary Arts, students of various nosti, itd.). fields of studies, etc.). Hemofarm je za dijalog sa stejkholderima u As a tool for dialogue with stakeholders in 2018, 2018. odabrao anketu, u verzijama na srpskom Hemofarm opted for a survey, both in Serbian i engleskom jeziku, a ukupno je anketiran 331 and English language versions, with a total of 331 ispitanik. respondents. TOP MENADŽMENT ZAPOSLENI POSLOVNI PARTNERI I DOBAVLJAČI TOP MANAGEMENT EMPLOYEES BUSINESS PARTNERS AND SUPPLIERS FARMACEUTI I ZVANIČNE DRŽAVNE PREDSTAVNICI DOKTORI INSTITUCIJE I MEDIJI NEVLADINOG I AKADEMSKOG SEKTORA PHARMACIESTS AND OFFICIAL STATE DOCTORS INSTITUTIONS AND REPRESENTATIVES OF MEDIA NON-GOVERNMENT AND ACADEMIC SECTOR 19 Stejkholderima je prezentovana 21 tema od In accordance with the new corporate developznačaja za poslovanje Hemofarma u skladu sa ment strategy, twenty-one topics of importance for novom korporativnom strategijom razvoja, a Hemofarm’s operations, confirmed by top managekoje su potvrdili članovi top menadžmenta. To ment members, were presented to stakeholders, je za jednu temu više nego u prethodnom krugu exceeding the number of topics in the previous diadijaloga. Teme su usaglašene i sa procenom logue cycle by one topic. The topics have also been uticaja aktuelnog i budućeg razvoja poslovanja harmonized with the assessment of impact of the na okruženje. Takođe, teme su usaglašene i sa current and future operation development on the novim korporativnim ključnim vrednostima. environment. The topics have also been harmonized with the new key corporate values. VREDNOST POKAZATELJI DRUŠTVENE ODGOVORNOSTI / TEMA OD ZNAČAJA ZA SDG SOCIAL RESPONSIBILITY INDICATORS / MATERIALITY TOPIC VALUE 1. Razvoj PORTFOLIJA i optimizacija PALETE PROIZVODA 1. PORTFOLIO development and PRODUCT RANGE optimization 2. Ostvarivanje KVALITETA i BEZBEDNOSTI PROIZVODA prema farmaceutskim standardima 2. Achieving PRODUCT QUALITY and SAFETY in line with pharmaceutical standards CILJ 3 / INTEGRITY 3. Razvoj i registracija NOVIH PROIZVODA koji su savremeni, komforni i pouzdani GOAL 3 3. Development and registration of NEW PRODUCTS that are contemporary, comfortable and reliable 4. Odgovoran MARKETING i transparentne KOMUNIKACIJE uz maksimalnu dostupnost informacija 4. Responsible MARKETING and transparent COMMUNICATIONS with maximum availability of information 5. Uvažavanje potreba i ZADOVOLJSTVA KORISNIKA PROIZVODA uz proaktivan odnos prema reklamacijama 5. Respecting the needs and SATISFACTION OF PRODUCT USERS with proactive attitude to complaints CILJ 4 i 5 / 6. Motivacija i edukacija ZAPOSLENIH i kontinuirani razvoj KORPORATIVNE KULTURE GOAL 4 & 5 6. Motivation and education of EMPLOYEES and continuing development of CORPORATE CULTURE 7. Ostvarivanje i unapređenje BEZBEDNOSTI i ZDRAVLJA NA RADU 7. Achieving and improving OCCUPATIONAL SAFETY and HEALTH ENTREPRENE8. Poslovna i društveno-socijalna USAGLAŠENOST i ANTIKORUPTIVNO delovanje 8. Business and social COMPLIANCE and ANTI-CORRUPTION activity CILJ 8/ URSHIP GOAL 8 9. Poštovanje LJUDSKIH PRAVA i sprečavanje prinudnog rada i bilo kakvih zloupotreba 9. Respecting HUMAN RIGHTS and preventing forced labour and any abuse 10. Razvoj ORGANIZACIONE EFIKASNOSTI i rast POSLOVANJA uz unapređenje tržišnih pozicija 10. Development of ORGANIZATIONAL EFFICIENCY & BUSINESS OPERATIONS growth with the improvement of market positions 11. Pouzdane SIROVINE od potvrđenih dobavljača 11. Reliable RAW MATERIALS from certiﬁed suppliers AGILITY 12. Bezbedno SKLADIŠTENJE i eﬁkasan TRANSPORT CILJ 9 / 12. Safe STORAGE and eﬃcient TRANSPORT GOAL 9 13. Usaglašenost i kontinuirano unapređenje TEHNOLOŠKIH KOMPETENCI 13. Compliance and continuous improvement of TECHNOLOGICAL COMPETENCIES 14. Brzo reagovanje na TRŽIŠNE PROMENE i IZAZOVE 14. Agile response to MARKET CHANGES & CHALLENGES 15. Uvažavanje mišljenja i DIJALOG SA KLJUČNIM ZAINTERESOVANIM STRANAMA ONE STADA 15. Appreciating the opinion and DIALOGUE WITH KEY STAKEHOLDERS CILJ 11 i 17 16. Unapređenje svesti i odgovornosti DOBAVLJAČA o društveno značajnim aspektima poslovanja / GOAL 11 16. Raising awareness and responsibility of SUPPLIERS in view of socially important aspects of business operations & 17 17. KORPORATIVNA DRUŠTVENA ODGOVORNOST i podrška lokalnim zajednicama 17. CORPORATE SOCIAL RESPONSIBILITY and support to local communities 18. Unapređenje ENERGETSKE EFIKASNOSTI i povećanje korišćenja obnovljivih izvoda energije ENTREPRENE18. Improvement of ENERGY EFFICIENCY and increase in the consumption of renewable energy sources 19. Odgovorno upravljanje potrošnjom VODE i smanjivanje generisanja OTPADA URSHIP + CILJ 12 / 19. Responsible WATER consumption management and reduced WASTE generation AGILITY GOAL 12 20. Odgovorno upravljanje EMISIJAMA GASOVA i smanjenje uticaja na životnu sredinu 20. Responsible GAS EMISSION management and reduced environmental impact 21. Prevencija i smanjivanje RIZIKA i upravljanje KRIZNIM SITUACIJAMA 21. RISK prevention and mitigation and CRISIS SITUATIONS management 20 Matrica materijalnosti i materijalne teme Materiality matrix and topics 102-31 102-47 Hemofarmovi ključni stejkholderi su u okviru Within the dialogue with the stakeholders for dijaloga sa zainteresovanim stranama za 2018, Hemofarm’s key stakeholders rated the 2018. godinu rangirali teme koje, po njihovom topics that in their opinion reﬂect the major commišljenju, odražavaju najveći dvosmerni uticaj pany’s two-way impact on the society. Accordingly, kompanije na društvo. U skladu sa tim, od out of a total of 21 topics, 13 were selected, thus ukupno 21 teme, odabrano je njih 13, koje su becoming Hemofarm’s materiality topics, which samim tim postale Hemofarmove materijalne will be covered this Report. teme, kojima će se kompanija baviti u ovom izveštaju. 5 2 4,75 1 6 17 11 7 3 4,5 19 4 18 13 5 9 8 10 4,25 16 12 4 20 21 14 3,75 3,5 3,25 3,5 3,75 4 4,25 4,5 4,75 5 21 Hemofarmove materijalne teme za 2018. su: 1. Razvoj PORTFOLIJA i optimizacija PALETE PROIZVODA. 2. Ostvarivanje KVALITETA i BEZBEDNOSTI PROIZVODA prema farmaceutskim standardima. 3. Razvoj i registracija NOVIH PROIZVODA koji su savremeni, komforni i pouzdani. 4. Odgovoran MARKETING i transparentne KOMUNIKACIJE uz maksimalnu dostupnost informacija. 5. Uvažavanje potreba i ZADOVOLJSTVA KORISNIKA PROIZVODA uz proaktivan odnos prema reklamacijama. 6. Motivacija i edukacija ZAPOSLENIH i kontinuirani razvoj KORPORATIVNE KULTURE. 7. Ostvarivanje i unapređenje BEZBEDNOSTI i ZDRAVLJA NA RADU. 10. Razvoj ORGANIZACIONE EFIKASNOSTI i rast POSLOVANJA uz unapređenje tržišnih pozicija. 11. Pouzdane SIROVINE od potvrđenih dobavljača. 13. Usaglašenost i kontinuirano unapređenje TEHNOLOŠKIH KOMPETENCI. 14. Brzo reagovanje na TRŽIŠNE PROMENE i IZAZOVE. 17. KORPORATIVNA DRUŠTVENA ODGOVORNOST i podrška lokalnim zajednicama. 19. Odgovorno upravljanje potrošnjom VODE i smanjivanje generisanja OTPADA. Hemofarm’s materiality topics for 2018 include: 1. PORTFOLIO development and PRODUCT RANGE optimization. 2. Achieving PRODUCT QUALITY and SAFETY in line with pharmaceutical standards. 3. Development and registration of NEW PRODUCTS that are contemporary, comfortable and reliable. 4. Responsible MARKETING and transparent COMMUNICATIONS with maximum availability of information. 5. Respecting the needs and SATISFACTION OF PRODUCT USERS with proactive attitude to complaints. 6. Motivation and education of EMPLOYEES and continuing development of CORPORATE CULTURE. 7. Achieving and improving OCCUPATIONAL HEALTH AND SAFETY. 10. Development of ORGANISATIONAL EFFICIENCY & BUSINESS OPERATIONS growth with improvement of market positions. 11. Reliable RAW MATERIALS from certiﬁed suppliers. 13. Compliance and continuous improvement of TECHNOLOGICAL COMPETENCIES. 14. Agile response to MARKET CHANGES & CHALLENGES. 17. CORPORATE SOCIAL RESPONSIBILITY and support to local communities. 19. Responsible WATER consumption management and reduced WASTE generation. Prateći kretanje materijalnih tema u odnosu na Monitoring the trend of materiality topics com2017. godinu, moguće je ustanoviti direktnu pared to 2017, it is possible to establish a direct vezu sa aktivnostima kompanije u domenu link between the company’s activities in the field održivog razvoja i unapređenja svesti ključnih of sustainable development and improvement of stejkholdera o tome. Na primer, unapređenje the awareness of key stakeholders thereon. For energetske efikasnosti i povećanje korišćeexample, improving energy efficiency and increasnja obnovljivih izvora u 2018. nije materijalna ing the use of renewable sources in 2018 are not tema, upravo zato što je Hemofarm percipimateriality topics precisely because Hemofarm is ran kod ključnih stejkholdera i zaposlenih kao perceived as an energy efficient and balanced conenergetski efikasan i izbalansiran potrošač. sumer by key stakeholders and employees. This is To je u skladu sa nalazima IFC (International in line with the findings of the IFC (International Finance Corporation), članicom Grupe Finance Corporation), a member of the World Svetske banke, koja je pogone Hemofarma Bank Group, which has ranked Hemofarm’s plants svrstala u top 20% energetski najefikasnijih among top 20% of the world’s most energy effiu svetu, u poređenju sa referentnim fabricient, compared with US reference factories. This kama iz Amerike. Svakako, ova važna tema important topic, nevertheless, remains one of ostaje jedan od prioriteta za Hemofarmov top the priorities for Hemofarm’s top management. 22 menadžment. Takođe, korporativna društvena Corporate social responsibility was previously a odgovornost je kod eksternih stejkholdera non-material topic with external stakeholders, ranije bila nematerijalna tema, dok je u 2018. while the awareness about the activities carried značajno porasla svest o aktivnostima koje out by Hemofarm Foundation was raised in 2018, realizuje Hemofarm fondacija, naročito zalain particular owing to Foundation’s advocating ganjem za promociju doniranja organa i borbu for the promotion of organ donation and fighting protiv visokog krvnog pritiska, pored ostalog, high blood pressure, among other things, which a što je direktno doprinelo većem značaju ove directly contributed to greater significance of this teme, čime je ona postala materijalna. topic, which made it material. Kvalitetan, efikasan i savremen farmaceutski A high-quality, efficient and modern pharmaceuproizvod i sve u vezi sa njim, što je i očekitical product and everything related to it, which vano u skladu sa branšom, ostaje u fokusu is implied considering the industry standards, materijalnih tema, kao i razvoj odnosa prema remains in the focus of materiality topics, as zaposlenima i bezbedno radno okruženje. well as the development of the attitude towards employees and a safe work environment. Hemofarmov top menadžment daje još više na značaju odnosu sa ključnim zainteresoHemofarm’s top management gives even more vanim stranama, ali i unapređenju svesti i significance to the relations with the key stakeodgovornosti dobavljača u domenu društveno holders, as well as improving the awareness značajnih aspekata poslovanja. Iako ovo nisu and responsibility of suppliers in the domain of materijalne teme, njihova pozicija na listi socially important aspects of operation. Although internih korporativnih prioriteta raste. these are not considered the materiality topics, their ranking on the list of in-house corporate priorities is ever higher. Proﬁl kompanije u 2018. Company proﬁle in 2018 102-1 102-2 102-3 102-4 102-5 102-6 102-7 102-8 102-10 102-12 102-13 102-17 102-18 102-32 102-45 202-2 58 godina rasta1 i razvoja2 danas jednog od omiljenih Portfolio obuhvata čak 415 () Oko 3.100 zaposlenih, od toga farmaceutskih brendova.3 proizvoda različitih formi i doza.4 2.342 u Hemofarmu a.d. 58 years of growth1 and Portfolio comprises as many as 415 () products of diﬀerent forms About 3,100 employees, of which development2 of presently one and dosages.4 2,342 in Hemofarm A.D. of the favourite pharmaceutical brands.3 PONOVO REKORD! 53% udeo žena u kompaniji 245 () miliona pakovanja 26,20% () udeo po broju kutija, i gotovo isto toliko na proizvedeno tokom godine. a vrednosno 12,03% ().5 rukovodećim pozicijama. RECORD AGAIN! 26,20% () share in packs, and 53% share of women in the 245 () millions of packs 12.03%() in value terms.5 company and almost as much in manufactured during the year. managerial positions. Preko 70% udeo u izvozu lekova Centar STADA Klastera za iz Srbije, a ukupno 60% godišnje Oko 30,03 () milijarde din. istočnu Evropu, prisutan na proizvodnje se izvozi. prihod od prodaje u 2018. preko 30 tržišta na 3 kontinenta. Over 70% share in export of Income from sales amounting to STADA Cluster hub for Eastern medicinal products from Serbia, and around RSD 30.03 () bil. in 2018. Europe, present in more than 30 60% of annual production exported, markets on 3 continents.6 in total. Hemofarm je farmaceutski lider u Srbiji i Hemofarm is a national and regional pharmaceregionu, čija je primarna delatnost proizvodnja utical leader, with production of quality, efficient, kvalitetnih, efikasnih, bezbednih i dostupnih safe and aﬀordable generic pharmaceuticals as generičkih farmaceutskih proizvoda. Upravo its core activity. It is precisely the leading position liderska pozicija u branši predstavlja viziju in the industry that represents the vision of the kompanije, koju dopunjuje i nastojanje da company, which is enhanced by the eﬀorts of Hemofarm bude lider i u brizi o zdravlju Hemofarm to be also the leader in the care for uopšte. Zato je njegova misija da unaprehealth in general. That is why its mission is to đuje kvalitet života ljudi kroz sveobuhvatnu improve the quality of life of people through brigu o zdravlju, u čemu posebnu ulogu ima i comprehensive health care, in which Hemofarm Hemofarm fondacija, kao vodeća zdravstvena Foundation plays a special role as the leading fondacija u Srbiji. To najbolje potvrđuje i novi healthcare foundation in Serbia. It is best confirglobalni korporativni slogan: med by the new global corporate slogan: Naša misija. Vaše zdravlje. Our mission. Your health. 24 1. Hemofarm je osnovan 01.06.1960. u Vršcu, gde i danas ima sedište; od 2006. deo je nemačke STADA Grupe, koju je 2017. preuzeo konzorcijum dva renomirana investiciona fonda Bain Capital i Cinven, u cilju daljeg rasta, razvoja i repozicioniranja na globalnom tržištu. Preko 130.000m2 zauzimaju Hemofarmovi proizvodi i poslovni objekti, koje čine: Centralni fabrički kompleks u Vršcu, fabrike u Dubovcu, Šapcu i Banovcima (Srbija), Banjaluci (BiH) i Podgorici (Crna Gora), predstavništva u Beogradu, Nišu, Novom Sadu i Kragujevcu, zavisna društva u Makedoniji, BiH, Crnoj Gori, Rumuniji, predstavništvo u Alžiru i laboratorija u Temišvaru (Rumunija). Hemofarm was founded on June 1st 1960 in Vršac where it is presently headquartered; since 2006, it has been a member of German STADA Group, which was taken over by a consortium of two renowned investment funds Bain Capital and Cinven in 2017, with the aim of further growth, development, and repositioning in the global market. Hemofarm’s products and business facilities which include: Central factory complex in Vršac, factories in Dubovac, Šabac and Banovci (Serbia), Banja Luka (B&H), and Podgorica (Montenegro), representative offices in Belgrade, Niš, Novi Sad, and Kragujevac, subsidiaries in Macedonia, B&H, Montenegro, Romania, representative office in Algeria, and laboratory in Timisoara (Romania) occupy more than 130,000m2. 2. Hemofarm je zahvaljujući svom razvoju ušao i u članstvo nekih od najprestižnijih poslovnih udruženja, kao što su: AHK – Nemačka privredna komora, SAM – Srpska asocijacija menadžera, FIC – Savet stranih investitora, PKS – Privredna komora Srbije, AmCham – Američka privredna komora, NALED, UN Global Compact itd. Owing to its development, Hemofarm has also become a member of some of the most prestigious business associations, such as: AHK – German-Serbian Chamber of Commerce, SAM Serbian Association of Managers, FIC Foreign Investors Council, PKS Serbian Chamber of Commerce and Industry, AmCham American Chamber of Commerce, NALED National Alliance for Local Economic Development, UN Global Compact, etc. 3. Hemofarm i Hemofarm fondacija su i u 2018. osvojili brojne nagrade, poput: 1) Nagrada Superbrands u kategoriji za najbolji korporativni brend u oblasti farmacije, 2) Kampanja „Ne dozvoli da pukne” dobitnik je 8 nagrada (Silver drum nagrada u kategoriji OOH na 25. Golden drum festivalu u Portorožu; Nagrada za najbolju kampanju u kategorijama integrisanih komunikacija i medija na Kaktus festivalu; Dva zlatna priznanja u kategorijama promotivna integrisana kampanja – zdravlje i BTL aktivnosti na vanstandardnim mestima Udruženja za tržišne komunikacije UEPS; Tri srebrna priznanja u kategorijama OOH, kreativna upotreba medija i društveno-odgovorni i humanitarni projekat u neprofitnom sektoru, Udruženja za tržišne komunikacije UEPS; Kampanja uvrštena među 10 najboljih kampanja u 2018. u Adriatik regiji), 3) Kampanja „Najvažniji poziv u životu” dobitnik je 4 nagrade (STADA Best Practice Award; Impact nagrada za najbolju neprofitnu društveno korisnu kampanju regionalne agencije „Brodoto”; Priznanje Društva Srbije za odnose s javnošću, kao najbolje komunicirana društveno odgovorna kampanja; Dokumentarni film „Najvažniji poziv u životu” autorke Danice Vučenić i reditelja Mateje Rackova, nagrađen je na kalifornijskom festivalu „Impact DOCS Awards”). Hemofarm and Hemofarm Foundation won many awards in 2018, such as: 1) Superbrands Award in the category of the best corporate brand in the field of pharmacy, 2) Don’t Let it Burst campaign won 8 awards (Silver Drum award in the category of OOH at the 25th Golden Drum Festival in Portorož; Award for the best campaign in the categories of integrated communications and media at the Kaktus Festival; Two golden awards in the categories of promotional integrated campaign Health and BTL activities in non-standard locations of UEPS Marketing Communications Association; Three silver awards in the categories of OOH, creative use of media and socially responsible and humanitarian project in the non-profit sector of UEPS Marketing Communications Association; Campaign ranked among the top 10 campaigns in the Adriatic region in 2018), 3) The Most Important Call in Life campaign won four awards (STADA Best Practice Award; Impact Award for the best non-profit socially responsible campaign of the regional agency Brodoto ; Award of the Serbian Public Relations Association, as the best communicated socially responsible campaign; The Most Important Call in Life documentary by the author Danica Vučenić and Director Matej Rackov was awarded at the Impact DOCS Awards festival in California). 4. Obuhvata lekove koji zse izdaju na recept (Rx), preparate koji se mogu kupiti bez lekarskog recepta i obuhvataju vitamine, minerale, dodatke ishrani (OTC, CHC), kao i dijetetske suplemente. Including prescription medicines (Rx), prescription-free medicines which comprise vitamins, minerals, food supplements (OTC, CHC). 5. Izvestan pad tržišnog udela u odnosu na prošlu godinu posledica je optimizacije portfolija i fokusiranja proizvodnje na izvoz i promet na interkompanijskim tržištima STADA Grupe i Hemofarm Grupe. A certain drop in market share compared to the previous year resulting from the portfolio optimization and production focus on exports and sales in intercompany markets of STADA Group and Hemofarm Group. 6. Tržišta Jugoistočne Evrope, EU, Bliskog Istoka, Severne Afrike i ZND The markets of Southeast Europe, EU, Middle East, North Africa and CIS 25 Hemofarm a.d. je akcionarsko društvo koje posluje u okviru nemačke STADA Grupe, a najviša upravljačka tela u kompaniji su generalni direktor dr Ronald Seeliger i SMT – Senior Management Team, koji obavlja ulogu Upravnog odbora i čine ga senior direktori i menadžeri vodećih korporativnih funkcija. SMT broji ukupno 12 članova, od kojih je čak 5 iz Vršca (14,67%), što najbolje ilustruje opredeljenost kompanije da eksperte prvo traži u okviru zajednica u kojima posluje. Hemofarm A.D. is a joint stock company operating within German STADA Group, and the Chief Executive Officer Dr Ronald Seeliger, and SMT – Senior Management Team, acting as the Board of Directors, which is composed of Senior Directors and Managers of leading corporate functions, are the top management bodies in the company. As many as five SMT members, out of a total of 12, come from Vršac (41.67%), which best illustrates the resolution of the company to seek for experts first within the communities it operates in. 27 Dr Seeliger rukovodi radom SMT-a, koji je Dr Seeliger manages the work of SMT, which is in odgovoran za kreiranje poslovne stratecharge of creating the business strategy and its gije i njeno usaglašavanje sa strateškim alignment with the strategic operation of STADA delovanjem STADA centrale u Nemačkoj. Headquarters in Germany. The top management Najviši menadžment kompanije svesrdno of the company is fully committed to respecting the se zalaže za poštovanje principa i vrednosti principles and values of sustainable development and održivog razvoja i njihovu primenu u svim their application in all aspects of business. The strateaspektima poslovanja. Strateški pristup top gic approach of the top management is based on the menadžmenta baziran je na primeni korporaapplication of the corporate governance Principles, tivnih Principa upravljanja, o kojima je bilo reči which were considered in the previous Sustainable u prethodnim Izveštajima o održivom razvoju, Development Reports, as well as 6 new sustainable kao i na novih 6 principa održivog razvoja development Principles of Hemofarm, which include: Hemofarma, koji obuhvataju: 1) Human Rights & Security, 1) Ljudska prava i bezbednost, 2) Dignified Work and Decent Employment, 2) Dostojanstven rad i častan posao, 3) Anti-corruption and Compliance, 3) Antikorupciju i usaglašenost, 4) Odgovorno poslovanje, kvalitet i održivu 4) Responsible Business, Quality and Sustainable proizvodnju, Production, 5) Etički marketing i komunikacije i 5) Ethical Marketing and Communications, and 6) Efikasnost, integritet i životnu sredinu.7 6) Efficiency, Integrity & Environment.7 7 Dostupni svim zainteresovanim stranama na korporativnoj sajtu. 7 Available to all stakeholders on the corporate website. Pored precizno definisane, efikasne i funkciIn addition to the precisely defined, efficient and onalne strukture upravljanja u Hemofarmu, functional management structure in Hemofarm, kompanija predstavlja dobar model matriks the company represents a good model of matrix organizacije. Osim funkcionalnog rukovoorganization. Apart from functional management, đenja, stručni timovi Hemofarma matrično Hemofarm’s expert teams work with their colleagues sarađuju sa svojim kolegama na nivou čitave across STADA Group while abiding by the matrix struSTADA Grupe, čime se ostvaruje značajna koncture, thus achieving significant competitive edge kurentska prednost i viši nivo adaptivnosti na and a higher level of adaptability to dynamic market dinamične tržišne uslove, dok znanje postaje conditions, while knowledge becomes the most najznačajniji globalni resurs u grupi. significant global resource within the group. Važnost Hemofarma za čitavu STADA Grupu The importance of Hemofarm for the entire STADA najbolje potvrđuje i činjenica što je na čelu Group is best confirmed by the fact that it heads the istočnoevropskog Klastera STADA Grupe, koji Eastern European Cluster of STADA Group, which čine još 13 tržišta. comprises 13 markets. NAŠE VREDNOSTI I NAŠI CILJEVI ODRŽIVOG RAZVOJA OUR VALUES AND OUR SUSTAINABLE DEVELOPMENT GOALS 102-16 Hemofarmov Izveštaj o održivom razvoju za Hemofarm’s Sustainable Development Report for 2018. prikazuje napredak kompanije iz ugla 2018 shows the company progress from the pernovih korporativnih ključnih vrednosti STADA spective of the new key corporate values of STADA Grupe, sa težnjom da se održivi principi na Group, with the aim of linking sustainable princinajbolji način povežu sa pristupom poslovaples with the approach to business and corporate nju i korporativnom kulturom. Svaka vrednost culture in the best possible way. Each value illusilustruje konkretne Ciljeve održivog razvoja trates the specific UN Sustainable Development (UN Sustainable Development Goals SDGs) Goals (SDGs) which are in the focus of Hemofarm, koji su u fokusu Hemofarma, a sa kojima je with which it is fundamentally associated based suštinski povezana na osnovu uticaja i značaja on the impact and significance in terms of the za tri osnovna stuba održivosti – ljude, dostithree basic pillars of sustainability people, achiegnuća i planetu. Upravo zato, novi Izveštaj vements, and the planet. That’s exactly why the predstavlja i jedan od najboljih načina da new Report is also one of the best tools for prose promovišu nove vrednosti Hemofarma i moting the new values of Hemofarm and STADA, STADA-e, što će nesumljivo doprineti i globalwhich will undoubtedly also contribute to the nom razvoju oba brenda. global development of both brands. 30 AGILITY ENTREPRENURSHIP INTEGRITY ONE STADA Za Hemofarm značajni su i ciljevi broj 5 – Goals number 5 Gender equality, and number 11 Rodna ravnopravnost i broj 11 – Održivi Sustainable cities and communities, are imporgradovi i zajednice. Bez rodne ravnopravtant for Hemofarm. Development of society and nosti nije moguć razvoj društva, a samim tim consequently of Hemofarm, or further progress, ni Hemofarma, niti dalji napredak. Isto važi could not be possible without gender equality. The i za održive gradove i zajednice. Bez održivih same goes for sustainable cities and communities. zajednica nisu mogući održivi gradovi, a bez Sustainable cities would not be possible without njih budućnost gotovo da i ne postoji. Budući sustainable communities, and without them, the da su vrednosti ovih ciljeva utkane u sve što future would almost not be possible at all. As the kompanija radi, oni neće biti posebno izdvovalues of these goals are embedded in everything jeni, već će u ovom Izveštaju biti obrađeni u the company does, they will not be particularly kontekstu primarnih, gorenavedenih ciljeva, singled out, but will be reviewed in this Report koji korespondiraju sa ključnim vrednostima. in the context of the primary, above-mentioned goals, which correspond to the key values. BUDUĆNOST JE U NAŠIM RUKAMA… THE FUTURE IS IN OUR HANDS … 31 AGILITY 32 Šta je za nas agilnost What agility means to us 102-9 103-1 103-2 103-3 204-1 301-1 308-1 414-1 Svako od nas je ﬂeksibilan i odlučan nosilac Each and every one of us leads change with ﬂexpromena na našem zajedničkom putu i u svom ibility and decisiveness as a part of our ongoing ličnom razvoju. journey of personal development. Fleksibilnost i odlučnost zaposlenih u Flexibility and decisiveness of Hemofarm employHemofarmu neki su od glavnih nosilaca ees are among the main drivers of strong indussnažnog industrijskog razvoja, brojnih inovatrial development, numerous innovations, and cija i jačanja infrastrukture. Ove osobine čine strengthening of infrastructure. These features kompaniju bržom i adaptibilnijom kako na make the company faster and more adaptive interne, tako i na eksterne izazove. U tom konto both internal and external challenges. In this tekstu, odgovorna potrošnja i proizvodnja čine context, responsible consumption and producsuštinu daljeg razvoja kompanije. tion constitute the essence of further company development. Materijalne teme, koje su u fokusu, prema strateškom pristupu poslovanju i vezane za The materiality topics in focus, according to straovu vrednost su: tegic approach to business, with regard to this value include: • Pouzdane SIROVINE od potvrđenih dobavljača • Reliable RAW MATERIALS from certified • Usaglašenost i kontinuirano unapređesuppliers nje TEHNOLOŠKIH KOMPETENCI • Compliance and continuous improvement • Brzo reagovanje na TRŽIŠNE PROMENE i of TECHNOLOGICAL COMPETENCIES IZAZOVE • Agile response to MARKET CHANGES & CHALLENGES 33 Agilna nabavka kao stub agilnog poslovanja Agile purchasing as a pillar of agile operations Agilnost, kao nova korporativna ključna Agility, as a new corporate key value and one of vrednost i jedan od novih fokusa Hemofarma, new focuses of Hemofarm, is a characteristic of karakteriše sve segmente poslovanja u all segments of the company operations, and kompaniji, a kada je u pitanju proizvodnja when production of pharmaceutical products is in farmaceutskih proizvoda – počinje od Sektora question – it starts from the Purchasing Division. nabavke. Pored agilnosti, jedan od ključnih Apart from agility, one of the key prerequisites preduslova poslovnog uspeha Hemofarma je of Hemofarm’s business success is also quality – i kvalitet – koji počinje nabavkom kvalitetnih which starts by purchasing high-quality pharmafarmaceutskih sirovina. ceutical ingredients. Nabavka farmaceutskih sirovina je vrlo komPurchase of pharmaceutical ingredients is very pleksna i zahtevna, posebno zato što je complex and demanding, especially because the dostupnost specifičnih sirovina limitirana availability of specific ingredients is limited (there (mali broj pouzdanih dobavljača, koji su geois a small number of reliable suppliers which are grafski uglavnom koncentrisani u određene geographically mainly located in certain world zone u svetu, a neretko na Daleki istok) ili areas, and often in the Far East) or very complex proceduralno vrlo složena (poput nabavke in terms of its procedure (like purchase of psychopsihoaktivnih kontrolisanih supstanci, koje active controlled substances, which are subject podležu zasebnim procedurama nabavke). to special purchasing procedures). Hemofarm’s Hemofarm u postupcima nabavke prioritet priority in the purchasing process is quality. All daje kvalitetu. Svi potencijalni dobavljači i potential suppliers and service providers, regarddavaoci usluga, bez obzira na teritorijalnu less of their territorial location, get equal chances pripadnost, dobiju jednake šanse i tretiraju and are treated equally8. Besides, Hemofarm se ravnopravno8. Pored toga, Hemofarm sa treats domestic suppliers coming from Serbia posebnom pažnjom tretira domaće dobavljače with special care, being aware that such an sa područja Srbije, bivajući svestan da je takav approach is a specific support to the developpristup svojevrsna podrška razvoju lokalne ment of local economy. The share of domestic ekonomije. Udeo domaćih dobavljača je ostao suppliers remained at the level of about 88%, and na nivou od oko 88%, s tim da ako se uzme u if taken into consideration that the total value of obzir da je ukupna vrednost nabavke porasla purchasing increased in 2018, then this percentu 2018, onda se i ovaj procenat može smatrati age too can be considered increased. The growth povećanim. Rast zastupljenosti domaćih of share of domestic suppliers was also recorded dobavljača zabeležen je u segmentu usluga i in the segment of services and it accounts for iznosi zavidnih 94%. enviable 94%. 8 Opšti uslovi poslovanja i nabavke nalaze se dostupni na zvaničnoj internet prezentaciji 8 General business and purchasing terms are available on the official internet presentation kompanije, a na svakoj porudžbenici je i link ka ovim uslovima, čime Hemofarm nastoji da bude fer of the company and each purchase order contains a link to these terms, as a way in which i transparentan poslovni partner: http://www.hemofarm.com/Binary/40471/Opsti-uslovi-poslovanHemofarm strives to be fair and transparent business partner: http://www.hemofarm.com/ ja-Nabavka-robe-i-usluga.pdf Binary/40471/Opsti-uslovi-poslovanja-Nabavka-robe-i-usluga.pdf 34 Grupa materijala Domaće tržište / % Ino tržište / % Ukupno učešće / % Material group Domestic market / % Foreign market / % Total share / % Sirovine 4 96 49 Raw materials Ambalaža 38 62 19 Packaging materials In bulk i GP 2 98 6 In bulk and FP Investicije 88 12 14 Investments Usluge Services 94 6 12 Kada se posmatra nabavka sirovina koja When purchasing of raw materials is concerned uključuje aktivne i pomoćne sirovine ukupna which includes active ingredients and excipients, količina iznosi oko 5,5 hiljada tona, dok je the total quantity amounts to about 5.5 thoustaklena ambalaža približno oko hiljadu sand tonnes, while the glass packaging material tona, papirna ambalaža oko 2,8 hiljada tona, amounts to approximately one thousand tonnes, drvena ambalaža oko 2 hiljade tona, metalna paper packaging material amounts to about 2.8 ambalaža oko 500 tona, te plastična ambalaža thousand tonnes, wooden packaging material oko 3,1 hiljadu tona. Od ukupne količine about 2 thousand tonnes, metal packaging mateosnovnih kutija za pakovanje Hemofarmovih rial about 500 tonnes, and plastic packaging mateproizvoda učešće recikliranih osnovnih kutija rial about 3.1 thousand tonnes. The share of recyje na nivou od zavidnih 80%. To praktično cled primary cartons out of total primary cartons znači da je oko 200 miliona pakovanja gotovih used for packaging of Hemofarm’s products is at proizvoda tokom 2018. bilo spakovano u recithe level of enviable 80%. This practically means kliranu ambalažu. that about 200 million of finished products were packed in the recycled packaging material over the course of 2018. Kategorija Category 2016 / % 2017 / % 2018 / % Sirovine 47 38 38 Raw materials Staklena ambalaža Glass packaging material 9 7 7 Papirna ambalaža 21 21 18 Paper packaging material Drvena ambalaža 11 15 14 Wooden packaging material Metalna ambalaža 2 4 3 Metal packaging material Plastična ambalaža Plastic packaging material 10 15 20 35 Pored agilnosti i kvaliteta, treći princip kojim se Apart from agility and quality, the third principle rukovodi Hemofarm u nabavci jeste transpathat guides Hemofarm in purchasing activities is rentnost. Svim dobavljačima je jasno predočen transparency. All the suppliers have been clearly zahtevani kvalitet, koji propisuje Hemofarm, a informed about the requested quality prescribed u skladu sa farmaceutskim standardima, zatim by Hemofarm, in line with the pharmaceutical da se od svih potencijalnih dobavljača očekuje standards, then all potential suppliers are expected da nude proizvode po prihvatljivoj ceni, isputo oﬀer products at the acceptable price, meet njavaju planirane rokove, pružaju adekvatnu the planned deadlines, render adequate support, podršku, servis i korisne informacije. A to je service and useful information. And that is only tek početak i preduslov saradnje. Zaokruženi the beginning and prerequisite of cooperation. monitoring celokupnog distributivnog lanca Complete monitoring of the overall distribution omogućava Hemofarmu aktivno učešće u chain enables Hemofarm to participate actively in smanjivanju uticaja na okolinu. Odgovorno reduction of environmental impact. Responsible upravljanje procesom nabavke podrazumeva purchasing process management involves evaluevaluaciju i praćenje solventnosti, poslovnosti ation and monitoring of solvency, credibility and i poštovanja prava zaposlenih od procesa observance of the employee rights, from the protestiranja potencijalnih dobavljača9, pa do cess of testing the potential suppliers9, to starting započinjanja i kontinuiranog održavanja and continuous maintenance of cooperation with saradnje sa njima. Performanse dobavljača them. Suppliers’ performances are continuously kontinuirano se prate, uključujući poštovanje monitored, including observance of agreed delivugovorenih rokova isporuka, kvaliteta, cena, ery dates, quality, prices, method, and payment načina i rokova plaćanja. Takođe, dobavljači terms. Also, suppliers are obliged to take over su u obavezi da preuzimaju odgovornost za the responsibility for potential or real problems potencijalne ili realne probleme u procesu in the purchasing process, and to timely inform nabavke, te da blagovremeno informišu Hemofarm about the problems related to the Hemofarm o problemima u vezi sa porudžbiorder or delivery. nom ili isporukom. Continuous optimization as the principle of comKontinuirana optimizacija kao princip poslopany operations is reﬂected also on the activities vanja kompanije odražava se i na aktivnosti of Purchasing Division. One of such initiatives is Sektora nabavke. Jedna od takvih inicijativa centralization of purchasing as the process at jeste i centralizacija nabavke kao procesa na the level of STADA Group, whereby local models nivou STADA Grupe, čime se lokalni modeli are replaced by global ones. Digitalization (data zamenjuju globalnim. Digitalizacija (baze bases, contracts, automatic ordering, etc.) and podataka, ugovori, automatsko poručivaintroduction of project management principle nje, itd.) i uvođenje principa projektnog are only additional actions to improve the purmenadžmenta samo su dodatne mere unachasing function in order to increase business pređenja funkcije nabavke radi povećanja and competitive performances, with reduction of poslovnih i konkurentskih performansi, uz the impact on the environment. Since Hemofarm smanjivanje uticaja na okolinu. S obzirom na exports the major part of its product portfolio, to da Hemofarm izvozi veći deo svog proizvefast and efficient transport is additionally eased denog portfolija, dodatna olakšanja za brz by simplified customs procedures. Hemofarm i efikasan transport predstavljaju pojednohas a status of the authorized economic operator stavljene carinske procedure. Hemofarm ima type F, granted by the Customs Administration, status ovlašćenog privrednog subjekta tipa F, which enables faster and simpler procedures of dodeljen od strane Uprave carine, što omogucustoms clearance and accelerates the sale of ćava brže i jednostavnije procedure carinjenja products, increases competitiveness and makes i ubrzava plasman proizvoda, povećava konthe business more efficient, thus making the kurentnost i poslovanje čini efikasnijim, a 9 Svi novi dobavljači, koji u aktuelnoj kalendarskoj godini dobiju priliku da započnu potencijalnu 9 All new suppliers, who get the chance in the current calendar year to start the potential coopersaradnju sa Hemofarmom, kroz sistem evaluacije obavezni su da popune i BSCI (Business Social ation with Hemofarm, are obliged to fill out BSCI (Business Social Compliance Initiative) questionCompliance Innitiative) upitnik, čime se procenjuje njihova društveno-socijalna usaglašenost naire, as a part of evaluation, which is used to evaluate social compliance of their business operaposlovanja. Ukoliko neki dobaljvač nije usaglasio svoje poslovanje i poslovnu kulturu sa održivim tions. If a supplier has failed to align its business operations and business culture with sustainable vrednostima, Hemofarm zadržava pravo da prekine saradnju sa datim dobavljačem. values, Hemofarm reserves the right to terminate the cooperation with the given supplier. 36 kompaniju dugoročnim i stabilnim partnecompany a long-term and stable partner in the rom u spoljnotrgovinskoj aktivnosti Srbije10. foreign trade of Serbia10. Održivo pakovanje ostaje u fokusu Hemofarma Sustainable packaging remains the focus of i Sektora nabavke, dok kreiranje održivih proHemofarm and Purchasing Division, while creation izvoda i održivi dizajn sve više dobijaju na of sustainable products and sustainable design značaju. Zamena nerecikliranog kartona za are getting more important. The replacement of osnovne kutije recikliranim kartonom dala non-recycled cardboard for primary packs with the je veliki doprinos održivom razvoju, kao i recycled cardboard contributed to the sustainable smanjenje gramature plastičnih zatvarača i development a lot, as well as the reduction of gramoptimizacija PVC folija za blisterisanje. Pored mage of plastic caps and optimization of PVC foils toga, Hemofarm razmatra na koje načine for blistering. Besides, Hemofarm is considering može da upotrebi preostale folije koje ostaju the ways how to use the foils remaining after comnakon zaokružene proizvodnje, te da ih iskopleted production for production of promotional risti za izradu promotivnih i marketinških and marketing material. Out of total quantity of materijala. Od ukupne količine osnovnih kutija primary packs for packaging of Hemofarm’s prodza pakovanje Hemofarmovih proizvoda učešće ucts, the share of recycled cartons is at the level of recikliranih osnovnih kutija je na nivou od oko about 80%, which can be treated as the increase of 80%, što se može tretirati kao porast udela jer share because production but also the purchase of su porasli i proizvodnja, ali i sama nabavka the packaging material has increased itself (1,024.7 ambalaže (1.024,7 tona u 2018. u odnosu na tonnes in 2018 compared to 931.5 tonnes in 2017). 931,5 tona u 2017. godini). Hemofarm nastoji Hemofarm endeavours to inspire the society by its da svojim primerima inspiriše društvo, pa own examples, thus instead of the New Year’s gifts, je tako kompanija umesto novogodišnjih the company has given to all business partners spepoklona, svim poslovnim partnerima podarila cial Christmas Tree Decorations made by decorating specijalne novogodišnje ukrase za jelku, koji su the unused glass vials for injection solutions. They nastali ukrašavanjem neiskorišćenih staklenih were decorated by mentally or physically challenged bočica za injekcione rastvore. Njih su ukrasili children and young people, attendees of the creadeca i mladi sa smetnjama u razvoju, polaznici tive-educational programmes of the organization kreativno-edukativnih programa organizacije KEC MNRO. Apart from the practical example how KEC MNRO. Ova saradnja je, pored praktičnog it is possible to recycle almost everything when primera kako je gotovo sve moguće reciklirati, there is enough imagination, this cooperation had ako postoji dovoljno mašte, imala mnogo znaa much more significant message – that the society čajniju poruku – da je društvo zajednica istih is a community of the same among equals and that među jednakima i da treba podržavati i uvathe rights of each individual should be supported žavati prava svakog pojedinca, jer to je jedini and respected, because that is the only way to make način da gradovi i zajednice zaista budu održivi. cities and communities truly sustainable. Kada su u pitanju CRC zatvarači, nastavljeno je smanjenje upotrebe plastike kao polazne When CRC closures are concerned, reduction of sirovine za oko 26,5%, bez narušavanja kvaliuse of plastics as the starting raw material by about teta i bezbednosti proizvoda, a Hemofarm je 26.5% continued, without compromising the quality počeo da radi studije izvodljivosti i opravdanosti and safety of products, and Hemofarm started to uvođenja istih ovakvih zatvarača i u ostale proconduct the feasibility studies related to introducizvodne pogone STADA Grupe u Velikoj Britaniji tion of the same stoppers also to other production i drugim zemljama. Projekat optimizacije CRC plants of STADA Group in Great Britain and other zatvarača implementiran je u Hemofarmovim countries. The project of optimizing CRC closures proizvodnim pogonima u Šapcu, Podgorici i has been implemented in Hemofarm’s producDubovcu, a pored uštede sirovina, mnogo je tion plants in Šabac, Podgorica and Dubovac, and važnije smanjenje negativnog uticaja na životnu apart from savings of raw materials, it is much more sredinu kroz smanjenje korišćenja plastike u important that negative impact on the environment proizvodnji i životnom ciklusu proizvoda. was reduced through reduction of consumption of plastics in the production and life cycle of a product. 10 Praktično je kompanija dobila „bescarinsku poziciju” i iz perspektive carine Srbije ali i Međunarodne 10 This applies also to Hemofarm. Practically the company got ’duty free position’ from the perspective of carinske organizacije. Pored efikasnijeg poslovanja, smanjenja troškova, bržeg protoka kapitala, uspostavlja the Customs of Serbia but also of the International Customs Organization. Beside more efficient business se i kvalitetna interna kontrola, uz usaglašavanje domaće zakonske regulative i prakse sa zakonodavstvom operations, reduction of costs, faster ﬂow of capital, high-quality internal control is also established with Evropske unije. harmonization of domestic legal regulations and practices with the European Union legislation. 37 Eﬁkasna proizvodnja i snažne tehnološke kompetence uslov brzog reagovanja na dinamično tržište Eﬃcient production and strong technological competencies – basics for fast responding to dynamic market U toku 2018. godine ostvaren je novi rekordan A new record-breaking production volume of obim proizvodnje od 245,3 miliona pakova245.3 million packs was achieved in 2018, with nja, čime je realizacija za 1% veća u odnosu a 1% increase in the output recorded compared na takođe rekordnu 2017. godinu. Dodatno to 2017, which was also a record-breaking year. ohrabruje i činjenica da su realizovani troškovi The fact that the incurred production costs were proizvodnje za 10,31% manji od planiranog lower by 10.31% than the planned budget, with budžeta, uz rast prihoda od 7% u odnosu na a 7% increase in revenues compared to the 2017 marginu 2017. godine. To najbolje svedoči o margin is additionally encouraging. This is the efikasnosti i racionalnosti dobro ustrojenih best evidence of the efficiency and cost-eﬀecproizvodnih procesa, a što se ne odražava tiveness of well-tailored production processes, na kvalitet gotovih proizvoda. Realizovan je not aﬀecting the quality of finished products. rekordan obim u proizvodnim jedinicama od A record-breaking volume of 5,592 billion pro5.592 milijarde (TPU) što je 5% više u odnosu duction units (TPU) was achieved, which is a 5% na prethodnu godinu, a celokupan proizvodni increase compared to the previous year, while the portfolio imao je 5% manju kompleksnost u entire production portfolio was by 5% less comodnosu na isti period 2017. godine. Zabeležena plex year-on-year. Record-breaking production je i rekordna proizvodnja farmaceutskih of pharmaceutical solid dosage forms was also čvrstih formi, koja je porasla za 7%. recorded, with a 7% increase. REALIZACIJA U PAKOVANJIMA (U MILIONIMA PAKOVANJA): OUTPUT IN PACKS (IN MILLIONS OF PACKS): Output in mio packs 111% 245 244 221 81 86 55 166 163 ACT 2016 ACT 2017 ACT 2018 West Balkan, Russia, Ukraina, Non Europian and 3rd party West Europe 38 REALIZACIJA U JEDINICAMA-TPU (U MILIONIMA JEDINICA): OUTPUT IN UNITS – TPUs (IN MILLIONS OF UNITS): Output in mio TPUs 128% 5592 5314 4374 3408 3200 2213 2161 2114 2183 ACT 2016 ACT 2017 ACT 2018 West Balkan, Russia, Ukraina, Non Europian and 3rd party West Europe U cilju pronalaženja novih inicijativa vezanih Strategic workshops involving the most renowned za optimizaciju procesa, tokom 2018. održane consulting companies (McKinsey, Teﬀen, AP&P su i strateške radionice sa najznačajnijim konAlbrecht, Prock and Partners) were held in 2018, sultantima (McKinsey, Teﬀen, AP&P Albrecht, in the eﬀort to identify new initiatives related to Prock and Partners). Fokus je bio na unaprethe optimization of processes. The focus was đenju fabrika i samih proizvodnih procesa u on improving the factories and production proVršcu i Šapcu, uz kreiranje osnovnih KPI-jeva cesses in Vršac and Šabac, along with the creakako bi se pratile performanse proizvodtion of basic KPIs to monitor the performances of nih sajtova i pojedinih sektora/pogona na production sites and individual divisions/plants at mesečnom nivou. a monthly level. Globalni OpEx program čiji je fokus bio na The global OpEx programme with the focus on susodrživim uštedama, implementiran na nivou tainable savings, implemented at the level of entire čitave STADA Grupe, rezultirao je sa ukupno STADA Group, resulted in a total of 140 initiatives in 140 inicijativa u Srbiji sa godišnjim potenciSerbia with an annual savings potential of EUR 7.2 jalom od 7,2 miliona evra. Očekivane uštede million. Expected savings in Hemofarm in 2018, u Hemofarmu u 2018, koje su iznosile 4,6 which amounted to EUR 4.6 million, were signifimiliona evra, značajno su premašene, te su cantly exceeded, and actual savings amounted to realne uštede iznosile čitavih 6,2 miliona evra, a total of EUR 6.2 million, which is by 35% more što je 35% više od očekivanog. Optimizacije su than expected. Optimizations were also reﬂected se ogledale i u smanjivanju suvišnih troškova in the reduction of redundant costs by as much za čitavih 1,6 miliona evra, dok je u okviru as EUR 1.6 million, while the benefit amounting to Programa kontinuiranog unapređenja proiEUR 4.1 million was achieved within Continuous zvodnje, kroz ukupno 41 realizovan projekat, Production Improvement Programme, through 41 ostvaren i benefit od 4,1 miliona evra. implemented projects in total. U toku 2018. godine proizvodni pogoni Hemofarm production facilities were subject Hemofarma bili su predmet 22 eksterne to 22 external audits (Ministry of Health of the inspekcije (Ministarstvo zdravlja Republike Republic of Serbia, Medicines Agency of B&H, Srbije, Agencije za lekove BiH, državne uprave State Administration of Ukraine, RP Darmstadt, Ukrajine, RP Darmstadt-a, WHO-a i Ministarstva WHO, Ministry of Industry and Trade of the Russian industrije i trgovine Ruske Federacije, Inspekcije Federation, audits by contractual partners, and ISO ugovornih partnera i ISO 9001 standarda). Kao 9001 standard compliance audit) during 2018. As i svake godine, uspešno su realizovane sve every year, all GMP inspections were successfully GMP inspekcije. Posebno se izdvaja uspešno completed. The successfully completed audit of 39 završeno inspektovanje Centra za pakovanje the Packaging Centre conducted by some of the od strane nekih od najzahtevnijih inspekcija most demanding auditing authorities Russian ruske i ukrajinske, čime su ostvareni važni and Ukrainian was singled out in particular, which preduslovi za dalji razvoj Hemofarma. Takođe, resulted in providing important preconditions for ostvareni trošak konverzije u Centru za pakofurther development of Hemofarm. Also, the convanje na 1.000 upakovanih tableta za 21.5% version cost achieved in the Packaging Centre on je ispod budžetiranog, što najbolje svedoči o 1,000 packed tablets is below the budgeted one optimalno i efikasno uspostavljenom sistemu. by 21.5%, which best proves the optimal and efficiently established system. Uspešno je započeta i realizacija EU FMD11 projekta, što je posebno značajno jer stalno The EU FMD11 project has also been successraste broj proizvoda koji podležu ovoj serifully launched, which is particularly significant jalizaciji (čak 186 u decembru 2018.). Pored as the number of products subject to such serinovog rekorda proizvodnje, impozantan je i alization is constantly increasing (as many as broj proizvedenih validacionih, optimizacio186 in December 2018). In addition to the new nih i probnih šarži, koji iznosi čak 112 šarži u record-breaking output, the number of manufacnesterilnim formama. Realizovano je ukupno tured validation, optimization, and trial batches is 20 novih INN-ova u 44 različita bulk proizvoda, impressive, amounting to as many as 112 batches a značajan je i broj site-to-site transfera. of non-sterile dosage forms. A total of 20 new Najbitniji proizvodi koji su lansirani u 2018. su INNs in 44 diﬀerent bulk products have been manEzetimib, Olmesartan/Amlodipin i Ibuprofen ufactured, and the number of site-to-site transfers Phenylephrine Ibumax. Takođe, shodno odluci is also significant. The most important products da se proizvodnja iz pogona u Banovcima launched in 2018 include Ezetimibe, Olmesartan/ u perspektivi prebaci u Šabac, završena je Amlodipine, and Ibuprofen Phenylephrine rekonstrukcija jednog dela pogona u Šapcu Ibumax. Additionally, in accordance with the decii pokrenut transfer proizvoda iz Banovaca u sion to prospectively transfer production from Šabac. Najveći deo procesa preseljenja proiBanovci plant to Šabac, the reconstruction of a zvodnih linija iz Banovaca u Šabac, kao i linija part of the plant in Šabac was completed, and the pakovanja iz Banjaluke u Vršac, realizovala je transfer of products from Banovci to Šabac was iniHemofarmova interna Služba održavanja, čime tiated. The largest part of the process of moving su omogućene značajne uštede ali i znatno the production lines from Banovci to Šabac, as well skraćeni rokovi za transfer. Istovremeno, as packaging lines from Banja Luka to Vršac was mašinska i bravarska radionica samostalno carried out by Hemofarm in-house Maintenance su izradile 60 setova alata za pakovanje na već Service, which resulted in significant savings, and postojećim linijama renomiranih proizvođača, considerably shorter transfer periods. At the same čime je ostvarena ušteda od 770.000 evra. time, the mechanical and locksmith workshop Efikasna proizvodnja ostvaruje svoj pun independently manufactured 60 sets of packaging potencijal po pitanju održivog razvoja tek tools for already existing lines of renowned manukada je prati isto tako efikasno skladištenje facturers, which resulted in savings amounting to i transport! U skladištu gotovih proizvoda i EUR 770,000. skladištu prijema sirovina instalirana je apliEfficient production achieves its full potential in kacija za planiranje i evidenciju pristiglih/ terms of sustainable development only when it otpremljenih kamiona/paleta (interno nazvan is accompanied by equally efficient storage and „red letenja“). Cilj je bio da se omoguće transpatransportation! An application for planning and rentni i vidljivi podaci o aktivnostima vezanim recording the incoming/dispatched trucks/pallets za utovar i istovar kamiona, uz mogućnost (internally referred to as ’ﬂight schedule’) has been provere statusa svakog kamiona u realnom installed in the finished product warehouse and vremenu (planiran, stigao, istovar, utovar, raw material receipt warehouse. The goal was to otpremljen…). Drugi cilj je bio lakša organiprovide transparent and visible data on activities zacija i praćenje aktivnosti utovara/istovara, related to loading and unloading of trucks, with 11 Centar za pakovanje je spreman za rad u potpunosti u skladu sa FMD standardom od 09.02.2019. 11 Packaging Centre is ready for operation in full compliance with FMD standard since 09/02/2019. 40 i precizno praćenje broja utovarno-istovarnih the possibility of checking the status of each truck paleta. Korist od ovakve platforme je razmena in real time (planned, arrived, unloaded, loaded, informacija između službi na moderan i dispatched...). The second goal was to achieve efikasan način, eliminisanje potrebe za easier organization and monitoring of the loaddodatnom komunikacijom između odeljeing/unloading activities, and precise tracking of nja, kako bi se dobile osnovne informacije o the number of loaded-unloaded pallets. The benstanju utovara/istovara kamiona. Takođe, na efit of such a platform is the exchange of inforportalu se vodi statistika o broju utovarenih/ mation between services in a state-of-the-art and istovarenih paleta po kamionu/danu, postoje efficient way, eliminating the need for additional jasne informacije za sve zaposlene i lakša je communication between departments in order organizacija zaposlenih. Implementacija je to obtain basic information about the loading/ sprovedena i u skladištu ambalažnog materiunloading status of trucks. Additionally, statistical jala u Vršcu, u Dubovcu i na sajtu u Šapcu. records of the number of loaded/unloaded pallets per truck/day are kept on the portal. There Hemofarm je tokom 2018. isporučio na tržište is clear information for all employees and organiz skladišta u Vršcu 10% više paleta gotovih ization of employees is easier. It was also impleproizvoda u odnosu na 2017. godinu. Proizvodi mented in the packaging materials warehouse in su distribuirani na tržišta Evrope, CIS regiona Vršac, Dubovac, and Šabac site. i MENA regiona. Za distribuciju gotovih proizvoda angažovano je 10 prevoznika, a u 2018. During 2018, Hemofarm delivered 10% more realizovan je i tender za izbor novih transportfinished product pallets to the market from the nih kompanija, na nivou STADA Grupe po warehouse in Vršac, compared to 2017. Products najsavremenijim metodama izbora dobavljača. were distributed to the markets of Europe, CIS Ovim tenderom sprovedeno je uvođenje novih region, and MENA region. There were 10 carriprevoznika koji su fokusirani na održivi razvoj ers hired for distribution of finished products, u svojim kompanijama, napredno planiranje and a tender for the selection of new transporruta uz minimum „praznih“ kilometara, a sam tation companies was also implemented in 2018 transport realizuju najmodernijim vozilima uz at STADA Group level, according to the most manju emisiju CO2, upotrebom TNG goriva kao advanced supplier selection methods. This tender i pilot projektima električnih kamiona sa komintroduced new carriers focused on sustainable panijom „Tesla“. To, uz činjenicu da je gotovo development in their companies, advanced route kompletan unutrašnji transport u Hemofarmu planning with minimum idle kilometres, and the zasnovan na automatizovanim regalnim dizatransport itself carried out by the top-notch vehilicama kao i viljuškarima na elektropogon, cles with lower CO2 emissions, using LPG fuels, najbolje svedoči da su, pored aspekata siguras well as electric trucks pilot projects with Tesla nosti, pozitivan uticaj na okruženje i smanjenje company. All that, along with the fact that almost emisije štetnih gasova među najbitnijim opreall in-house transportation in Hemofarm is based deljujućim faktorima. on automated rack lifting system as well as electric forklift trucks, best illustrates that, in addition to the safety aspects, the positive environmental impact and reduced emissions of harmful gases are among the most important deciding factors. 41 Operativna izvrsnost, kontinuirana unapređenja i upravljanje projektima: Dodatnu podršku kako optimizaciji proizvodnje, tako i unapređenju performansi čitave kompanije daju inicijative i projekti realizovani u okviru Programa operativne izvrsnosti i Kancelarije za projektni menadžment. Samo neki od njih, koji su pokrenuti ili realizovani u toku 2018. godine, jesu: • Početak digitalizacije u Centru za pakovanje koji je obuhvatio razvoj i implementaciju sistema za praćenje performansi mašina za pakovanje u realnom vremenu, što omogućava pouzdane podatke o statusu mašina u svakom trenutku, proaktivno rešavanje problema i eliminisanje ručnog prikupljanja različitih podataka. Nakon uspešno realizovanog pilot projekta na jednoj mašini i planiranog početka primene na svim ostalim linijama, sledi faza programiranja internet aplikacije sa centralizovanim praćenjem svih linija za pakovanje i to na mobilnim uređajima. Ovaj koncept je razvijen unutar kompanije, čime su ostvarene uštede od oko 600.000 evra, a puna implementacija čekuje se do sredine 2019; • Redukcija kozmetičkih defekata na ampulama u toku procesa proizvodnje, kroz unapređenje procesa punjenja i zatvaranja ampula; količina defekata je smanjena za 2.500 ampula po šarži, čime je podignuta efikasnost i rentabilnost proizvodnje, uz smanjenu količinu farmaceutskog otpada; • Uvećanje šarži optimizacijom procesa proizvodnje za proizvod SNUP, čime je ostvarena ušteda u konverzionim troškovima od oko 715.000 evra u 2018; • Upotreba recikliranih tonera u celoj kompaniji, čime je ostvarena ušteda od 56.000 evra, uz veoma veliki doprinos pozitivnom uticaju na okruženje, s obzirom na to da je pažljivo odabran dobavljač koji nudi ekološke tonere, a sam proces recikliranja je sam po sebi važan dodatni doprinos; • Nastavak digitalizacije svih procesa, bliža i agilnija komunikacija unutar matriks organizacije i objedinjena nabavka potrošnih materijala za celu STADA Grupu, kroz blizak timski rad, što je rezultiralo dodatnim godišnjim uštedama od oko 550.000 evra. Operational Excellence, Continuous Improvements and Project Management: Management Oﬃce provide additional support to both production optimization and improvement of performance of the overall company. Some of them initiated or implemented over the course of 2018 are the following: • Beginning of digitalization in the Packaging Centre, which included the development and implementation of the system for performance monitoring of the packaging machines in the real time, providing reliable data on the machine status at any time, proactive problem solving and elimination of manual collection of diﬀerent data. After successfully implemented pilot project on one machine and planned beginning of implementation in all other lines, the following phase is the phase of programming of internet application with central monitoring of all packaging lines on mobile devices. This concept has been developed within the company, whereby the savings of about EUR 600,000 have been achieved, and full implementation is expected by mid-2019; • Reduction of cosmetic defects on ampoules during the production process, through the improvement of the process of ampoule ﬁlling and closing; quantity of defects was reduced by 2,500 ampoules per batch, whereby the eﬃciency and cost-eﬀectiveness of production was achieved, with reduced quantity of pharmaceutical waste; • Increase of batches by manufacturing process optimization for the product SNUP, whereby the savings in conversion costs of about EUR 715,000 were achieved in 2018; • Use of recycled toners in the whole company, whereby savings of EUR 56,000, were achieved with very signiﬁcant contribution to the positive impact on the environment, since the supplier oﬀering eco toners has been carefully selected and the recycling process itself is an important additional contribution; • Continuation of digitalization of all processes, closer and more agile communication within matrix organization and joint purchase of consumables for the overall STADA Group, through close teamwork, which resulted in additional annual savings of about EUR 550,000. 42 Kada su u pitanju inovatorske ideje i iniciWhen innovating ideas and initiatives of the jative zaposlenih, u 2018. bilo ih je 51, od employees are in question, there were 51 of čega je njih 7 odmah implementirano, bez them in 2018, 7 of which were immediately implepokretanja projekata, dok je isto toliko ideja mented, without initiating a project, while the same prihvaćeno i odobreno u projektnoj formi. number of ideas was accepted and approved in Kompanija trenutno analizira 22 ideje, koje the project form. The company currently analyses bi uskoro mogle da postanu projekti. Većina 22 ideas that could soon become projects. Most ideja je podneta putem lako dostupne sekcije of the ideas were submitted via easily accessible Kancelarije za projektni menadžment na korsection of the Project Management Office on the porativnom intranetu. corporate intranet. Obuka za PMP (Project Management PMP (Project Management Professional) trainProfessional) po metodologiji Instituta za ing according to the methodology of the Project upravljanje projektima (PMI) i edukacija Management Institute (PMI) and education of the zaposlenih u svrhu kontinuiranog unapređeemployees for the purpose of continuous improvenja ostali su u fokusu Hemofarma i u 2018. ment remained the focus of Hemofarm also in Na osnovu odgovora u anketi koja je orga2018. Requirements for further trainings were idennizovana tokom godine, kao i zadovoljstva tified on the basis of replies in the survey organized zaposlenih iskustvom sa Kancelarijom za over the course of the year, as well as based on the upravljanje projektima (PMO), identifikoemployee satisfaction with the Project Management vani su zahtevi za daljim obukama, uveden je Office (PMO), new Standard Operating Procedure novi Standardni operativni postupak (SOP) o (SOP) on risk managing (on projects) was introupravljanju rizicima (na projektima) i ustanovduced and relevant trainings have been established. ljene su relevantne obuke. Vrsta, teme i broj Type, topics and number of trainings have been obuka prilagođeni su zahtevima funkcionalnih adjusted to requirements of Functional Managers menadžera i projektnih menadžera, te potreand Project Managers as well as requirements of bama zaposlenih i dinamici projekata. employees and project dynamics. PMI obuke u 2018 Br. obučenih zaposlenih PMI trainings in 2018 No. of trained employees Standardna PMI obuka 31 Standard PMI trainings MS projekat i Projektni Server 58 MS Project and Project Server SOP 118 SOP Priprema PMI PMP sertifikacionog ispita 12 Preparation of PMI PMP certification exam Upravljanje programom, radionica 11 Programme management, workshop UKUPNO 230 TOTAL 43 Počevši od 2011, Hemofarmovi zaposleni As of 2011, Hemofarm’s employees have been obučavaju se na različitim nivoima Lean & Six trained on diﬀerent levels of Lean & Six Sigma Sigma znanja za Crni (Black), Zeleni (Green) i knowledge for Black, Green and Yellow Belt who Žuti (Yellow) pojas, a interno postaju mentori, internally become mentors, instructors, leadinstruktori, lideri ili učesnici u inicijativama za ers or participants in initiatives for improvement. unapređenje. Tokom 2018. godine, vlasnici Over the course of 2018, the holders of Black and Crnog i Zelenog pojasa bavili su se internim Green Belt dealt with in-house trainings within the obukama u okviru Programa kontinuiranog Continuous Improvement Programme with 4,415 unapređenja sa 4.415 časova obuke zaposlehours of employee training, which is by 70% more nih, što je za 70% više u poređenju sa 2017. compared to 2017. Training for Green Belt was godinom. Obuku za Zeleni pojas završilo je completed by additional 25 employees, for develdodatnih 25 zaposlenih, u cilju razvoja novih oping new project managers who will manage projektnih menadžera koji će rukovoditi aktivactivities within implementation of savings pronostima u okviru realizacije programa ušteda gramme in the company. Out of 37 employees u kompaniji. Od 37 zaposlenih obučenih trained for Green Belt in 2017/18, 12 employees za Zeleni pojas u 2017/18, njih 12 je tokom passed the exam of ASQ (American Society for godine položilo ispit ASQ (Američkog društva Quality) for the Certified Holder of Six Sigma Green za kvalitet) za sertifikovanog nosioca Six Sigma Belt (CSSGB) over the course of the year. So, as Zelenog pojasa (CSSGB). Tako je čak 38 zaposlemany as 38 of employees out of totally trained 67 nih od ukupno 67 obučenih vlasnika Zelenog holders of Green Belt were certified by ASQ (which pojasa sertifikovano od strane ASQ (što iznosi amounts to 56.7% of all trained employees). 56,7% svih obučenih). Sixteen Yellow Belt workshops were held in 2018: 7 U 2018, održano je 16 radionica za Žuti pojas: 7 in Vršac, 3 in Šabac, 2 in Banjaluka, 2 in Belgrade, 1 u Vršcu, 3 u Šapcu, 2 u Banjaluci, 2 u Beogradu, in Dubovac, and 1 in Timisoara. Totally 173 employ1 u Dubovcu i 1 u Temišvaru. Ukupno 173 ees were trained by four of their colleagues who zaposlena obučeni su od strane četvoro svojih are certified for Green Belt and one certified for kolega koji su sertifikovani za Zeleni pojas i Black Belt. By the way, the total number of employjednog sertifikovanog za Crni pojas. Inače, ees who attended the Yellow Belt training is 820, ukupan broj zaposlenih koji su pohađali with the greatest share of the employees in proobuku za Žuti pojas iznosi 820, sa najvećim duction (59%), and then Quality Management udelom zaposlenih u proizvodnji (59%), a zatim (QA&QC – 19.6%), etc. In addition, over the course upravljanju kvalitetom (QA&QC 19,6%), itd. of 2018, 5 two-day trainings were held on the topic Dodatno, tokom 2018. održano je i 5 dvodnevof Statistics Fundamentals and Minitab package, nih obuka iz Osnova statistike i Minitab paketa, with 70 trained employees, who will be dealing sa 70 obučenih zaposlenih, koji će se baviti with detailed analytics of data for further process detaljnom analitikom podataka radi daljih optioptimization in the company. mizacija procesa u kompaniji. Krajem 2017. godine, započet je razvoj Programa konAt the end of 2017, the development of Continuous tinuiranog unapređenja u operativnoj izvrsnosti na Improvement Programme in the operational excellence globalnom nivou, sa prvim aktivnostima u Hemofarmu. started at the global level, with first activities in Hemofarm. Započeta su 2 velika programa: Two extensive programmes were initiated: 1. Hemofarmov program ušteda sa ciljem ušteda od 6 1. Hemofarm’s savings programme with the goal of EUR 6 miliona evra u 2018, koji uključuje: million savings in 2018, which includes: • Kratkoročne i srednjoročne inicijative • Shortand mid-term initiatives • Godišnje uštede 94 inicijative: 32 operativne akcije, 41 • In year savings of 94 initiatives : 32 operational eﬀorts, 41 Green Belt projekat, 11 Yellow Belt projekata i 10 PMI Green Belt projects, 11 Yellow Belt projects and 10 PMI projekata projects • Finansijske efekte praćene u bilansu uspeha (P&L) • Financial eﬀect monitored in P&L 44 2. Globani Program Operativne izvrsnosti sa ciljem 2. Global Operational Excellence Programme with the ušteda većim od 6 miliona evra do 2021. na nivou grupe, goal of EUR 6 million savings until 2021 at the group level, koji uključuje: including: • Dugoročne i srednjoročne inicijative • Longand mid-term initiatives • Projektovane uštede do 2021. koje se aktivno • 2021 Run rate savings are tracked in global system prate na globalnom nivou • 140 initiatives (94 from sites savings programme) • 140 inicijativa (94 dolaze od programa ušteda na proizvodnim lokacijama) Dosadašnji efekat ovih programa veoma je značajan. The eﬀect of these programmes achieved so far is very Finansijski rezultat u 2018. je sledeći: significant. Financial result in 2018 is as follows: • ostvareno je oko 6,2 miliona evra ušteda, • EUR 6.2 million savings • izbegnuto je suvišnih troškova u visini od oko 1,6 • EUR 1.6 million cost avoidance miliona evra, uz • EUR 5.5 P&L eﬀect of initiatives • 5,5 miliona evra pozitivnog uticaja efekata navedenih inicijativa na bilans uspeha (P&L) DOBAVLJAČI* PROIZVODNJA KONTROLA KVALITETA APOTEKE SUPPLIERS* PRODUCTION QUALITY CONTROL PHARMACIES KRAJNJI POTROŠAČI END CONSUMERS KONTROLA KVALITETA SKLADIŠTE SKLADIŠTE VELEDROGERIJE QUALITY CONTROL WAREHOUSE WAREHOUSE WHOLESALERS • Preko 700 dobavljača: potrošni materijal, sirovine, • More than 700 suppliers: consumption material, raw ambalaža, promotivni materijal, poluproizvod/bulk, material, packaging, promotional material, semifinisgotov proizvod/upakovan, usluge. hed, finalized good/packed, services • U lancu nabavke, nije bilo značajnijih promena u • There were no significant changes in the supply chain, odnosu na Izveštaj za 2017, kao ni negativnih uticaja in reference to 2017 Report, as well as no negative na okruženje. impacts on the environment. 45 ENTREPRENEURSHIP Šta je za nas preduzimljivost What entrepreneurship means to us 103-1 103-2 103-3 201-1 201-3 203-2 301-2 302-1 302-3 302-4 302-5 303-1 303-2 303-3 303-4 303-5 305-1 305-2 305-4 305-5 305-6 305-7 306-1 306-2 306-4 306-5 403-1 403-2 403-3 403-4 403-5 403-6 403-7 403-8 403-9 403-10 Svako od nas razvija nove ideje i inicijative, Each and every one of us drives new ideas and čime stvaramo budući rast i vrednost. actions, creating future growth and value. Poslovno okruženje koje je bazirano na vredThe business environment based on the values of nostima dostojanstvenog rada dodatno decent work is further empowered by the opporosnažuje prilika da svaki zaposleni iskaže i svoj tunity of each employee to express also his/her preduzetnički duh! Korporativna kultura koja entrepreneurial spirit! The corporate culture suppodržava kreativnost i inovativnost svakog porting creativity and innovation of each person ponaosob, omogućava postizanje boljih individually enables the achievement of better poslovnih rezultata u okviru kojih su odgobusiness results within which responsible provorna proizvodnja i potrošnja samo polazna duction and consumption are only the starting osnova. Ekonomski rast kompanije tada jeste point. Economic growth of the company is then tek logičan sled ovakvog pristupa poslovanju. only a logical follow-up of such an approach to busines.s Materijalne teme, koje su u fokusu, prema strateškom pristupu poslovanju i vezane za The materiality topics in focus, according to straovu vrednost su: tegic approach to business, with regard to this value include: • Razvoj ORGANIZACIONE EFIKASNOSTI i rast POSLOVANJA uz unapređenje • Development of ORGANISATIONAL tržišnih pozicija EFFICIENCY & BUSINESS OPERATIONS • Ostvarivanje i unapređenje growth with improvement of market BEZBEDNOSTI i ZDRAVLJA NA RADU positions • Odgovorno upravljanje potrošnjom • Achieving and improving OCCUPATIONAL VODE i smanjivanje generisanja OTPADA HEALTH AND SAFETY • Responsible WATER consumption management and reduced WASTE generation 47 Najznačajniji ﬁnansijski pokazatelji The most important ﬁnancial indicators Hemofarm a.d. beleži rast prihoda od prodaje Hemofarm A.D. recorded growth in income from u 2018. godini za 14,36% u odnosu na 2017. sales by 14.36% compared to 2017. godinu. u 000 RSD / in 000 RSD 31.12.2016. 31.12.2017. 31.12.2018. prihodi od prodaje / income from sales 26.409.722 26.263.215 30.035.802 Tržišta Intercompany interkompaniGroup Sales 6.456.089 2018 jske grupe (Hemomont, Hemofarm Banja Luka, 3.000.728 2017 (Hemomont, Rumunija i Banja Luka, Hemopharm 2016 1.176.321 Rumunija i GMBH) Hemopharm GMBH) 13.878.602 Intercompany Intercompany Stada market Stada market 14.058.837 11.956.416 Direct sales to Direct sales to 9.701.111 the third the third parties parties (in the (in the country 9.203.649 country and and abroad) abroad) 13.276.985 STRUKTURA PROMETA TURNOVER STRUCTURE Izraženo u hiljadama dinara Stated in thousands of dinars U odnosu na 2017. godinu, rast beleži prodaja Sales to third parties in the country and abroad ka trećim licima u zemlji i inostranstvu. Na recorded a growth compared to 2017. There was interkompanijskim tržištima na nivou STADA a slight decline in intercompany markets at the Grupe dolazi do blagog pada, dok je na interSTADA Group level, while there was an increase kompanijskim tržištima Hemofarm grupe of revenues in the intercompany markets of došlo do porasta prihoda. Hemofarm Group. 48 Direktno generisana vrednost veća je za Directly generated value is higher by 14.17% 14,17% u odnosu na 2017. godinu, zahvacompared to 2017, owing to the increase in ljujući porastu prihoda od prodaje u 2018. income from sales in 2018. Distributed economic godini. Distribuirana ekonomska vrednost u value in 2018 recorded a growth of 1.21% 2018. godini beleži rast za 1,21% u odnosu na compared to 2017. 2017. godinu. PODACI IZ REVIDIRANIH IZVEŠTAJA NA DAN 31.12.2018. DATA FROM AUDITED STATEMENTS AS ON 31/12/2018 u 000 RSD 2017. 2018. in 000 RSD Direktno generisana vrednost 26.542.888 30.304.008 Directly generated value Distribuirana ekonomska vrednost 26.503.769 26.823.637 Economic value distributed Operativni troškovi 20.618.658 20.758.424 Operating costs Zarade zaposlenih i ostale nadoknade 5.522.978 5.356.559 Employees’ salaries and fringe beneﬁts Kamate za primljene kredite 223.322 167.369 Interest for loans received Porezi 113.009 481.251 Taxes Investicije u zajednicu 25.802 60.034 Investments in community Uvećanje ekonomske vrednosti kompanije 39.119 3.480.371 Increase in company economic value Kompanija u 2018. godini beleži značajno povećaCompany recorded a significant increase in nje ekonomske vrednosti, pre svega zahvaljujući economic value in 2018, primarily owing to the rastu direktno generisane vrednosti. growth of directly generated value. U 2014. Hemofarm a.d. započeo je implemenHemofarm AD started implementing a ten-year taciju korišćenja desetogodišnjeg poreskog tax incentive in 2014, which will result in signifipodsticaja, koja će imati za posledicu značajne cant savings for the company in the upcoming uštede kompanije u narednom periodu. U period. In 2018, tax savings amounted to EUR 2018. godini, poreska ušteda iznosi 2,31 milion 2.31 million (RSD 273,287,522). EUR-a ( 273.287.522 RSD). 49 Uticaj na okruženje Impact on environment Emisije gasova Gas Emissions U toku 2018. godine, za upotrebu u rashladIn the course of 2018, a total of 829.9 kg of ‘ozonoj tehnici, Hemofarmu je isporučeno ukupno ne-friendly’ freon was delivered to Hemofarm 829,9 kg „ozone-friendly“ freona, što je za for use in cooling technology, which is about oko 26,8 % manje nego u prethodnoj godini. 26.8% less than in the previous year. This inforOvaj podatak potvrđuje da su proizvodni mation confirms that production processes were procesi dodatno zaokruženi i optimizovani, additionally rounded-up and optimised, which čime se ostvaruje doprinos krovnoj strategiji represents contribution to the umbrella strategy kompanije koja je okrenuta ka postizanju što of the company which has focused on achieving pozitivnijeg uticaja na okruženje. as positive impact on the environment as possible. Količina isporučenih „ozone-friendly“ freona The quantity of delivered ‘ozone-friendly’ freon za upotrebu u rashladnoj tehnici u 2018. for the use in cooling technology in the year 2018 godini prikazana je na sledećom grafiku: is presented in the following graph: 768 800 700 525 600 500 360 400 305,1 259,9 300 210 200 79,1 60 90,4 100 0 R404A R507 R134A Potrošnja u 2016/kg Potrošnja u 2017/kg Potrošnja u 2018/kg Consumption in 2016/kg Consumption in 2017/kg Consumption in 2018/kg Upravljanje vodom Water Management Voda je i dalje jedan od najvažnijih resursa za Water is still one of the most important resources Hemofarm, koji se najviše koristi u procesu for Hemofarm, which is largely used in pharmaproizvodnje farmaceutskih proizvoda. ceutical products manufacturing process. Striving Nastojeći da svoje poslovanje učini što efikato make its business operations as efficient and snijim i odgovornijim, po pitanju uticaja na as responsible as possible in view of the impact okruženje, kompanija kontinuirano optimizuje on the environment, the company continuously 50 svoje proizvodne procese. Rezultat toga je u optimises its manufacturing processes. As a result, 2018. godini bilo smanjenje upotrebe vode za the consumption of water in 2018 was reduced by čitavih 8.5%, iako je proizvodnja bila rekordna as much as 8.5%, in spite of the record-breaking i porasla za čak milion pakovanja gotovih production, which was increased by as many as proizvoda.12 one million packs of finished products.12 Za svoje potrebe Hemofarm koristi vodu iz For its own needs, Hemofarm uses municipal javnog vodovoda i arteškog bunara. Gradska water and water from an artesian well. Municipal voda troši se u tehnološkim postupcima i za water is used in technological processes and for proizvodnju prečišćene vode (PW), vode za producing purified water (PW), water for injectiinjekcije (WFI) i čiste pare. Takođe, voda se ons (WFI) and clean steam. Water is also used koristi i za proizvodnju tehničke pare i tople for producing technical steam and hot water, as vode, kao i za funkcionisanje sistema za well as for the functioning of the cooling system hlađenje (rashladna voda) i sanitarne potrebe. (cooling water) and for sanitary purposes. The Ukupna zahvaćena količina vode iz javnog total quantity of withdrawn municipal water was vodovoda smanjena je sa 360.094 m3 u 2017. reduced from 360,094 m3 in 2017 to 354,947 m3 godini na 354.947 m3 u 2018. godini. Za razliku in 2018. As opposed to the previous years, lower od ranijih godina, zabeležena je manja potrošconsumption of water by 1.4% was recorded. The nja vode od 1,4%. Ukupna količina zahvaćene total quantity of water withdrawn from the artesian vode iz arteškog bunara smanjena je za 30,4% well was reduced by 30.4%, i.e. from 116,970 m3 odnosno sa 116.970 m3 u 2017. godini na in 2017 to 81,416 m3 in 2018. Hemofarm does 81.416 m3 u 2018. godini. Hemofarm svojim not jeopardise any of the water withdrawal resozahvatanjem vode ne ugrožava nijedan od urces by its withdrawal of water. resursa vodozahvata. Overview of total quantities of withdrawn water Pregled količina ukupno zahvaćene vode (u (in cubic metres), per source: kubnim metrima), po izvoru: 477.064 500.000 436.363 422.265 350.349 360.094 354.947 400.000 300.000 200.000 116.970 71.916 81.416 100.000 0 Ukupno Javni vodovod Arteški bunar Total Public water supply Artesian well system 2016 2017 2018 12 Hemofarm teži očuvanju resursa i kroz rekuperaciju i druge vidove ušteda. Jedan od takvih 12 Hemofarm makes every eﬀort to save resources through recuperation as well as though other primera je i tehnička para. Tehnička para u Hemofarmu nigde nema kontakt sa proizvodom, ways of saving. One of such examples is technical steam. Technical steam in Hemofarm has no te se u procesu proizvodnje tehničke pare sav kondenzat vraća u kotlarnicu na ponovnu contact with the product, so that in technical steam production process, the entire quantity of upotrebu. Time se, praktično, vrši kontinualna rekuperacija vode koja se koristi u procesu condensate gets returned to the boiler plant for reuse. This practically ensures continuous recuproizvodnje i upotrebe tehničke pare. Takođe, toplotna energija otpadne vode parnih peration of the water used in the process of production and use of technical steam. Likewise, the kotlova, koja bi se u regularnom radu odbacivala kao rezultat procesa desalinacije i uklanjaheating energy of the waste water from steam boilers, which is usually discarded as a result of the nja taloga iz parnog kotla, u Hemofarmu se koristi kao izvor toplote za pripremu sanitarne process of desalination and sediment removal from a steam boiler, is used in Hemofarm as a source tople vode u Pogonu sterilnih proizvoda. of heat for preparing sanitary hot water at the Sterile Products Plant. 51 Upravljanje potrošnjom električne energije i Managing Consumption of Electricity and Natural Gas prirodnog gasa Natural gas and electricity are used as primary Kao osnovni izvori energije u Hemofarmu energy sources in Hemofarm. Electricity is used koriste se prirodni gas i električna energija. in manufacturing processes, for operation of air Električna energija se koristi u proizvodnim compressors, chillers and HVAC. The largest conprocesima, za rad vazdušnih kompresora, sumers are exactly air compressors and chillers, čilera i HVAC. Najveći potrošači su upravo which use as much as 1/3 of the totally spent vazdušni kompresori i čileri, koji za proizvodnju electricity for production of compressed air and komprimovanog vazduha i vode za hlađenje cooling water in the production complex in Vršac. utroše čak 1/3 ukupne potrošnje električne energije za proizvodni kompleks u Vršcu. Overview of consumption of electricity (Vršac and Šabac complexes): Prikaz potrošnje električne energije (kompleksi Vršac i Šabac): Godina Električna energija, KWh Električna energija, GJ Year Electricity, KWh Electricity, GJ 2016 45.371.748 163.338.29 2017 47.278.126 170.201.25 2018 45.615.616 164.216.22 Potrošnja električne energije u 2018. smanjena Electricity consumption in 2018 was reduced by je za 3,6% u odnosu na prethodnu godinu.13 3.6% in relation to the previous year . The scheNa smanjenje potrošnje uticala je planska duled production downtime in August as well as obustava proizvodnje u avgustu, ali i sve bolje the increasingly improved consumption manageupravljanje samom potrošnjom. ment had an impact on the reduced consumption. Najviše prirodnog gasa troši se u odeljeThe largest quantity of the natural gas is consumed njima za hemijsku pripremu vode: 34,2% at the chemical water treatment departments: proizvedene toplotne energije potrebno je za 34.2% of the produced heat is required for proproizvodnju prečišćene vode, vode za injekduction of purified water, water for injections and cije i čiste pare u Vršcu. Ostali veći segmenti clean steam in Vršac. The other larger segments potrošnje prirodnog gasa su grejanje prostora of consumption of natural gas are heating of i drugi tehnološki procesi. premises and other technological processes. Prikaz potrošnje gasa: Overview of gas consumption: Godina Gas, m3 Year Gas, m3 2016 6.135.542 2017 6.830.641 2018 6.452.489 Smanjenje utroška gasa u 2018. za 5,5% The reduction in gas consumption by 5.5% in rezultat je planske obustave proizvodnje u 2018 was a result of the scheduled production avgustu, ali i primenjenih mera poboljšanja downtime in August, but also of the implemenenergetske efikasnosti u upravljanja potrošted measures for improving energy efficiency njom. Kao i kada se posmatra utrošak vode i in consumption management. Similarly to the 13 Od čega je 36,713,124 kWh bila potrošnja u Vršcu, a 8,902,492 kWh u Šapcu. 13 36,713,124 kWh was the consumption in Vršac, while 8,902,492 kWh were consumed in Šabac. 52 električne energije, smanjenje potrošnje gasa consumption of water and electricity, the reduje još značajnije, ako se uzme u obzir rast ction of gas consumption is even more significant obima proizvodnje. in view of the increase in production volume. Hemofarm neprekidno razmatra potencijale za Hemofarm is constantly considering potentials realizaciju strateških, ali i taktičkih inicijativa i for implementation of strategic as well as tactical projekata u domenu upravljanja energijom i initiatives and projects in the domain of electricity energetske efikasnosti, uz uvažavanje principa management and energy efficiency, while obserodrživog razvoja. Kompanija nastoji da, pored ving the principles of sustainable development. In kratkoročnih aktivnosti, pomeri fokus na sredaddition to the short-term activities, the company njoročne i dugoročne investicione projekte, is striving to shift the focus to mid-term and longkojima bi se obezbedila još veća stabilnost i term investment projects, which would ensure održivost poslovanja, a samo neki od aktueleven better stability and sustainability of business nih primera energetske efikasnosti su: operations. We are going to mention just a few of the current examples of energy efficiency: • Zamena ﬂuo cevi LED osvetljenjem u 2018. nastavljene su aktivnosti na kon• Replacement of ﬂuorescent tubes by LED tinuiranoj modernizaciji osvetljenja, lights – activities on continuous modernimontažom 1.330 novih LED sijalica. sing of lighting were resumed in 2018 by • Smanjenje toplotnih gubitaka na cevovomounting 1,330 new LED lights. dima tehničke pare i kondenzata tokom • Reduction of heat loss on technical steam 2018. nastavljeno je sa ugradnjom „izolaand condensate pipelines – the fitting cionih jakni“14 na ventile u sistemima za of insulation jackets 14 on valves on the distribuciju tehničke pare i kondenzata; systems for distribution of technical steam implementacijom četvrte i pete faze „izoand condensate continued in 2018; by lacionih jakni“ u Vršcu ukupan finansijski the implementation of the fourth and fifth benefit je uvećan za dodatnih 6.390 evra phases of insulation jackets in Vršac, the godišnje. U pogonu u Šapcu završeno total financial benefit was increased by je više od 50% planiranih montaža ovih additional EUR 6,390 per annum. More „jakni“. than 50% of the planned installation of the • Korišćenje otpadne toplote čilera za ‘jackets has been completed in Šabac. grejanje Pogona čvrstih formi u cen• Utilisation of the waste heat from chillers tralnom proizvodnom kompleksu u for heating of the Solid Dosage Forms Plant Vršcu tokom 2018. realizovan je prvi the first project of implementation of the projekat implementacije modula Total Total Heat Recovery15 (THR) module, which Heat Recovery15 (THR), koji omogućava facilitates the use of waste heat , was comkorišćenje „otpadne toplote“. Na osnovu pleted at the central manufacturing complex podataka prikupljenih na mernim uređain Vršac in the course of 2018. Based on jima tokom prve grejne sezone, u 2018. the information collected from measuring je ostvarena ušteda od 58.000 evra, dok devices during the first heating season, the je ukupna jednogodišnja ušteda ovog savings of EUR 58,000 were achieved in postrojenja (pri aktuelnim cenama ener2018, while the total annual savings in this genata) procenjena na 68.400 evra. plant (given the current energy prices) has been estimated at EUR 68,400. 14 Montažno-demontažni elementi koji doprinose umanjenju toplotnih gubitaka usled 14 The mounting/dismounting elements which contribute to the reduction of heat loss due to the zračenja na ventilima koji rade na visokoj temperaturi, po preporuci IFC (International emissions at the valves which operate at high temperatures, according to the recommendation of Finance Corporation), članice Grupe Svetske banke (World Bank Group). Očekuje se da IFC (International Finance Corporation), a member of the World Bank Group. The return on this će se ova investicija isplatiti u roku manjem od jedne godine, uz smanjivanje toplotnih investment is expected in less than a year, with reduction in heat loss to only 11-20% at the valves gubitaka na ovako izolovanim ventilima trebalo bi da bude svega 11-20% u odnosu na one insulated in such a manner in comparison with those which have not been insulated. neizolovane. 15 The chiller primarily produces cooling energy and in this process heat is released from the 15 Čiler primarno proizvodi rashladnu energiju i u tom procesu iz radnog ﬂuida odvodi se working utility. Instead of being discharged into the atmosphere, the heat released in such a mantoplota. Ta odvedena toplotna energija („otpadna toplota”), kroz THR modul čilera, umesto ner (‘waste heat’) through the THR module of the chiller is being used for heat supply which can da se izbacuje u atmosferu koristi se za isporučivanje toplotne energije u vrednosti i do reach up to 130% of the cooling capacity of the chiller. The return on this investment is expected 130% od rashladnog kapaciteta čilera. Ova investicija se može isplatiti za manje od dve in less than two heating seasons, which has already been confirmed through the monitoring of grejne sezone, što je već potvrđeno praćenjem potrošnje. Značajan deo projekta realizovan consumption. A considerable portion of the project has been implemented with in-house resourcje internim resursima i THR modul je pušten u rad krajem februara; testiranja kapaciteta i es and THR module was put into operation in the end of February. The capacity and performance učinka u različitim režimima rada i pri različitim spoljnim temperaturama, koja su obavljena tests ran at diﬀerent operation modes and at diﬀerent outdoor temperatures in 2018, have gone tokom 2018, nadmašila su očekivanja. Pokazalo se da je postrojenje u mogućnosti da beyond the expectations. It was proved that the plant was capable of supplying heat to the Solid snabdeva PČF toplotnom energijom potpuno samostalno, bez dogrevanja parom, dok su Dosage Forms Plant completely independently, without additional heating with steam, as long as spoljne temperature „iznad nule“. the outdoor temperatures were above zero. 53 • Poboljšanje sagorevanja na gorioni• Improvement of combustion on steam cima parnih kotlova implementacija boiler burners by implementing oxygen sistema za kontrole sadržaja kiseocontent control system16 heat losses with nika16 primenom ovog sistema, gubici combustion products are reduced through toplote sa produktima sagorevanja se the application of this system, while the umanjuju, a očekivane godišnje uštede expected annual savings are estimated se procenjuju na 1% ukupnog utroška at 1% of the total fuel consumption. This goriva. Ovaj projekat je dovršen u 2017. project was completed in 2017, which godini, što je u 2018. omogućilo uštedu yielded the savings of EUR 16,370 in 2018. od 16.730 evra. Dodatni benefit ovog An additional benefit of this system is a sistema je smanjenje emisije azotnih reduction in emissions of nitrous oxides oksida i ugljen-monoksida. and carbon monoxide. • Rekonstrukcija sistema za pripremu • The reconstruction of the system for prepatople sanitarne vode u Pogonu čvrstih ration of warm sanitary water at the Solid formi u Vršcu marta 2018. dovršena Dosage Forms Plant in Vršac implementaje realizacija projekta rekonstrukcije tion of the project of reconstruction of the sistema za pripremu tople sanitarne system for preparation of warm sanitary vode u ovom pogonu. Umesto starog i water in this plant was completed in March dotrajalog rezervoara sanitarne vode, 2018. In place of the old and run-down sada se koristi novi i ekonomičan. sanitary water tank, a new and economic Zagrevanje vode se vrši korišćenjem one is used now. The water is heated using „otpadne toplote“, nusproizvoda the waste heat , the by-product of regular regularnog rada sistema prikupljanja operation of the condensate collection kondenzata, koji umesto uobičajenog system, which now becomes a heating ispuštanja u atmosferu, sada postaje resource instead of being routinely discgrejni resurs. Realizacijom ovog projekta harged into the atmosphere. The costs of smanjeni su troškovi grejanja i eliminiheating have been reduced while the costs sani troškovi održavanja starog sistema. of maintenance of the old system have U 2018. je ostvarena ušteda od 9.640 been eliminated by the completion of this evra, a jednogodišnja ušteda (pri aktuelproject. Savings of EUR 9,640 were achieved nim cenama energenata) procenjena je in 2018, while the annual savings were na 14.700 evra. estimated at EUR 14,700 (given the current energy prices). 16 Na osnovu kontinualnog merenja sadržaja kiseonika u produktima sagorevanja može 16 The burner operation can be controlled based on continuous measuring of oxygen content se upravljati radom gorionika. Time se u svakom trenutku sadržaj kiseonika i vrednost in products of combustion. The oxygen content and the value of the coefficient of excessive air koeficijenta viška vazduha za sagorevanje održavaju na optimalnom nivou, prema karakterfor combustion are thus maintained on the optimal level at all times, in accordance with the istikama goriva. characteristics of the fuel. Odgovorno upravljanje otpadom Responsible waste management Održivi razvoj je priča o „uticaju“ kompanija na The sustainable development is about the ‘impact’ društvo i okruženje. U tom kontekstu, važan of companies on society and environment. In this aspekt predstavlja i otpad koji nastaje kao context, the waste generated as a result of perforposledica vršenja svake delatnosti, a posebno ming any activity, especially production, represents proizvodnje. Iako se Hemofarm, kao i sama an important aspect. In spite of the fact that farmaceutska industrija, svrstava u „bele“ Hemofarm, like the pharmaceutical industry itself, industrijske grane, koje nisu veliki zagađifalls under the ‘White Category’ of industries, which vači niti obimni generatori otpada, kompanija are not large polluters or large waste generators, sa posebnom pažnjom pristupa upravljanju the company nevertheless pays special attention to otpadom. Kao i kod ostalih farmaceutskih prowaste management. As any other pharmaceutical izvođača, Hemofarm generiše otpad koji nastaje manufacturer, Hemofarm generates waste created kako u samom procesu proizvodnje, tako i u in the manufacturing process itself, as well as in čitavom životnom ciklusu farmaceutskog proithe entire life cycle of a pharmaceutical product. zvoda. Otpad koji se generiše u okviru delatnosti The waste generated in the course of Hemofarm’s Hemofarma moguće je klasifikovati u: business activities can be classified as: • otpad nastao izvan proizvodnih lokacija • waste generated outside the manufacturing kompanije i sites of the company; and • industrijski otpad, koji je nastao u • industrial waste, generated in the manufaokviru proizvodno-poslovnih kompleksa cturing and business facilities of the kompanije company In accordance with legal regulations, Hemofarm U skladu sa zakonskom regulativom, Hemofarm has no direct contact with the end users of nije u direktnom kontaktu sa krajnjim korisniproducts, because of which it cannot collect cima proizvoda, zbog čega nije u mogućnosti the waste packaging material of its products da prikuplja otpadnu ambalažu od svojih prothe life cycle of which has finished. Therefore, izvoda čiji je životni ciklus završen. Zato the company meets its obligations indirekompanija svoje obaveze ispunjava posredno, ctly, in line with the national Plan for Reducing u skladu sa nacionalnim Planom smanjenja Packaging Material Waste.17 According to this ambalažnog otpada.17 Hemofarm, prema tom Plan, Hemofarm shall collaborate with the autPlanu, sarađuje sa ovlašćenim operaterom, koji horised operator that undertakes the obligation preuzima na sebe obavezu da se pomenuta to dispose of the above-mentioned packaging ambalaža zbrine na pravilan način.18 material in the proper manner.18 17 Njime su utvrđeni opšti ciljevi u pogledu ponovnog iskorišćavanja i reciklaže ambalažnog 17 It stipulates general goals with regard to reuse and recycling of packaging material waste, as otpada, kao i specifični ciljevi za reciklažu papira/kartona, plastike, stakla, metala, drveta iz well as specific goals for recycling of paper/cardboard, plastic, glass, metal, and wood from waste ambalažnog otpada. packaging material. 18 Uglavnom pakovanja i transportna ambalaža, te uputstva o leku, od materijala koji mogu 18 Chieﬂy cartons and transportation packaging material, as well as patient information leaﬂets, biti predmet recikliranja. made of materials which can be subject to recycling. Količina ambalaže za koju je obaveza upravljanja preneta na operatera Quantity of packaging material with management liability transfered to operator 31.888 t 743.454 t 590.570 t Plastika (PET) Plastic (PET) packaging ambalaža material Staklo Glass 334.641 t Aluminijum Aluminium 105.496 t Papir i karton Paper and cardboard Drvo (palete) Wood (pallets) Druge vrste Other types of 1.167.196 t ambalaže packaging material Pregled kretanja industrijskog otpada, po Overview of industrial waste trend, according vrsti (opasan/neopasan) kao i po upotrebnoj to type (hazardous/non-hazardous) and usage vrednosti (ima/nema upotrebnu vrednost) u value (with/without usage value) in tonnes for the tonama za 2018. godinu prikazan je u tabeli i year 2018 is presented in the table and the graph grafiku ispod. below. 2018. godina Generisano Predato Year 2018 Generated Handed over Ukupno neopasan otpad 619.806 616.576 Total non-hazardous waste Neopasan otpad koji ima upoNon-hazardous waste with usage trebnu vrednost (predat ovlašćenim value (consigned to authorised operators 603.086 603.086 operaterima na moguću reciklažu) for possible recycling) Neopasan otpad koji nema upoNon-hazardous waste without trebnu vrednost (predat ovlašćenim usage value (consigned to authori16.720 13.490 operaterima na deponovanje) sed operators for disposal) Ukupno opasan otpad 173.388 192.501 Total hazardous waste Opasan otpad koji ima upotrebnu Hazardous waste with usage value vrednost (predat ovlašćenim operate(consigned to authorised operators for 8.027 8.270 rima na moguću reciklažu) possible recycling) Opasan otpad koji nema upotrebnu vrednost 165.361 184.231 Hazardous waste without usage value Samostalno izvezen 170.48 Exported individually Predat operaterima 13.751 Consigned to operators UKUPNO (opasan i neopasan) 793.194 809.077 TOTAL (hazardous and non-hazardous) 56 Hemofarm je u 2018. generisao ukupno In the year 2018, Hemofarm generated a total 793,194 tone industrijskog otpada, od of 793,194 tonnes of industrial waste, 173,388 t čega 173,388 t opasnog otpada. Od ukupne of which was hazardous waste. Out of the total količine opasnog otpada koji nema upotrebnu quantity of hazardous waste which does not have vrednost Hemofarm je samostalno izvezao usage value, Hemofarm individually exported 170,48 tona (93%), nakon obnavljanja dozvole 170.48 tonnes (93%), having renewed the licence za samostalni izvoz od nadležnog ministarstva. for individual export with the responsible ministry. Neopasan otpad koji ima upotrebnu vrednost The non-hazardous waste which has usage value i koji se može reciklirati (603,086 t) predat je and which can be recycled (603,086 t) was consioperaterima na dalju obradu. gned to operators for further processing. Količina reciklabilnog neopasnog otpada predate operaterima Quantitites of recyclable non-hazardous waste consigned to operators 38,87 t Papirna i Paper and cardboard 41,39 t 1,07 t kartonska packaging material 24,03 t ambalaža Plastična Plastic packaging 117,38 t ambalaža material 251,63 t Drvena Wood packaging ambalaža material Metalna Metal packaging ambalaža material Staklena Glass packaging ambalaža material Gvožđe i Iron and steel čelik packaging material 133,58 t Uprkos porastu proizvodnje (za 1%), Hemofarm je u 2018. generisao manje otpada u odnosu Notwithstanding the increase in production (by na prethodnu godinu, i to: 1%), Hemofarm generated less waste in 2018 in relation to the previous year, specifically: • 4,6% manje opasnog otpada i • 1,5% manje neopasnog otpada. • 4.6% less hazardous waste; and • 1.5% less non-hazardous waste. Ovi podaci, a posebno nelinearno smanjenje This information, especially the nonlinear reduotpada, najbolje svedoče o visokom nivou ction of waste, are the best illustration of the high optimizovanosti proizvodnih procesa u komlevel of optimisation of manufacturing processes paniji i najvišem nivou svesti menadžmenta in the company and the highest level of awareHemofarma o značaju smanjivanja neminess of Hemofarm’s management about the novnih pratećih činilaca proizvodnje, ali i importance of reducing the unavoidable accompotrošnje lekova. panying by-products of manufacturing as well as consumption of medicinal products. 57 Bezbednost i zaštita zdravlja na radu Occupational health and safety Bezbedan i zdrav tim sigurna je investicija za A safe and healthy team is a reliable investment in uspešnu budućnost successful future Bezbednost i zaštita zdravlja na radu sve više Occupational health and safety are increasingly dobijaju na značaju, kako u poslovnoj javnosti, gaining in importance in both the business and tako i u široj društvenoj zajednici. Hemofarm, wider social community. Hemofarm, as a responkao odgovorna kompanija i pozitivan primer sible company and a good practice example19, iz prakse,19 nastoji da ukaže kako svojim seeks to point out not only to its employees, but zaposlenima, tako i dobavljačima i lokalnim also to its suppliers and local communities it zajednicama u kojima posluje, da bezbedno i operates in, that there is no substitute for safe zdravo radno okruženje nemaju kompromis. and healthy working environment. Ključna reč za bezbednost i zaštitu zdravlja na The key word for occupational health and radu u Hemofarmu jeste prevencija. Niz sinsafety in Hemofarm is prevention. A number hronizovanih i povezanih aktivnosti, baziranih of synchronized and related activities, based on na najsavremenijim tehnologijama, usmerene state-of-the-art technologies, are focused primarsu prvenstveno na prevenciju i edukaciju. ily on prevention and education. The company Bezbednost zaposlenih, poslovnih partnera, achieves the safety of its employees, business dobavljača, resursa i okruženja, kompanija partners, suppliers, resources and the environostvaruje putem sistema video nadzora, sopment through video surveillance systems, its own stvene službe fizičko tehničkog obezbeđenja,20 physical-technical security service20, fire detecjavljača požara21 i sopstvene profesionalne tors21, and its own professional fire brigade22. For vatrogasne jedinice.22 Zakonska regulativa je Hemofarm, legal regulations are only the starting za Hemofarm tek polazna osnova za najviši point for the highest level of occupational safety stepen bezbednosti i zaštite zdravlja na radu, and health, and the company has been certified a kompanija je sertifikovana u pogonima also for the integrated environmental protection u Vršcu, Šapcu i Dubovcu i za integrisani management system (ISO 14001) and occupasistem upravljanja zaštitom životne sredine tional health and safety management system (ISO 14001) i sistem upravljanja bezbedno(OHSAS 18001) in Vršac, Šabac, and Dubovac šću i zdravljem na radu (OHSAS 18001). Na plants. There are ’info scoreboards’ installed at all svim proizvodnim lokacijama Hemofarma Hemofarm production sites, showing the number postavljeni su „info semafori“ na kojima je of occupational injuries at a particular site in the prikazan broj povreda na radu na konkretcurrent year, number of days without injury and noj lokaciji u tekućoj godini, broj dana bez the date of the last injury.23 These ‘scoreboards’ povreda i datum poslednje povrede.23 Ovi have in many ways raised the awareness of people „semafori“ višestruko su unapredili svest ljudi about the importance of preventive actions in 19 Povodom 28. aprila – Svetskog i Nacionalnog Dana bezbednosti i zdravlja na radu, Minis19 On the occasion of marking April 28th – The World and National Occupational Safety and tarstvo za rad, zapošljavanje, boračka i socijalna pitanja i Uprava za bezbednost i zdravlje na Health Day, the Ministry of Labour, Employment, Veteran and Social Policy and the Directoradu više puta su nagradili Hemofarm u ovoj oblasti. rate for Occupational Safety and Health have repeatedly awarded Hemofarm in this area. 20 Svaki član ove službe, po zapošljavanju u Hemofarmu, prolazi obaveznu obuku za 20 Each member of this Service, upon employment with Hemofarm, passes a mandatory trainpoštovanje ljudskih prava, uz kontinuirane reobuke i provere znanja. ing on the observance of human rights, with continuous re-trainings and knowledge tests. 21 Sve prostorije u Hemofarmu opremljene su sistemima i opremom za dojavu, detekciju i 21 All premises in Hemofarm are equipped with fire signalling, detecting and extinguishing gašenje požara, protivpožarnim klapnama, panik rasvetom i sl. systems and equipment, fire ﬂaps, panic lighting, etc. 22 Vatrogasna jedinica je na raspolaganju kako Hemofarmu, tako i za hitne potrebe vršačke 22 The fire brigade is available to both Hemofarm and Vršac municipality and surrounding opštine i okolnih naselja. settlements in emergency situations. 23 U Hemofarmu je postavljena adekvatna horizontalna i vertikalna signalizacija, uz 23 Adequate horizontal and vertical signalization with indicated movement paths for pedesnaznačene putanje kretanja pešaka i vozila, kao i brzinomer za kontrolu kretanja. trians and vehicles, as well as a speedometer for movement control has been installed in Hemofarm. 58 o značaju preventivnih mera u bezbednosti i occupational safety and health, as well as the zaštiti zdravlja na radu, kao i važnost prijavimportance of reporting any situation or event ljivanja svake situacije ili događaja koji mogu that may be unsafe (’near miss’ ). Hemofarm’s biti nebezbedni („near miss“24). Hemofarmov Safety Committee plays an important role in Odbor za bezbednost25 ima važnu ulogu u defining and implementing a number of actividefinisanju i sprovođenju niza aktivnosti za ties for each workplace to be safe and secure. In bezbedno i sigurno svako radno mesto. Osim addition, as the best link between the managetoga, kao najbolja veza između menadžmenta i ment and employees, it also participates in the zaposlenih, učestvuje i u istragama potencijalinvestigation of possible incidents and giving nih incidenata i davanju predloga i sugestija za proposals and suggestions for system improveunapređenje sistema,. Tokom 2018. godine, u ment. Inspections and tests of equipment for sklopu preventivnih mera, izvršeni su pregledi work and personal protection, electrical installai ispitivanja opreme za rad i ličnu zaštitu, elektions, and environmental working conditions as tričnih instalacija i uslova radne sredine, kao well as safety management of chemicals, which i bezbednost upravljanja hemikalijama, koja is regulated by in-house procedures and legal je regulisana internim procedurama i zakonregulations , were carried out within preventive skom regulativom.26 Edukacija svih zaposlenih actions during 2018. Education of all employees predstavlja jednu od najvažnijih preventivnih is one of the most important preventive actions mera u Hemofarmu, jer osposobljava za prein Hemofarm, because it enables them to identify poznavanje potencijalnih opasnosti i primenu possible hazards and apply protective actions mera za zaštitu od njih. against them. Tokom 2018. izvršeno je 1.285 obuka (2.108 u During 2018, 1,285 trainings (2,108 in 2017) were 2017.) iz bezbednosti i zaštite zdravlja na radu, carried out in the field of occupational health and zaštite životne sredine, zaštite od požara, presafety, environmental protection, fire protection, vencije udesa i usklađenosti poslovanja, a svi accident prevention, and the compliance, and all zaposleni su prošli i testiranje opšteg znanja employees passed the general knowledge test iz navedenih oblasti. Oni su učestvovali i u in the specified fields. They also participated in redovnim vežbama evakuacije u slučaju vanregular emergency evacuation exercises at the rednih situacija u fabrikama u Vršcu, Šapcu i factories in Vršac, Šabac, and Dubovac, in accordDubovcu, u skladu sa internim procedurama ance with the company in-house procedures. In kompanije. Takođe, nastavljeno je stručno addition, professional training for providing first osposobljavanje za Pružanje prve pomoći aid (basic and advanced training), as well as pro(osnovna i napredna obuka), kao i stručno fessional training for safe operation of forklift osposobljavanje za bezbedno rukovanje trucks and other means of in-house transporviljuškarima i ostalim sredstvima unutrašnjeg tation, professional training for work with tanks transporta, stručno osposobljavanje za rad sa under pressure, as well as professional training sudovima pod pritiskom kao i stručno osposofor work in transformer substations, has been bljavanje za rad u trafo-stanicama. continued. Hemofarm bezbednosti i zaštiti zdravlja na Hemofarm has equal approach to the occuparadu svojih dobavljača pristupa jednako kao i tional health and safety of its suppliers, as to za svoje zaposlene. U okviru redovnih provera, its own employees. The solvency of business utvrđuje se i solventnost poslovnih partnera, partners, fulfilment of legal conditions for work, ispunjenost zakonskih uslova rada, kao i as well as degree of compliance with occupational stepen uvažavanja mera bezbednosti i zdravlja health and safety requirements are determined na radu. Zato svaki dobavljač pre otpočiwithin regular audits. Therefore, prior to the njanja saradnje prilaže potvrde o plaćenom beginning of cooperation, each supplier submits 25 U skladu sa zakonskom regulativom i Pojedinačnim Kolektivnim ugovorom o bezbednosti 25 U skladu sa zakonskom regulativom i Pojedinačnim kolektivnim ugovorom o bezbednosti i zdravlju na radu. i zdravlju na radu. 26 Na Intranetu se nalazi baza hemikalija sa uputstvima za bezbedno rukovanje i ponašanje 26 Na Intranetu se nalazi baza hemikalija sa uputstvima za bezbedno rukovanje i ponašanje u eventualnim opasnim situacijama, dostupna svim korisnicima. u eventualnim opasnim situacijama, dostupna svim korisnicima. 59 porezu, izjave o poštovanju ljudskih prava i certificates of paid tax, statements on the obserprava zaposlenih, zatim dokaze da su radnici vance of human rights and employees’ rights, prijavljeni, uz popunjavanje Kvalifikacionog evidence that the workers have been regisi BSCI upitnika.27 Tek nakon pozitivno ocenjetered, and fills out the Qualification and BSCI nih upitnika, potpisuje se obavezujući Aneks o questionnaire27. Only after questionnaires have bezbednosti i zdravlju na radu, zaštiti životne been positively assessed, the binding Annex on sredine i zaštiti od požara. Tokom 2018. u Occupational Health and Safety, Environmental Hemofarmu svakodnevno je bio prisutan veliki Protection and Fire Protection is executed. During broj izvođača radova, a njihova bezbednost i 2018, a large number of contractors were present zaštita zdravlja bile su na prvom mestu: in Hemofarm on a daily basis, and their safety and health protection were the top priority: • u centralnom fabričkom kompleksu u Vršcu, boravilo je 216 firmi koje su • there were 216 companies with about 7,500 izvodile neku vrstu radova sa oko 7.500 employees who performed some type of zaposlenih, dok je works in the central factory complex in • u šabačkom kompleksu taj broj iznosio Vršac, while oko 84 firme sa oko 4.000 zaposlenih. • that number amounted to approximately 84 companies with about 4,000 employees in Najveću nagradu za sav uloženi trud, kao i the Šabac complex. potvrdu da su složene procedure neophodne, The fact that none of contractors’ workers suﬀered predstavlja činjenica da nije bilo povreda na any injury at work represents the greatest recradu ni jednog od radnika izvođača radova. ognition for all invested eﬀorts, as well as a confirmation that the complex procedures are Analizu stanja bezbednosti i zdravlja na radu u necessary. 2018. prikazuje sledeća tabela: An overview of the occupational safety and health status in 2018 is outlined in the following table: Indikator performansi 2016 2017 2018 Performance Indicator Broj zaposlenih Headcount 2.323 2.184 2.342 Broj povreda na radu Broj povreda na radu 21 19 14 Broj obuka/kurseva Služba za BiZ Number of injuries at work 4.601 2.108 1.285 % broja povreda u odnosu na ukupan broj zaposlenih % of number of injuries compared to the total number of employees 0.9 0.85 0.60 Prosečan broj dana odsustvovanja sa posla Average number of days of absence from work 26.6 31.7 62.3 Broj izgubljenih časova usled akcidenta na milion časova rada Number of lost hours due to accidents per million working hours 966.91 1061.92 855.89 Broj registrovanih nebezbednih događaja Number of recorded near misses 20 30 67 Svaki zaposleni je ostvario 1.776 sati rada (222 Each employee achieved 1,776 working hours (222 radna dana), što je ukupno 4.159.392 sata working days), which totals 4,159,392 working hours rada (za svih 2.342 zaposlenih). Izgubljeno je (for all 2,342 employees). There were 445 working 445 radnih dana28 (3.560 radnih sati) usled days28 (3,560 working hours) lost due to injuries. 27 Ove upitnike popunjavaju svi novi dobavljači koji su bili potencijalni poslovni partneri 27 These questionnaires were filled out by all new suppliers who were potential business Hemofarma u 2018. godini. Pored toga, u skladu sa specifičnim potrebama, potencijalni partners to Hemofarm in 2018. In addition, in accordance with the specific needs, potential izvođači radova dužni su da dostave i potvrde o obukama za bezbedan i zdrav rad, lekarska contractors are required to submit also safe and healthy work training certificates, medical uverenja, polise osiguranja, stručne nalaze, elaborate, procedure, pravilnike… certificate, insurance policies, expert findings, elaborated studies, procedures, rule books… 28 Broj izgubljenih časova usled akcidenta na milion časova rada smanjen je za 19,4%u 28 Number of lost hours due to accidents per million hours of work was decreased by 19.4% odnosu na 2017. godinu. compared to 2017. povreda. U odnosu na 2017. godinu zabeleženo A decrease in the total number of injuries by approxije smanjenje ukupnog broja povreda za 9,5% mately 30% was recorded, with a decrease in the OKO 30%, uz smanjenje procenta povređenih percentage of injured workers in relation to the total radnika u odnosu na ukupan broj zaposlenih headcount by 5.5%, compared to 2017. In addition, za 5,5%. Pored toga, pohvalna je i činjenica da the fact that the number of registered near misses je broj registrovanih nebezbednih događaja increased by 123% is also commendable, which is povećan za 123%, što nije posledica manje beznot the result of lower security in Hemofarm, but bednosti u Hemofarmu, već upravo višeg nivoa rather quite the opposite, of an increased level of svesti zaposlenih, zahvaljujući edukaciji o ovoj awareness of employees, owing to the education važnoj temi, što je presudan aspekt prevencije. on this important topic, which is a crucial aspect of prevention. U toku 2018. godine započelo je izveštavanje sa drugačijim indikatorima performansi procesa. Reporting with diﬀerent process performance Svrha izračunavanja stopa je dobijanje uniindicators started during 2018. The purpose of formnih rezultata koji se računaju na 200.000 calculating the rates is to obtain uniform results radnih sati i prosečan broj radnih dana u mesecu calculated per 200,000 working hours and average (18,5), a dobijeni rezultati su uporedivi za sve number of working days per month (18.5), and lokacije STADA grupe. Takođe, ovi indikatori su obtained results are comparable across all STADA u saglasnosti sa zahtevima novog standarda group sites. These indicators are also in compliance bezbednosti i zdravlja na radu, ISO 45001:2018, with the new Occupational Health & Safety standard koji će biti implementiran u toku 2019. na ISO 45001:2018, which will be implemented at Hemofarmovim proizvodnim lokacijama. Hemofarm’s manufacturing sites during 2019. . 61 2016 2017 2018 Broj zaposlenih u Hemofarmu / Headcount in Hemofarm Izvođači Broj zaposlenih sa punim radnim vremenom 2.323 2.184 2.341 radova: Full-time employees Contractors: 216 Broj zaposlenih sa pola radnog vremena 0 0 1 Part-time employees Akcidenti / Near Miss / Accidents / Near Miss Broj akcidenata sa fatalnim ishodom ili veoma teškim posledicama (gubitak ekstremiteta) na radu u posmatranom vremenskom periodu (ne računaju se povrede na radu prilikom dolaska i odlaska sa posla) 0 0 0 0 Number of accidents resulting in a fatality or major injury (amputation) at work during the observed period (accidents while commuting to work are excluded) Ukupan broj povreda na radu sa izgubljenim radnim danima (ne računaju se povrede na radu prilikom dolaska i odlaska sa posla) 21 19 14 0 Total number of injuries at work with lost time (accidents while commuting to work are excluded) Ukupan broj incidenata bez izgubljenog vremena (sitne povrede koje su sanirane pružanjem prve pomoći i dolazak hitne pomoćizaposleni nastavljaju sa radom posle zdravstvene intervencije) 0 0 6 0 Total number of accidents without lost time (minor injuries remedied by providing first aid and emergency service employees continue to work after a medical intervention) Ukupan broj near miss (uključujući near miss, nebezbedno stanje, nebezbedan događaj, nebezbedno ponašanje) 20 30 67 0 Total number of near miss reports (including near miss, unsafe condition, unsafe event, unsafe behaviour) Ukupan broj izgubljenih radnih dana usled povreda na radu (ne računaju se izgubljeni radni dani usled povreda na radu prilikom dolaska i odlaska sa posla) 567 603 445 0 Total number of lost working days resulting from injuries at work ((lost working days due to accidents while commuting to work are excluded) Ukupan broj izgubljenih radnih dana usled povreda na radu 4.125.648 3.878.784 4.158.504 Total number of working hours for all employees Izračunate vrednosti / Calculated numbers OSHA stopa incidenata sa izgubljenim radnim vremenom 1,0 1,0 0,7 0 OSHA incident rate with lost time Stopa Near miss događaja 1,0 1,5 3,2 0 Near miss rate U okviru Hemofarma dostupni su i stručni There are also expert associates available within saradnici za pružanje psihosocijalne podrške Hemofarm for providing psychosocial support to zaposlenima i njihovim porodicama, kako employees and their families in order to balance bi na najkvalitetniji način izbalansirali svoju their career and family life in the best quality karijeru sa porodičnim životom i tako se potmanner, and thus achieve full potential in both punije ostvarili na oba polja. Kompanija, pored fields. In addition to direct investments29, taking direktnih ulaganja29, brinući o unapređenju care of improving the health of its employees, zdravlja svojih zaposlenih, nudi i niz dodatnih the company also oﬀers a number of additional beneficija: osiguranje od posledica nesrećnog benefits: insurance against consequences of an slučaja (svih 24h, i na radu i van rada, ukljuaccident (24/7, both at work and out of work, incčujući nastanak invaliditeta ili gubitak života), luding the occurrence of disability or loss of life), dobrovoljni penzioni fond30 (zarad dobrih voluntary pension fund30(for good living conuslova života i po odlasku u penziju), dobroditions also upon retirement), voluntary health voljno zdravstveno osiguranje (namenjeno insurance (intended to all employees, covering svim zaposlenima a pokriva troškove lekova, costs of medicines, specialist examinations, trespecijalističkih pregleda, lečenja, operacija atment, surgical interventions, etc.), as well as i sl.), kao i Fond solidarnosti (finansiranje Solidarity Fund (financing the work of sports rada sportskih sekcija i rekreacije zaposlesections and recreation of employees, finannih; pomoć usled bolesti i bolovanja dužeg cial aid for illness and sick leave longer than 6 od 6 meseci; pomoć zaposlenom za rođenje months, financial aid to an employee for birth and i usvojenje deteta, pomoć samohranim rodiadoption of a child, assistance to single parents, teljima, pomoć zaposlenom prilikom smrti assistance to an employee in case of death of člana uže porodice…). U Hemofarmu, u okviru a close family member...). The Voluntary Blood Fonda solidarnosti, već godinama funkcioniše Donor Section, with between 400 and 500 active i Sekcija dobrovoljnih davalaca krvi, u okviru donors at all times, has been functioning for years koje je u svakom trenutku aktivno između within the Hemofarm Solidarity Fund. In addition, 400 i 500 davalaca. Pored toga i Samostalni the Autonomous Trade Union also has available sindikat raspolaže sredstvima za organizofunds for organizing recreational events, sports vanje rekreacija, sportskih sekcija i sportskih sections, and sports gatherings of employees, susreta zaposlenih, pružanje pomoći u kriznim providing assistance in crisis situations, as well as situacijama, kao i za kontinuirano održavanje i continuous maintenance and improvement of the unapređenje prava radnika uopšte. employees’ rights, in general. 29 Koja obuhvataju: periodične lekarske preglede za određene poslovne pozicije, redovne 29 They include: periodical medical examinations for certain business positions, regular sanitary sanitarne i oftalmološke preglede, saradnju sa medicinom rada, osposobljavanje za and ophthalmological examinations, cooperation with occupational medicine, first aid training, pružanje prve pomoći, ispitivanje uslova radne sredine, opreme za rad i sredstava i opreme testing the working environment conditions, equipment for work and personal protection means lične zaštite, itd. and equipment, etc. 30 Kompanija uplaćuje 2.000 dinara mesečno zaposlenima koji su u neprekidnom radnom 30 The company pays RSD 2,000 dinars per month to employees who have been employed longer odnosu duže od tri godine, a koji iz svojih sredstava uplaćuju najmanje 1.000 dinara u ovaj than three years without interruptions, and who pay minimum RSD 1,000 of their funds to this fond. fund. INTEGRITY Šta je za nas integritet What integrity means to us 103-1 103-2 103-3 202-1 301-3 401-1 401-2 401-3 404-1 404-2 404-3 405-1 405-2 410-1 412-1 412-2 412-3 416-1 416-2 417-1 417-2 417-3 Svako od nas postupa etički u skladu sa Each and every one of us acts ethically in line with internim i eksternim standardima. Otvoreno the company’s internal and external standards. iskazujemo mišljenje i uzajamno se poštujemo Our actions are led by speaking up and respect. u svemu što radimo. Institution, company or brand with the highest Institucija, kompanija ili brend koji uživaju degree of integrity appears as most trustworthy najviši nivo integriteta ulivaju najveće povereto the people whom they wish to address with nje ljudima kojima žele da se obrate savetima advice on good health and well-being (UN Goal 3) o dobrom zdravlju i blagostanju (UN Cilj br. 3) or education (UN Goal 4). The essence is in this ili obrazovanju (UN Cilj br. 4). Upravo u tom very integrity! This is why Hemofarm is a reliaintegritetu leži smisao! Zato je Hemofarm ble counterpart for discussing prevention as the siguran sagovornik na temu prevencije, kao basis of good health, as well as when it comes osnove zdravlja, kao i kada je reč o razvoju to development of healthy life styles! In addition, zdravih životnih stilova! Takođe, isti taj integrithis very integrity empowers the company to be tet omogućava kompaniji da bude relevantan a relevant advocate and interlocutor on the subzagovornik i sagovornik o konceptu dualnog ject of dual education concept. Firmly believing in obrazovanja. Čvrsto verujući u suštinu dualnog the essence of dual education, Hemofarm oﬀers obrazovanja, Hemofarm nudi praktična znanja practical knowledge and internship to young i praksu mladima, koji su budući eksperti, kroz people, future experts, through collaboration saradnju sa stručnjacima Hemofarmovih tehwith the professionals from Hemofarm Technical ničkih operacija i drugih sektora. Operations and other divisions. Materijalne teme, koje su u fokusu, prema The materiality topics in focus, according to strastrateškom pristupu poslovanju i vezane za tegic approach to business, with regard to this ovu vrednost su: value include: • Odgovoran MARKETING i transparentne • Responsible MARKETING and transparent KOMUNIKACIJE uz maksimalnu dostuCOMMUNICATIONS with maximum availabipnost informacija lity of information • Razvoj PORTFOLIJA i optimizacija PALETE • PORTFOLIO development and PRODUCT PROIZVODA RANGE optimization 65 • Ostvarivanje KVALITETA i BEZBEDNOSTI • Achieving PRODUCT QUALITY and SAFETY in PROIZVODA prema farmaceutskim line with pharmaceutical standards standardima • Development and registration of NEW • Razvoj i registracija NOVIH PROIZVODA PRODUCTS that are contemporary, comforkoji su savremeni, komforni i pouzdani table and reliable • Uvažavanje potreba i ZADOVOLJSTVA • Respecting the needs and SATISFACTION KORISNIKA PROIZVODA uz proaktivan OF PRODUCT USERS with proactive attitude odnos prema reklamacijama to complaints • Motivacija i edukacija ZAPOSLENIH i kon• Motivation and education of EMPLOYEES tinuirani razvoj KORPORATIVNE KULTURE and continuing development of CORPORATE CULTURE Odgovoran marketing i transparentne i pouzdane komunikacije Responsible marketing and transparent and reliable communications S obzirom na to da je Cilj broj 3 održivog razvoja As Goal 3 of sustainable development – good – dobro zdravlje i blagostanje, najvažniji cilj health and well-being is the most important goal Hemofarma, kompanija na mnogobrojne načine of Hemofarm, company strives in numerous ways teži da doprinese njegovom ispunjavanju. Jedan to contribute to its achievement. Perhaps one of od možda najznačajnijih načina je pomeranje the most important ways to do it is to shift focus fokusa sa lečenja na prevenciju, što je kompafrom treatment to prevention, which the company nija već uradila, posebno kroz edukaciju opšte has already done, especially by educating general i stručne javnosti i zalaganje za razvoj zdravih and professional public and advocating for develživotnih stilova. Takav pristup svakog pojedinca opment of healthy lifestyles. Such an approach uključuje u menadžment sopstvenog zdravlja, involves each individual in managing their own dok istovremeno rasterećuje javni zdravstveni health, while simultaneously reducing the burden sistem. Farmaceutski marketing za Hemofarm on the public healthcare system. Pharmaceutical predstavlja visokoetičku kategoriju marketinga marketing for Hemofarm is a highly ethical cati svaka informacija koja se komunicira u vezi sa egory of marketing and every piece of informaproizvodima iz Hemofarmovog portfolija, osim tion communicated with regard to products from što je usklađena sa zakonskim okvirima, proveHemofarm portfolio, apart from being harmonized rena je, potvrđena i podržana odgovarajućim with the legal framework, has been checked, connaučnim referencama. Zato ne iznenađuje činjefirmed and supported by adequate scientific refernica što novi slogan, koji je uveden za celu STADA ences. It is, therefore, not surprising that the new Grupu, glasi: Naša misija – Vaše zdravlje. slogan, introduced for the entire STADA Group, is: Our mission – Your health. 66 Hemofarm se svesrdno zalaže za predstavljanje Hemofarm is fully committed to presenting theraterapijskih prednosti, namene i upotrebe farmapeutic advantages, indications and use of pharmaceutskih proizvoda, kroz aktivan dijalog za svim ceutical products through an active dialogue with zainteresovanim stranama, a posebno lekarima all stakeholders, especially doctors and pharmai farmaceutima. Istovremeno, kompanija cists. At the same time, the company encourages podstiče javnost na prijavu svih potencijalnih, pa the public to report all possible, even the smallest, čak i najmanjih, sumnji na neželjeno dejstvo leka. suspected adverse drug events. In this regard, Sa tim u vezi, kompanija se zalaže i da odgovorno the company advocates for responsible drug conkonzumiranje lekova, koje je u skladu sa zakonsumption, in line with legal regulations and based skim normama i bazirano isključivo na stručnom solely on expert authority of medical professionautoritetu medicinskih profesionalaca, što je als, which is especially important when it comes posebno važno kada je u pitanju odgovorno to responsible use of antibiotics. Hemofarm sees konzumiranje antibiotika. Hemofarm vidi veliku a great opportunity in the increasing use of digišansu u većoj upotrebi digitalnih platformi i alata, tal platforms and tools, i.e. digitization in general, tj. digitalizaciji uopšte, usmerenoj ka bližem upoaimed at familiarizing patients with proper use of znavanju pacijenata sa pravilnom upotrebom medicines, reminding them to take the medicine lekova, podsećanju da na vreme uzmu lek, ali i on time, but also providing health-related advice, pružanju zdravih saveta, te dvosmernog komuand two-way communication with doctors and niciranja sa lekarima i farmaceutima. Sve to pharmacists. All this together can significantly zajedno, značajno može da unapredi delotvorimprove the efficacy of medicines, which basically nost lekova, u čijoj osnovi se nalazi ispravna i depends on proper and timely administration of pravovremena konzumacija propisane terapije. the prescribed therapy. Primarna delatnost Hemofarma je proizvodnja Hemofarm’s core activity is the production of kvalitetnih, efikasnih, bezbednih i dostupnih good-quality, efficient, safe and aﬀordable pharfarmaceutskih proizvoda, koji su namenjeni maceutical products, intended for care of the peobrizi o zdravlju ljudi. Jedna od najvažnijih uloga ple’s health. One of the most important roles here u tome pripada savremenoj, pouzdanoj i širokoj belongs to contemporary, reliable and extensive paleti proizvoda, koju kompanija neprekidno product range, which is being continuously optioptimizuje. Hemofarm je lider na domaćem mized by the company. Hemofarm is the leader in farmaceutskom tržištu u konkurenciji od 26 the local pharmaceutical market competing with domaćih proizvođača i 34 distributera, sa 26 domestic manufacturers and 34 distributors, učešćem od 26,19% naturalno, tj. 12,03% with a share of 26.19% in packs, i.e. 12.03% in vrednosno. value terms. PROMETUJEMO PREPARATE U 12 (OD U PORTFOLIJU IMA 14) FARMAKOTERAPIJSKIH GRUPA PO ATC KLASIFIKACIJI 415 PROIZVODA RAZLIČITIH FORMI I DOZA WE SELL PRODUCTS IN 12 (OUT OF 14) PHARMACOTHERAPEUTIC GROUPS BY THE PORTFOLIO CONTAINS ATC CLASSIFICATION 415 PRODUCTS IN DIFFERENT FORMS AND DOSAGES PORTFOLIO FOKUSIRAN NA PREPARATI KOJI SE IZDAJU BEZ NAJBITNIJE FARMAKOTERAPIJSKE LEKARSKOG RECEPTA (OTC), GRUPE, POPUT PREPARATA ZAUZIMAJU LIDERSKU POZICIJU NA ZA KARDIOVASKULARNE FARMACEUTSKOM TRŽIŠTU SRBIJE, SA BOLESTI, ANTIBIOTIKE I NEUROUDELOM OD 16,2%, VREDNOSNO PSIHIJATRIJSKE PREPARATE 16,2% OTC MEDICINES ARE IN THE LEADING PORTFOLIO FOCUSED ON THE MOST POSITION IN THE SERBIAN PHARMA IMPORTANT PHARMACOTHERAPEUTIC MARKET, WITH A SHARE OF 16.2% IN GROUPS, SUCH AS DRUGS FOR VALUE TERMS CARDIOVASCULAR DISEASES, ANTIBIOTICS AND NEUROPSYCHIATRIC MEDICINES Hemofarm svoju podršku zdravstvenom sistemu Hemofarm shows its support to the healthcare iskazuje i kroz bogat portfolio farmaceutskih system by maintaining an extensive portfolio of proizvoda koji odgovaraju upravo kliničkoj pharmaceuticals which precisely match the clinislici Srbije, odnosno potrebama stanovništva i cal image of Serbia, that is, the needs of citizens pacijenata. and patients. PREPARATI HEMOFARMA U ODNOSU NA OSTALE VODEĆI PREPARATI NA TRŽIŠTU PROIZVOĐAČE (U MLN EUR)*: SRBIJE KOJI SE IZDAJU NA RECEPT (RX, PO INN-U)* SU: HEMOFARM PRODUCTS COMPARED TO OTHER MANUFACTURERS (IN EUR MIO)*: LEADING RX PRODUCTS (BY INN) IN THE SERBIAN MARKET ARE: C CARDIOVASCULAR SYSTEM 32/106 A ALIMENTARY TRACT & METABOLISM 12/102 • BROMAZEPAM N NERVOUS SYSTEM 19/92 • METFORMIN L ANTINEOPLASTIC & IMMUNOMOD AG 0/103 • DICLOFENAC R RESPIRATORY SYSTEM 6/68 • LORAZEPAM B BLOOD & BLOOD FORMING ORGANS 11/67 • BISOPROLOL J ANTIINFECTIVES FOR SYST USE 11/52 • AMOXICILLLIN, M MUSCULO – SKELETAL SYSTEM 7/36 CALVULANIC ACID G URINARY SYST & SEX HORMONE 3/30 • METOPROLOL H SYST HORM PREP EXCL SEX HORM 2/22 • AZITHROMYCIN D DERMATOLOGICALS 1/15 • ENALAPRIL S SENSORY ORGANS 1/11 • PROPAFENONE V VARIOUS 0/4 *Izvor: IMS baza za 2018. VODEĆI OTC PREPARATI NA TRŽIŠTU SRBIJE SU: LEADING OTC PRODUCTS IN THE SERBIAN MARKET ARE: 68 U cilju maksimalnog doprinosa zdravlju ljudi In order to give maximum contribution to peoi unapređenju kvaliteta života, Hemofarmove ple’s health and improvement of life quality, marketinške aktivnosti u 2018. rezultirale su znaHemofarm’s marketing activities in 2018 resulted čajnim poslovnim uspesima, koji, pored ostalog, in significant business success, including, among obuhvataju i sledeće: others, the following: • Rast proizvodnje ispratio je i rast • Sales growth kept pace with production prodaje, čemu su značajno doprinele i growth, whereby marketing, promotional Hemofarmove marketinške, promotivne and sales activities of Hemofarm contrii prodajne aktivnosti; stručni i agilni buted to this significantly; professional and timovi dva važna sektora marketinga i agile teams of two important divisions prodaje, pored pouzdanog predstavljanja marketing and sales, in addition to reliable karakteristika i primene proizvoda radi presentation of product characteristics and unapređenja terapije i prevencije, bili su administration in order to promote therapy prava podrška svim učesnicima domaćeg and prevention, were a true support to all farmaceutskog tržišta u cilju njegovog participants in the local pharmaceutical što boljeg osnaživanja, a na zadovoljstvo market in making it stronger, to the satisfapacijenata čija terapija treba da bude što ction of patients whose therapy should be komfornija i delotvornija. as comfortable and eﬀective as possible. • Lansirano je 7 novih proizvoda, u različitim formama i dozama, od kojih su 3 • 7 new products were launched, in diﬀerent jedinstveni na tržištu. forms and dosages, out of which 3 are • Ostvaren je i konstantan rast tržišnog unique in the market. udela i u grupama proizvoda koje su u padu (Pressing raste 10,5% a tržište • Constant growth of market share has been antihistaminika pada 5%), što je direktan achieved also in product groups which rezultat sinhronizovanog rada stručnih experience decline (Pressing recorded a medicinskih i prodajnih saradnika, pored growth of 10.5% while antihistamine market tradicionalnog kvaliteta Hemofarmovih decreased by 5%), which is a direct result of proizvoda, koji je već svima poznat i synchronized work of professional medical kome se veruje. and sales representatives, apart from the • Povećano učešće OTC/CHC proizvoda traditional quality of Hemofarm products, u odnosu na Rx za 5% za pacijente je which is already widely known and trusted. to korak bliže prevenciji, a za kompaniju mogućnost ostvarivanja stabilnije • Increased share of OTC/CHC products prodaje compared to Rx by 5% for patients it is • Povećanje prodaje proizvoda ostvareno a step closer to prevention, and for the je i kroz komercijalne i druge akcije company an opportunity to achieve more uz pomoć Velexfarm call centra, što je stable sales praćeno smanjenim operativnim troškovima (rast 13%, smanjena davanja za 5%) • Sales growth was also achieved by com• Dodatno je unapređen, usklađen i mercial and other promotions with the učinjen atraktivnijim i sveukupni vizuelni help of Velexfarm call centre, accompanied identitet medijskih kampanja, čime je by reduced operating costs (growth 13%, ostvarena jedinstvenost i prepoznatljireduced rebates by 5%) vost Hemofarmovih proizvoda u odnosu na konkurenciju; to olakšava izbor • The overall visual identity of media proizvoda od strane korisnika, sa punom campaigns was additionally improved, sigurnošću da iza njih stoji renomirani harmonized and made more attractive, domaći proizvođač, uz jasne savete čemu which led to uniqueness and recognisluži svaki konkretan proizvod, u skladu sability of Hemofarm products when sa zakonom. compared to competition; this makes it • Povećano je prisustvo na digitalnim easier for the user to choose the product, medijima i društvenim mrežama, kada with the utmost confidence that it comes je promocija OTC/CHC proizvoda u from a renowned domestic manufacturer, pitanju; proizvodi su praktično tamo gde with clear advice for use of each specific su konzumenti, uz nikad intenzivnije product, in accordance with the law. mogućnosti ostvarivanja kvalitetne i kontinuirane dvosmerne komunikacije; • Presence in digital media and social jedan od najboljih primera je i zalaganje networks has been increased, regarding za razvoj svesti ljudi i podrška u odvikapromotion of OTC / CHC products; products vanju od pušenja, uz mnoštvo saveta, are practically where consumers are, with tehnika i konkretnih preporuka, uz ever more intensive possibilities of achieneizostavni duh kolektivne podrške, koji ving high-quality and continuous two-way je kreirao čitavu jednu zajednicu ljudi communication; one of the best examples okupljenih oko digitalnih kanala Tabex-a, is support to raising people’s awareness preparata koji pomaže upravo u odvikaand helping them quit smoking, with a lot vanju od konzumiranja cigareta. of advice, techniques and practical recommendations, along with the indispensable • Nastavljena je edukacijom lekara i spirit of collective support, which created farmaceuta kroz programe kontinuan entire community of people gathered iranih medicinskih edukacija, kao i edukacija korisnika proizvoda. Jedan od primera je edukacija o potrebi dodatne zaštite od sunca u letnjim mesecima, radi smanjivanja štetnog uticaja UVA i around the digital channels of Tabex, the UVB zraka, kao i IR zračenja, sa prepoproduct which helps precisely in quitting rukama za primenu jedne od najboljih smoking. linija proizvoda za zdravo sunčanje na svetu – Ladival, kao i dva najnovija „ • Educating doctors and pharmacists was Aktiv“ oblika, koji najbolje do sada štite continued through CME programmes, as od sunca, a istovremeno omogućawell as education of product users; one of vaju tamniji ten, na zdrav način (za tu the examples includes education on the namenu kompanija je uradila jedinu need for additional protection from the studiju o UVA/UVB/IR zračenju prevensun during summer, in order to reduce ciji). Osim toga, tokom protekle godine harmful eﬀects of UVA and UVB rays, as well dosta pažnje je posvećeno i opštoj eduas IR radiation, with recommendations for kaciji o značaju konzumiranja probiotika use of one of the best sunscreen product uz antibiotike, radi normalizacije crevne ranges in the world – Ladival, as well as mikroﬂore i dovođenja organizma u optitwo latest Aktiv forms, which oﬀer the best malno stanje nakon zapaljenskih procesa sun protection so far, and at the same time i drugih bolesti lečenih antibiotskom allow healthy tanning (for this purpose, the terapijom. company conducted a study on UVA/UVB/ IR radiation and prevention); additionally, Važno je napomenuti da je čitav pravni sektor, during the past year much attention was a posebno menadžer za usaglašenost poslovapaid to general education on the impornja, od 2018. aktivno uključen u sve aktivnosti tance of taking probiotics together with koje su vezane za marketing Hemofarma. Na antibiotics to balance intestinal microtaj način, kompanija štiti i sopstvene interese, ﬂora and restore the optimal condition of ali ravnopravno i interese svih uključenih the body after inﬂammations and other strana – od stručne javnosti do krajnjih potrodiseases treated with antibiotics. šača i pacijenata. It is important to emphasize that the entire Legal Kada je u pitanju komunikacija sa zainteresovaAﬀairs Division, and Compliance Manager in parnim stranama, kompanija na prvo mesto stavlja ticular, has been actively involved since 2018 in transparentnost i naravno agilnost. Upravo je all marketing-related activities in Hemofarm. komunikacija jedan od sastavnih delova farThereby, the company protects its interests, but maceutske industrije, zato što je utkana u sve at the same time equally protects the interests of faze nastanka proizvoda, a posebno u okviru all stakeholders – from professional public to end njegovog tržišnog životnog ciklusa. Za komusers and patients. paniju je izuzetno važna reputacija domaćeg farmaceutskog tržišnog lidera, koja je pažljivo When communication with stakeholders is conrazvijana čitavih 60 godina i koja se bazira cerned, the company puts transparency and, of prvenstveno na kvalitetu Hemofarmovih procourse, agility at the forefront. Communication izvoda. Zato Sektor za korporativne poslove is one of the integral parts of pharmaceutical industry, because it is embedded in all phases of creating a product, especially within its market lifecycle. Reputation of the local pharmaceutical market leader, carefully developed over the entire i komunikacije Hemofarma ne pravi razliku period of 60 years and based primarily on the u odgovaranju na potrebe za informacijama quality of Hemofarm products, is extremely imporkako interne, tako i eksternih javnosti, jer tant for the company. Hemofarm’s Corporate upravo kvalitetna, pravovremena i tačna Aﬀairs and Communications Division therefore informacija predstavljaju jedan od ključnih makes no diﬀerence when responding and prostubova zdravlja. Takođe, podrška medijima viding requested information, to both internal u vidu relevantnih stručnih informacija predand external public, as good-quality, timely and stavlja dodatni vid osnaživanja domaćeg accurate information is one of the key pillars of zdravstvenog sistema. Hemofarm nudi health. Likewise, support to the media in the form pregršt načina za uspostavljanje dijaloga sa of relevant professional information is another svim zainteresovanim stranama, koji uključuju way of strengthening the local healthcare system. i: info linije u Vršcu – 013/803100 i Beogradu Hemofarm oﬀers numerous ways to establish dia– 011/3811200, a koje su vidno navedene na logue with all stakeholders, including: info telesvim kanalima komunikacije, zatim korporaphone lines in Vršac – 013/803100 and Belgrade tivni sajt dostupan na adresi www.hemofarm. – 011/3811200, visibly shown in all communicacom, mejl za sva pitanja unutar ili van komtion channels, then the corporate website availpanije svakodobro@hemofarm.com, kao i able at www.hemofarm.com, email for any ques„svako dobro Hemofarm“ profile na društvetions within or outside the company svakodobro@ nim mrežama Fejsbuk, Instagram, Tviter i hemofarm.com, and also ‘svako dobro Hemofarm’ Jutjub. Pored toga što su svi zaposleni obučeni profiles on social networks Facebook, Instagram, za prijem informacija o neželjenom dejstvu Twitter, and YouTube. Apart from all employees lekova iz Hemofarmove palete, radi suštinske i being trained to receive information on adverse strateške preventive i smanjivanja bilo kakvih reactions to medicines from Hemofarm product rizika primene na minimum. Zaposleni u range, in order to essentially and strategically presektoru komunikacija posebno su motivisani i vent and reduce any risks of use to a minimum, spremni da budu podrška svakoj zainteresovaemployees in communications division are espenoj strani kojoj se ukaže potreba da se obrati cially motivated and prepared to support any party kompaniji. in need of addressing the company. Upravljanje kvalitetom je garancija razvoja Quality management is the key enabler of development Kvalitet je jedan od ključnih vrednosti i principa Quality is one of the key values and principles of Hemofarma, koji se iskazuje stalnim usklađiHemofarm demonstrated by constant harmovanjem i poboljšanjem sistema menadžmenta nization and improvement of quality managekvalitetom u skladu sa smernicama Dobre ment system according to the guidelines of Good proizvođačke prakse (GMP), zahtevima ISO Manufacturing Practice (GMP), requirements standarda i smernicama koje se odnose na of ISO standards and guidelines pertaining to proizvodnju i promet lekova i medicinskih production and sales of medicines and medical sredstava. devices. Prioritet zaposlenih u Sektoru kvaliteta Work on improving the health of product users Hemofarma jeste rad na unapređivanju zdravlja and enhancing their quality of life is the priorkorisnika proizvoda i poboljšanju njihovog kvaity of employees in Hemofarm Quality Division. liteta života. Neprestano se traga za novim New ways of increasing knowledge and skills are načinima unapređivanja veština i znanja kako sought after constantly, so that the quality system bi se kroz razvoj zaposlenih razvijao i sistem could be developed through development of kvaliteta. Poštuju se zakonski zahtevi i zahtevi employees. Legal requirements and requiremeđunarodnih standarda. Aktivno se radi na ments of international standards are adhered to. komunikaciji i uspostavljanju saradnje sa reguCommunication and establishing of cooperation latornim autoritetima i drugim farmaceutskim with regulatory authorities and other pharmakompanijama, kako domaćim tako i inostraceutical companies, local as well as international, nim. Hemofarmovi eksperti se upoznaju sa are actively pursued. Experts from Hemofarm zahtevima novih tržišta gde postoji interes za investigate requirements in new markets in which plasman proizvoda iz Hemofarma, a zatim se there is interest in selling Hemofarm products. specifičnosti regulative novih zemalja i partnera After that, specifics of regulatory requirements of ugrađuju u procedure i elemente sistema kvalithese new countries and partners are embedded teta Hemofarma. in procedures and elements of Hemofarm quality system. Tokom 2018. godine, interdisciplinarni tim Sektora kvaliteta, zadužen za obezbeđivanje During 2018, interdisciplinary team of Quality kvaliteta (QA) i kontrolu kvaliteta (QC) uspešno Division, responsible for Quality Assurance (QA) je realizovao mnoge zadatke i projekte, u koje and Quality Control (QC) successfully implespadaju: mented many tasks and projects, including: • Globalni FMD projekat, jedan od naj• Global FMD project, one of the most signifiznačajnih u STADA Grupi, za uvođenje cant in STADA Group, for introducing safety mera bezbednosti protiv falsifikovanja measures against counterfeiting medicines 73 lekova na tržištu EU. Stupanje na snagu in the EU market. The EU regulation, which EU regulative u februaru 2019. je veliki came into eﬀect in February 2019, is a great izazov za celu kompaniju. Sektor kvaliteta challenge for the entire company. Quality je imao značajnu ulogu u projektu u delu Division had an important role in the prilagođavanja više od dve hiljade kompoproject, in the part of adapting more than nenti pakovnog materijala novom načinu two thousand packaging material compoobeležavanja serijalizaciji i kontroli prvog nents to the new serialization and tamper otvaranja – „temper evident“. evident labelling requirements. • Iniciran je globalni projekat za uvođenje • A global project has been initiated for the EQMS elektronskog sistema za upravljapurpose of introducing EQMS electronic nje kvalitetom u STADA Grupi. Uvođenje system for quality management in STADA elektronskog sistema za upravljanje kvaGroup. Introduction of electronic Quality litetom (eQMS) od veoma velike važnosti Management System (eQMS) is very imporje kako za Hemofarm tako i za celu STADA tant for both Hemofarm and the entire Grupu. Automatizovan elektronski sistem STADA Group. Automated electronic system će veoma pozitivno uticati na efikasnost will have a very positive eﬀect on efficiency samih procesa kvaliteta, smanjiti potrebu of the quality-related processes, reduce za papirnom dokumentacijom i manuelthe need for paperwork and manual work, nim radom, pružiti veću transparentnost provide higher transparency and improve i unaprediti usaglašenost sa GMP zahteharmonization with the GMP requirements. vima. Takođe, ovaj projekat će doprineti This project will also contribute to a better boljem imidžu kompanije i njenoj konkuimage of the company and its competitirentnosti na tržištu. Uzimajući u obzir da će veness in the market. Considering that the softver biti jedinstven za sve STADA lokacije software will be equal for all STADA sites, i da se paralelno sa njegovim uvođenjem and that global quality procedures are radi i na razvijanju globalnih procedura being developed in parallel with its introkvaliteta, projekat na najbolji način duction, the project demonstrates actual demonstrira konkretnu primenu u poslu application of the new company values novih vrednosti kompanije INTEGRITY i INTEGRITY and ONE STADA in practice, in ONE STADA. Hemofarmov tim Kvaliteta the best possible way. Hemofarm’s Quality ima značajnu ulogu u ovom projektu i vodi Team plays an important role in this project radionice za nekoliko procesa u sistemu, and conducts workshops for several procesuz vođenje harmonizacije globalnih ses in the system, along with managing the procedura. harmonization of global procedures. • Obezbeđivanja internacionalnog EU CE • Providing the international EU CE sign for znaka za medicinsko sredstvo Hemodrops the medical device Hemodrops plus (artifiplus (veštačke suze), uključujući usaglašacial tears), including harmonization of the vanje sistema menadžmenta kvalitetom quality management system with the regusa zahtevima regulative za medicinska latory requirements for medical devices sredstva (EN ISO 13485:2016, EU Directive (EN ISO 13485:2016, EU Directive 93/42/ 93/42/EEC), što je potvrđeno od EU notifiEEC), which has been confirmed by the EU kacionog tela). Ovaj projekat pruža dalje notification authority. This project provides mogućnosti razvoja i proizvodnje drugih further opportunities for development and medicinskih sredstava iz grupe oftalmološproduction of other medical devices from kih i nazalnih sprejeva u Hemofarmu. the group of ophthalmological and nasal • 22 uspešno sprovedene inspekcije od sprays in Hemofarm. strane regulatornih autoriteta iz zemalja • 22 successfully conducted audits by the EU (Nemačke, Hrvatske), Rusije, Belorusije, regulatory authorities from the EU counUkrajine, Srbije i okolnih zemalja, kao i od tries (Germany, Croatia), Russia, Belarus, strane ugovornih partnera i ISO notifikaciUkraine, Serbia and the neighbouring counonih tela. tries, as well as by the contractual partners • Doprinos uvođenju novih proizvoda, and ISO notification bodies. kroz transfer tehnologije iz STADA-e i iz • Contribution to introduction of new partnerskih firmi. Primer je saradnja sa products, through transfer of technokompanijom Roche na plasiranju leka logy from STADA and partner companies. Ocrevus na tržište Srbije, u kojoj je Kvalitet Cooperation with company Roche in markeimao značajnu ulogu. ting of the medicine Ocrevus in the Serbian • Uspešno je pokrenut projekat za uspostavmarket, in which Quality had an important ljanje „performance management“-a, koji role, is an example. je rezultovao većom efikasnošću internih • The project of establishing ’performance QA/QC procesa. management’, was successfully initiated, and • Odobreni su projekti implementacije resulted in higher efficiency of internal QA/ elektronskog upravljanja laboratorijskim QC processes. procesima (LIMS), nabavke softvera za • Projects for implementation of electronic stabilnost, i stvoreni tehnički uslovi za dalje management of laboratory processes (LIMS) uvođenje Nova EM Mobile u Pogonu injekand purchasing of stability software have cionih proizvoda u Vršcu. been approved, and technical conditions • Odobrena je nabavka izolatora za created for continued introduction of Nova Mikrobiološku laboratoriju, što predstavlja EM Mobile at the Injectables Plant in Vršac. state of the art uslove za izvođenje testa • Purchasing of isolator for Microbiological sterilnosti u kojima je višestruko smanjena Laboratory has been approved, which mogućnost radne kontaminacije. provides state of the art conditions for per• Završen projekat optimizacije nabavke forming sterility testing in which possibility of referentnih standarda, koji je u 2018. work contamination is reduced significantly. obuhvatio sve Hemofarmove sajtove i • The project of optimization in purchasing rezultirao uštedom od 46.000 evra. of reference standards, which covered all • Pokrenut je i završen projekat „Principle of Hemofarm sites and resulted in savings of bracketing / matrixing of diﬀerent strenEUR 46,000 in 2018, has been completed. gths of product for on-going stability study • The project Principles of Bracketing / – STADA products in Vršac“, koji je doneo Matrixing of Diﬀerent Strengths of Product uštedu od 15.300 evra. for Ongoing Stability Study – STADA Products • Realizovana je nabavka još jedne sobe za in Vršac , has been initiated and completed, ispitivanje stabilnosti lekova čime su proširesulting in savings of EUR 15,300. reni kapaciteti za studije stabilnosti. • Another room for stability testing of medi• Informacija da sirovina Valsartan od cines has been purchased which increased proizvođača Huahai sadrži genotoksičnu capacities for stability studies. nečistoću NDMA uzrokovala je povlačenje • Information that the raw material valsartan lekova koji sadrže ovu API širom sveta. made by Huahai contains genotoxic impurity Uvedena je i validirana metoda za odreNDMA caused the recall of medicines which đivanje ove nečistoće NDMA u veoma contain this API all over the world. A method kratkom roku, sa krajnjim ciljem da se for the assay of impurity NDMA was introduobezbedi bezbednost svakog pacijenta. ced and validated in a very short time period, Za ovaj uspeh, tim iz hemijske laboratowith the ultimate goal to ensure safety to rije osvojio je treću nagradu „Najbolja each patient. For this success, the chemical praksa″ na nivou STADA Grupe. laboratory team won the third ‘Best Practice’ prize at the level of STADA Group. Istraživanje i razvoj – stub unapređenja palete proizvoda Research and development – the pillar of product portfolio improvement Istraživanje i razvoj (R&D) predstavljaju jedan R&D is one of the key aspects of maintaining a od ključnih aspekata održavanja tržišne koncompany’s market competitiveness through midkurentnosti kompanije kroz srednjoročno i term and long-term planning, as well as contindugoročno planiranje, kao i kontinuiranog uous modernization of product range. In pharosavremenjavanja palete proizvoda. U farmamaceutical industry, this is particularly complex ceutskoj industriji to je posebno kompleksno due to strict industry standards, and at the same usled strogih standarda branše, a istovretime intensive changes in people’s lifestyles and meno intenzivnih promena životnih stilova development of new approaches to the treatljudi i razvoja novih pristupa u lečenju tegoba ment of health problems and ailments. In 2018, i oboljenja. Tokom 2018. godine, Hemofarmov Hemofarm’s R&D was transformed into: R&D je transformisan u: • Development Division • Sektor razvoja • Regulatory Aﬀairs Division, and • Sektor regulatornih poslova i • Medical Aﬀairs Division • Sektor medicinskih poslova SEKTOR RAZVOJA DEVELOPMENT DIVISION Istraživačko razvojna laboratorija Hemofarma Research-development laboratory in Hemofarm osnovana je krajem 1989. godine, a danas was established late in 1989, and nowadays Sektor razvoja broji 50 zaposlenih. Za prethodDevelopment Division has 50 employees. In the nih 30 godina razvijeno je i na tržište pušteno past 30 years, more than 270 products in various više od 270 proizvoda iz različitih kategocategories – Rx medicines, OTC products, food rija – lekovi na recept, OTC proizvodi, dodaci supplements, cosmetic products have been hrani, kozmetički proizvodi. Zastupljeni su developed and launched to the market. Almost all gotovo svi farmaceutski oblici. U periodu od pharmaceutical forms are covered. In the period 2006. godine, nakon što je Hemofarm postao since 2006, after Hemofarm became a member član STADA Grupe, uspešno je realizovano 47 of STADA Group, 47 development projects have razvojnih projekata koji uključuju ukupno 106 been implemented successfully, including a total novih proizvoda. of 106 new products. 76 Aktivnosti Sektora razvoja usmerene su na: Activities of development division are directed towards: • Razvoj novih proizvoda za celu STADA Grupu, uključujući zemlje EU, ali i ostala • Development of new products for entire tržišta na kojima je STADA prisutna: STADA Group, including the EU countries, Rusija, CIS, Azija, MENA; as well as other markets in which STADA • Transfer novih proizvoda iz razvoja u operates: Russia, CIS, Asia, MENA; proizvodnju; • Transfer of new products from development • Uvođenje novih tehnologija i tehnika. to production; • Introduction of new technologies and Tokom 2018. godine, pored lansiranja novih techniques. proizvoda, definisan je projekat unapređenja procesa razvoja novih proizvoda, koji za In 2018, in addition to new product launches, the cilj ima skraćenje vremena razvoja, smanjeproject for improving the process of new product nje troškova, pojednostavljenje procesa i brži development was defined, aimed at reducing the izlazak na tržiste. Prepoznata je stručnost development time, cutting costs, simplifying proi kompetentnost našeg tima, pa je Sektor cesses and shortening time-to-market. Expertise razvoja Hemofarma odabran kao ekspertski and competences of our team have been recogcentar za razvoj generičkih proizvoda, čime nized, thus Hemofarm Development Division was smo dobili značajnu ulogu u daljem napretku selected as the expertise centre for development STADA Grupe. of generic products, giving us a significant role in further progress of STADA Group. SEKTOR REGULATORNIH POSLOVA REGULATORY AFFAIRS DIVISION Sektor regulatornih poslova, pod različitim Regulatory Aﬀairs Division, under diﬀerent names nazivima i u različitim organizacionim struktuand in diﬀerent organizational structures, has rama, postoji gotovo koliko i sama kompanija existed almost as long as the Hemofarm company Hemofarm. Danas ga čini 31 zaposleni, 26 itself. It presently has 31 employees, 26 in Serbia u Srbiji i 5 na ostalim tržištima Zapadnog and 5 in the remaining Western Balkans markets. Balkana. U ovom trenutku Hemofarm a.d. At this point, Hemofarm A.D. is the owner of 1,610 vlasnik je 1.610 Rešenja o registraciji lekova Marketing Authorisations in 22 countries, as well u 22 zemlje, kao i 92 upisa medicinskih sredas 92 registrations for medical devices and 170 stava i 170 dodataka ishrani. Tokom 2018. for food supplements. In 2018, 42 new Marketing godine dobijena su 42 rešenja o novim regiAuthorisations we obtained and another 100 stracijama lekova i predato je još 100 zahteva applications for new marketing authorisations za nove registracije. have been submitted. Aktivnosti Sektora regulatornih poslova Activities of Regulatory Aﬀairs Division include: usmerene su na: • Registration of new products in the terri• Registracije novih proizvoda na teritoritory of Western Balkans (Serbia, Bosnia, jama Zapadnog Balkana (Srbija, Bosna, Macedonia, Montenegro, Albania,…) and in Makedonija, Crna Gora, Albanija… ) kao i markets where Hemofarm has its own MAs: na tržištima gde Hemofarm ima vlastite Russia, CIS, Asia, MENA, Romania; registracije: Rusija, CIS, Azija, MENA, • Maintenance of existing registrations Rumunija; 77 • Održavanje postojećih registracija kroz through applications for variations and prijave varijacija i obnove na svim naverenewals in all indicated markets; denim tržištima; • Maintenance of 1,187 Hemofarm’s dossiers • Održavanje 1.187 Hemofarmovih dosijea and 576 global STADA dossiers for 59 i 576 globalnih STADA dosijea za 59 markets (back in 2012, this division was the tržišta (još 2012. godine, ovaj sektor je first one in Hemofarm to be given a role in prvi u Hemofarmu dobio ulogu u globalglobal STADA activities); nim STADA aktivnostima); • Unapređenje regulatornih aktivnosti kroz • Improvement of regulatory activities praćenje aktuelnih EU propisa, kao i sve through keeping up with the current EU zahtevnijih nacionalnih/lokalnih propisa regulations, as well as ever more demanvan EU, kako za lekove tako i za mediding national/local regulations outside the cinska sredstva, dijetetske proizvode i EU, for both medicines and medical devices, kozmetiku. food supplements, and cosmetics. Tim za regulatorne operativne poslove u okviru The Regulatory Operating Aﬀairs Team within Hemofarma postao je operativan u februaru Hemofarm has started to operate in February 2017. i deluje u okviru globalnog Regulatory 2017 as a part of the global Regulatory Operations Operations tima iz Bad Vilbela, gde se nalazi team from Bad Vilbel, where STADA Group headcentrala STADA Grupe. Njegov zadatak je i quarters are located. Its task is also to support pružanje podrške korisnicima na nivou celousers in the entire STADA Group through technical kupne STADA Grupe kroz tehničku podršku i/ support and/or training in applications: FirstDoc, ili obuku u aplikacijama: FirstDoc, DocuBridge, DocuBridge, Register, serving, inter alia, for subRegister, a koje služe, između ostalog i za podmitting electronic registration dossiers to the nošenje elektronskih registracionih dosijea ka European Medicines Agency (EMA). Evropskoj medicinskoj agenciji (EMA). The Regulatory Aﬀairs Division, in accordance Sektor regulatornih poslova, u skladu sa with the STADA Group strategy of portfolio develstrategijom STADA Grupe u domenu razvoja opment, through constant support to all producportfolija, kroz konstantnu podršku svim tion sites, quality assurance, as well as local sales proizvodnim lokacijama, obezbeđenju kvateams, improves processes in order to produce liteta, kao i lokalnim prodajnim timovima, highly professional data which are submitted to unapređuje procese u cilju produkcije regulatory authorities, in order to shorten the time visokostručnih podataka koji se predaju reguneeded for regulatory processes and reduce costs. latornim vlastima, a u cilju skraćenja vremena za regulatorne procese i smanjenje troškova. The main goals of all activities of this sector are timely release of STADA Group products to the Glavni ciljevi svih aktivnosti ovog sektora su market, preservation of the continuity of product pravovremeni plasman preparata iz STADA release and constant care for the quality of prodGrupe na tržište, očuvanje kontinuiteta ucts from the STADA family. That is precisely why plasmana proizvoda i stalna briga o kvalitetu the expertise and competence of the team has preparata STADA porodice. Upravo zato, stručbeen recognized by the regulatory authorities in nost i kompetentnost tima prepoznata je i kod all the countries where the STADA Group operates, regulatornih vlasti u svim zemljama u kojima which is an additional contribution to further proposluje STADA Grupa, što je dodatni doprinos gress of the Group. daljem napretku Grupe. 78 SEKTOR MEDICINSKIH POSLOVA MEDICAL AFFAIRS DIVISION Sektor medicinskih poslova čini tim stručnjaka Medical Aﬀairs Division comprises a team of posvećenih pripremi medicinske dokumentaexperts dedicated to preparation of medical doccije i postmarketinškom praćenju bezbednosti umentation and post-marketing monitoring of Hemofarm proizvoda. Aktivnosti ovog sektora safety of Hemofarm’s products. Activities of this usmerene su na: division include: • Pripremu medicinske dokumentacije za • Preparation of medical documentation for nove proizvode i kontinuirano ažuriranje new products and continuous updating of dokumentacije za postojeće proizvode; documentation for the existing ones; • Kontinuirano praćenje svih novih saznanja o bezbednosti primene i obradu • Continuous monitoring of all new findings svih prijava neželjenih reakcija u poson the safety of use and processing of all tmarketinškoj fazi životnog ciklusa naših reported adverse reactions in the post-marproizvoda. keting phase of our products’ lifecycle. Tokom 2018. godine, pripremljena je medicinDuring 2018, medical documentation was preska dokumentacija za nove razvojne projekte za pared for new development projects for the EU EU i druga tržišta od interesa i istovremeno ažuand other markets of interest and at the same rirana medicinska dokumentacija za potrebe time medical documentation for renewal of obnova dozvola za 190 proizvoda kao i osnovne authorisations for 190 products was updated, informacije o leku sadržane u Sažetku karakteas well as the basic information on medicinal ristika i Uputstvu za lek za 180 proizvoda. products contained in the Summary of Medicinal Product Characteristics and Patient Information Sve aktivnosti sektora medicinskih poslova, Leaﬂet for 180 products. usklađene sa najvišim standardima i regulatornim zahtevima rezultiraju kvalitetom koji se All activities of the Medical Aﬀairs Division, in prepoznaje i doprinose sve snažnijem integricompliance with the highest standards and regsanju u STADA Grupu. ulatory requirements, result in recognized quality and contribute to even stronger integration into Otkrivanje, razumevanje, procena i sprečavanje STADA Group. neželjenih dejstava i reakcija na lekove nisu samo etičke norme, već i odgovornost i obaveza kako Detection, understanding, assessment and prenosilaca dozvole za stavljanje leka u promet, vention of adverse eﬀects and drug reactions are tako i čitavog sistema javnog zdravlja. Ovaj not just ethical standards, but also the responsibilvažan aspekt regulisan je u okviru farmakoviity and obligation of both marketing authorization gilance, čija relevantnost ima globalni karakter. holders and the entire public health system. This Prijave neželjenih dejstava lekova mogu pristići important aspect is regulated within the framedirektno od zdravstvenih radnika, regulatornih work of pharmacovigilance, the relevance of which tela, pacijenata, potrošača, stručnih časopisa, has a global character. Adverse drug reactions can medija i zaposlenih u kompaniji. Svi zaposleni u be reported directly by healthcare professionals, Hemofarm a.d. adekvatno su obučeni za prijem regulatory bodies, patients, consumers, profesprijava neželjenih dejstava. Naša kompanija sional magazines, media and employees in the je omogućila i prijavu putem e-formulara na company. All employees in Hemofarm A.D. are zvaničnom korporativnom veb sajtu, zatim adequately trained in receiving reports of adverse putem mejlova svakodobro@hemofarm.com reactions. Our company has also enabled reporti nezeljena.dejstva@hemofarm.com, kao i na ing via e-form on the official corporate website, sve dostupne brojeve telefona. Pored toga, via email at svakodobro@hemofarm.com and nezeljena.dejstva@hemofarm.com, as well as via predstavnici Sektora marketinga i Sektora all available phone numbers. In addition, repreprodaje uvek su na raspolaganju, prvenstveno sentatives of the Marketing Division and the Sales lekarima i farmaceutima, za prihvatanje prijava Division are always available, primarily to doctors neželjenih dejstava na Hemofarm proizvode. U and pharmacists, for receiving reports of adverse slučaju identifikovanja neželjenog dejstva leka, reactions to Hemofarm products. In the event of Hemofarm postupa u skladu sa lokalanom identifying an adverse drug reaction, Hemofarm regulativom države u kojoj se lek primenjuje i acts in compliance with the local regulations of standardnim operativnim procedurama za prothe country in which the medicinal product is cenjivanje profila bezbednosti registrovanih sold and the standard operating procedures for preparata. U slučaju prepoznavanja potenciassessing the safety profile of the registered prodjalnog rizika kompanija inicira evaluaciju svih ucts. In case of recognizing the potential risk, the raspoloživih podataka u odnosu na bezbednu company initiates the evaluation of all available primenu leka i preduzima adekvatne mere data concerning safe use of the medicinal prod(npr.: prosleđivanje pisma zdravstvenim radniuct and takes appropriate actions (for example: cima, povlačenje serije leka sa tržišta, izmena forwarding letters to healthcare professionals, uputstava za primenu leka, edukativni materirecalling batches of medicinal product from the jal za zdravstvene radnike i pacijente itd.). market, changing patient information leaﬂets, educational material for healthcare professionals Tokom 2018. godine, sa svih tržišta na kojima and patients, etc.) je Hemofarm nosilac dozvole za stavljanje leka u promet primljeno je od zdravstvenih radnika In 2018, 105 reports of adverse reactions were i pacijenata 105 prijava neželjenih dejstava. received from healthcare professionals and Dvadeset sedam prijava/slučajeva je procepatients from all markets in which Hemofarm njeno kao ozbiljno, a 78 prijava kao ne tako was the marketing authorization holder. Twentyozbiljne. Deset prijava neželjenih dejstava seven reports/cases31 were assessed as severe, sadržalo je i sumnju na kvalitet leka, odnosno and 78 reports as not so severe. Ten reports of reklamaciju na kvalitet leka. U ovakvim situaciadverse eﬀects also included a suspicion of the jama, kada u prijavi postoje i neželjena dejstva i quality of the medicinal product, i.e., a complaint reklamacija na kvalitet leka – Odeljenje farmakoabout the quality of the drug. In such situations, vigilance sarađuje sa Odeljenjem usaglašenosti when the report contains undesirable eﬀects and proizvoda / QA. U slučaju istovremeno prijavljea complaint about the quality of the drug the nih: medicinskog pitanja i neželjenog dejstva Pharmacovigilance Department cooperates with – Sektor Marketinga je nadležan za medicinsko the Product Compliance Department/QA. In the pitanje a Odeljenje farmakovigilance za prijavcase of simultaneous reporting: medical issue ljena neželjena dejstva. and adverse eﬀect Marketing is responsible for the medical issue, and Pharmacovigilance U 2018. godini zabeleženo je povećanje broja Department for the reported adverse eﬀects. prijavljenih slučajeva za 13,01 % u odnosu na broj slučajeva zabeležen u 2017. godini: Increase in the number of reported cases by 13.01% was recorded in 2018, compared to the number of cases recorded in 2017: 200 153 150 144 115 99 102 105 100 85 80 50 21 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 31 Jedna prijava predstavlja jedan slučaj neželjenih dejstava na lek koji se odnosi na jednog 31 One report stands for one adverse drug reaction case referring to one patient and it may conpacijenta i može da sadrži više neželjenih dejstava, kao i lekova za koje se sumnja da su tain several undesirable eﬀects as well as medicines suspected to have caused their manifestation doveli do njihovog ispoljavanja. 80 Najveći broj prijava prosledili su lekari, zatim Highest number of reports was sent by doctors, farmaceuti, korisnici leka/pacijenti i ostali then pharmacists, medicine users/patients and zdravstveni radnici: other healthcare professionals: Izveštač Broj prijava NDL Ozbiljna NDL Ne tako ozbiljna NDL Reporting party Number of ADR reports Severe ADR Not so severe ADR Lekari Doctors 61 21 40 Farmaceuti Pharmacists 24 4 20 Pacijenti Patients 10 2 8 Ostali zdravstveni radnici Other healthcare professionals 10 10 Ukupno Total 105 27 78 Posmatrano po tržištima i po ozbiljnosti – Observed by markets and severity – reports of prijave neželjenih dejstava mogu se prikazati adverse reactions can be shown as follows: na sledeći način: Prodaja 90 Sales 80 80 70 64 60 50 40 30 20 16 12 11 10 7 8 Srbija BIH 5 BIH 2 3 2 Serbia 0 0 Crna Gora Makedonija Ukupan broj ND Ozbiljna ND Ne tako ozbiljna ND Montenegro Macedonia Number of ADR Severe ADR Not so severe ADR • Od ukupno 696 reklamacija u 2018, 653 reklamacije su proizvodno-tehničke • Out of 696 complaints in 2018, 653 complaints were of a produprirode (PTR), 13 reklamacija su komercijalne (CR) i 30 reklamacija koje ction-technical nature (PTR), 13 were commercial (CR) and there u sebi sadrže, pored reklamacije na kvalitet leka, i elemente neželjenog were 30 complaints that, in addition to medicine quality comdejstva leka (R-ADR). Reklamacije su u porastu, što je očekivano usled plaints, contain elements of the adverse drug reaction (R-ADR), povećanja obima proizvodnje i u najvećem procentu se odnose na pakotoo. Complaints increased which was affected by the increase of vanje i etiketiranje, a ne na sam kvalitet i funkcionalnost proizvoda. Kada production. They are mostly related to packaging and labelling, je pakovanje i obeležavanje proizvoda u pitanju, Hemofarm prati stroge and not to the quality and functionality of the product itself. zakonske zahteve branše, uz nastojanje da uvek ponudi više korisnicima Hemofarm follows strict pharmaceutical laws and regulations svojih proizvoda, pa tako i OTC/CHC proizvode obeležava pismom za slepe i for packaging and labeling of its products, while striving to offer slabovide, što inače nije obavezno. added value to its consumers, i.e. OTC/CHC products are marked with letters suitable for blind people although it is not obligatory. 81 U okviru pristiglih i dokumentovanih prijava Within the received and documented reports, 62 zabeleženo je 62 potencijalna neželjena dejstva, potential adverse reactions were recorded, mainly najveći broj pripada sledećim: poremećajima including: immune system disorders, general and imunog sistema, opštim i gastrointestinalnim gastrointestinal disorders, and skin and subcuporemećajima i poremećajima u funkciji kože i taneous tissue disorders. Among the reported potkožnog tkiva. Među zabeleženim prijavama adverse drug reactions recorded in Hemofarm neželjenih dejstava lekova, koje su tokom 2018. in 2018, there were also cases with two or more evidentirane u Hemofarmu, bilo je i slučajeva reported suspected medicines. Accordingly, the sa dva ili više prijavljenih suspektnih lekova. total number of medicines suspected to have U skladu sa tim, ukupan broj lekova za koje se caused adverse reactions is 109. The largest sumnja da su izazvali neželjena dejstva iznosi number of reports relates to medicines belong109. Najveći broj prijava odnosi se na lekove ing to the group J – Anti-infective medicines for koji pripadaju grupi J antiifektivni lekovi za systemic use, followed by: C Cardiovascular sistemsku primenu, zatim slede lekovi: C za system and N Nervous system. kardiovaskularni sistem i N nervni sistem. By analysing the reports received by the Analizom prijava koje su u 2018. godini pristiPharmacovigilance Department in 2018, it was gle u Odeljenje farmakovigilance, ustanovljeno found out that there was an increase in the je da je zabeležen porast broja prijava u odnosu number of reports compared to the previous na prethodnu godinu i prijave su mahom year, and reports mostly came from doctors. It potekle od strane lekara. Može se zaključiti da can be concluded that there is still no increase se još uvek ne beleži porast broja prijava koje in the number of reports that patients directly su pacijenti direktno prijavili nosiocu dozvole reported to the marketing authorization holder, za stavljanje leka u promet, što upućuje na which emphasizes the necessity of raising awareneophodnost unapređenja svesti i motivacije ness and motivation of citizens to report each, građana da prijavljuju svaku, pa i najmanju, even the smallest, suspicion about the medicine sumnju na lek koji koriste. Prijavljivanje nežethey use. Reporting of adverse reactions enaljenih dejstava omogućava otkrivanje izuzetno bles detection of extremely important, additional važnih, dodatnih, informacija o leku, koje nisu information about the medicinal product, which bile poznate odnosno koje nisu medicinski veriwere not known or which were not medically verfikovane u prethodnom periodu. ified up to that time. Praćenje neželjenih dejstava / incidenata pri Monitoring adverse reactions/incidents during primeni medicinskih sredstava i sve što podrause of medical devices and everything implied by zumeva vigilanca medicinskih sredstava u vigilance of medical devices falls within the comnadležnosti je Odeljenja farmakovigilance. petence of the Pharmacovigilance Department. Vigilanca medicinskih sredstava predstavlja Vigilance of medical devices is a new area of work novo polje rada u Hemofarmu i novi izazov in Hemofarm and a new challenge faced by the kome su eksperti kompanije posvećeni. experts from the company. 82 Motivisani zaposleni kao formula uspeha Motivated employees are the formula for success Odnos prema zaposlenima jedan je od najboljih Attitude towards employees is one of the best ways načina na koji je moguće dokazati uspešnost to prove the success of a company. Analogous to kompanije. Isto kao i u odnosu društva prema the attitude of society towards people, employljudima, zaposleni bi za kompaniju trebalo da ees should be the most valuable resource of a budu najvredniji resurs. Upravo to, Hemofarm company. Hemofarm has been proving this year potvrđuje iz godine u godine, nastojeći da istu after year, endeavouring to share the same care tu brižnost podeli i kroz svoj lanac dobavljača. throughout its supplier chain as well. Hemofarmov tim u 2018. činila su 2.342 zapoHemofarm team consisted of 2,342 employees in slena, što je porast za oko 7,2% u odnosu na the year 2018, which is an increase of about 7.2% in prethodnu godinu. Uprkos porastu broja zaporelation to the previous year. Notwithstanding the slenih, Hemofarm je postao bezbednije mesto increase in the headcount, Hemofarm has become za rad, te je broj povreda na radu značajno a safer place for work, since the number of work-resmanjen. I dalje većinu u kompaniji predlated injuries has dropped significantly. Women stavljaju žene, koje čine više od 53% ukupnog still represent the majority of company employbroja zaposlenih i većinski su zastupljene i u ees, with a share in the total number of employmenadžmentu kompanije. Tokom godine, u ees exceeding 53%; they also represent majority in kompaniji je ukupno bilo 145 porodilja, a na the company management. Throughout the year, kraju godine njih 82. Sve koleginice su se posle there were 145 women on maternity leave, with 82 porodiljskog odsustva vratile na istu poslovnu of them on maternity leave at the end of the year. poziciju. All the female colleagues resumed the same work post after their maternity leave. Tokom 2018. godine, u Hemofarmu je organizovano ukupno 4.338 internih i eksternih obuka In the course of 2018, a total of 4,338 in-house i treninga za zaposlene. Porast broja edukacija and external education and training courses for za čak 33%, što je pet puta više u odnosu na rast employees were organised in Hemofarm. The broja zaposlenih, najbolja je potvrda strateškog number of education courses has risen by as much opredeljenja menadžmenta da kontinuirano as 33%, which is five times more in relation to the ulaže u razvoj ljudi, unapređenje njihovih znanja increase in the headcount, and it represents the i ekspertskih veština. Zaposleni su tokom 2018. best evidence of the strategic commitment of the ostvarili ukupno 8.676 sati obuka, edukacija management to continually invest in development i usavršavanja u Hemofarmu. Od toga, svaki of people, improvement of their knowledge and zaposleni je edukacijama posvetio 23% više professional skills. Employees received a total of vremena u odnosu na 2017. ili ukupno oko 3,7 8,676 hours of training, education and specialisasati. Gotovo 470 zaposlenih bilo je u prilici da tion courses in Hemofarm in the year 2018. This se upozna sa najnovijim evropskim i svetskim means that each employee has devoted 23% more trendovima u onim oblastima koje su ključne za time to education in 2018 in relation to 2017, which njihovu poslovnu poziciju, a 417 osoba bilo je amounts to 3.7 hours. Almost 470 employees had 83 uključeno u soft skills edukacije, što je gotovo the opportunity to get acquainted with the latest tri puta više u odnosu na 2017. godinu. Neke od European and global trends in the fields which ključnih tema bile su i Efektivne komunikacije were essential for their jobs, while 417 persons i Upravljanje promenama. Pored toga, realiparticipated in soft skills education, which is almost zovani su i četvorodnevni razvojni programi three times more than in the year 2017. Eﬀective za rukovodioce ali i zaposlene koji su se prvi communication and Change Management were put našli na rukovodećim pozicijama, kako bi among the key topics. In addition, four-day develna najkonstruktivniji način ovladali vođenjem opment programmes were organised for managi upravljanjem. Kroz specifične razvojne ers as well as for employees who were appointed to programe ukupno je prošlo 97 ljudi, a najavljen managerial positions for the first time, so that they je i program za razvoj liderskih veština koji će could master leadership and management skills in biti realizovan u 2019. the most constructive manner. A total of 97 people attended specific development programmes, and U interne i eksterne edukacije, u okviru a leadership skills development programme has Hemofarm Grupe, investirano je 492.098 also been announced for the year 2019. evra, od čega je za Hemofarma a.d. izdvojeno ukupno 421.027 evra, što je za oko 45% više u A total of EUR 492,098 was invested in in-house odnosu na 2017. godinu. Investirajući u zapoand external education courses within Hemofarm slene, Hemofarm nastoji da se diferencira na Group, out of which EUR 421,027 was allocated to tržištu rada i u odnosu na konkurenciju, upravo Hemofarm A.D., which is higher by approximately na osnovu njihovih veština, znanja i motivacije, 45% in relation to the year 2017. By investing in ali i da poboljša ukupne poslovne i organizaciemployees, Hemofarm aspires to stand out on the one performanse. labour market among the competition, as well as improve its overall business and organisational Sektor ljudskih resursa Hemofarma posebnu performance, precisely based on the skills, knowlpažnju posvećuje pružanju jednakih šansi edge and motivation of its employees. svim kandidatima koji su zainteresovani za otvorene poslovne pozicije u kompaniji ili za The Human Resources Division of Hemofarm pays rad u Hemofarmu uopšte. Zato ne iznenađuje special attention to oﬀering equal chances to all činjenica da broj testiranih kandidata, koji candidates interested in the vacant posts at the su aplicirali na neki od konkursa, iz godine u company or in working for Hemofarm in general. godinu raste, a baza potencijalnih kadrova It therefore does not come as a surprise that the postaje sve bogatija. Pored toga, kompanija number of tested candidates, who have applied sve više intenzivira i nastup na specijalizovanim for one of the job vacancies, has been increasing sajmovima zapošljavanja, kao i promociju otvoyear after year, while the pool of potential candirenih pozicija na društvenim mrežama – upravo dates is becoming richer. In addition, the company tamo gde su mladi, uz značajno viši stepen has been intensifying its appearance at job fairs, as brendiranja poslodavca (employer branding). well as the promotion of vacant posts in the social network space – exactly where you can find young people, coupled with a significantly higher degree of employer branding. STRUKTURA ZAPOSLENIH / EMPLOYEE STRUCTURE Hemofarm a.d. 47,27 % 52,73 % 21-30 15,99 % 31-40 31,31 % 41-50 33,41 % 51-60 17,48 % 61-70 1,77 % 71-80 0,03 % KVALIFIKACIONA STRUKTURA / QUALIFICATION STRUCTURE Nekvalifikovan Unqualified 1,55 % Srednja stručna sprema Secondary school qualifications 51,34 % Viša stručna sprema Two-year post secondary school qualifications 5,61 % Univerzitetska diploma University degree qualifications 41,18 % Doktorat Doctoral degree qualifications 0,32 % Pored toga što se nude jednaki uslovi rada i Apart from oﬀering equal working conditions and benefiti svim zaposlenima, bez obzira na njihov benefits to all employees, regardless of their gender pol i status zaposlenja u Hemofarmu, kompanija and employment status in Hemofarm, the comje obezbedila i zarade koje su iznad republičpany also provided the salaries that were above the kog proseka. Najniža bruto zarada u Srbiji u republic average. The lowest gross salary in Serbia decembru 2018. godine iznosila je 32.131,24 amounted to RSD 32,131.24 in December 2018, dinara, dok je u istom period najniža bruto while the lowest gross salary in Hemofarm in the zarada u Hemofarmu bila 41.522,36 dinara. same period amounted to RSD 41,522.36. 85 Usaglašenost poslovanja je ključ sigurnosti i izvesne budućnosti Compliance is the key to safety and certain future 102-9 102-11 102-17 205-1 205-2 Biti lider nije moguće bez pravne usklađenosti It is not possible to be a leader without legal comi usaglašenosti poslovanja. U Hemofarmu je pliance and business compliance. It is especially to poseban izazov zato što kompanija obavlja challenging in Hemofarm because the company svoju matičnu delatnost u 4 države, od kojih is performing its main activity in 4 countries, one je jedna članica EU. Uz to, Hemofarm ima i of which is an EU member state. In addition, svoja predstavništva u inostranstvu, a ono Hemofarm has its representative offices abroad, što je najznačajnije posluje u okviru multiand what is most important – it operates within nacionalne STADA Grupe na 3 kontinenta u the multinational STADA Group on 3 continents, in 34 zemlje. Kompleksnost pravne usklađenosti 34 countries. The complexity of legal compliance uslovljava i sama farmaceutska industrija, kao is conditioned also by the pharmaceutical indusstrogo regulisana branša sa veoma zahtevtry, as the strictly regulated branch with highly nim standardima. Svi Hemofarmovi uspesi ne demanding standards. All Hemofarm’s successes bi bili održivi da kompanija ne neguje visoke would not be sustainable hadn’t there been for etičke i stroge korporativne standarde, gde the company cherishing high ethical and strict su zakonski okviri tek nužan početak, a oprecorporate standards, where the legal framework deljenost kompanije na transparentan i fer is only the necessary beginning and the compaodnos u svakom aspektu poslovanja suštinny’s dedication to a transparent and fair relation ski imperativ. Kontinuirano podizanje svesti o in every aspect of business is absolutely a must. sprečavanju koruptivnog delovanja i poštovaContinuous raising of the awareness about the nju ljudskih prava ostaju u fokusu kompanije, prevention of corruptive actions and respecting te postaju deo obavezne obuke prilikom ukljuhuman rights remain the focus of the company, čivanja novozaposlenih u redovne poslovne and become a part of the mandatory training aktivnosti. when involving the newly employed in the regular business activities. Pravni sektor kontroliše sve poslovne operacije Hemofarma u cilju sprečavanja bilo kakve Legal Aﬀairs Division controls all business operagreške i zakonske neusklađenosti. Poseban tions of Hemofarm aimed at preventing any errors značaj u tom procesu ima e-portal sa bazom and legal incompliances. E-portal with the conugovora, ali i predefinisanih templejta za tracts database, as well as pre-defined templates kreiranje novih ugovora, pod simboličnim for creation of new contracts, symbolically named nazivom „E-sekretarica“. Ovo jedinstveno sof‘E-secretary’, is especially important in such a protversko rešenje je tokom 2018. dostiglo punu cess. This unique software solution achieved its primenu, uz obavezu da svaki pojedinačni full implementation in 2018, with obligation that ugovor prođe evaluaciju i validaciju kroz ovaj each individual contract should be evaluated and sistem. U protivnom, ni jedan ugovor nije validated through this system. Otherwise, it is not moguće zaključiti. Na ovakav način vrši se propossible to conclude any contract. Legal risks are aktivna prevencija i smanjivanje pravnih rizika thus proactively prevented and reduced as much na najmanju moguću meru. as possible. 86 Tokom 2018. godine, Pravni sektor je zaposlio Over the course of 2018, Legal Aﬀairs Division specijalizovanog menadžera za usaglašenost hired a specialized Compliance Manager in order poslovanja (Compliance Manager) kako bi to additionally focus on this field and harmopružio dodatni fokus na ovu oblast, i dodatno nize business operations with the rules of STADA usaglasio poslovne operacije sa pravilima Group. Numerous compliance trainings were also STADA Grupe. Takođe, organizovane su i brojne organized, mainly in the form of practical workobuke o usklađenosti i usaglašenosti posloshops which were attended by over 250 employvanja, i to uglavnom kroz praktične radionice, ees. The project of implementation of GDPR was kojima je prisustvovalo preko 250 zaposlenih. U conducted and corresponding local documents oblasti zaštite podataka sproveden je projekat were adopted in the field of data protection, with implementacije GDPR-a i usvojeni su odgovaramuch more systematic approach to this topic. jući lokalni dokumenti, uz znatno sistematičniji Communication strategy for the field of business pristup ovoj temi. Komunikacijska strategija za compliance covered the CEO and top manageoblast usaglašenosti poslovanja obuhvatila je ment, in order to draw the attention of all the generalnog direktora i top menadžment, kako employees to this important field. Informative bi se skrenula pažnja svih zaposlenih na ovu and motivational video message featuring CEO važnu oblast. Snimljena je i emitovana informaand Compliance Manager was recorded and tivno-motivaciona video poruka sa generalnim broadcast, which preceded the educational direktorom i menadžerom za usaglašenost, survey, with the participation of about 1,750 koja je prethodila edukativnoj anketi, kojoj se employees, including also Hemofarm’s manageodazvalo oko 1.750 zaposlenih, uključujući i ment. The objective of the survey was to raise the menadžment Hemofarma. Cilj ankete je bilo awareness of the employees about this important podizanje svesti zaposlenih o ovoj važnoj temi, topic, but also to review the real degree of knowlali i sagledavanje realnog stepena poznavanja edge about compliance, and giving everybody a oblasti usaglašenosti, te pružanje prilike svima chance to indicate anything they consider incomkoji to žele da ukažu na nešto što smatraju pliant in Hemofarm. This specific internal ‘complyneusaglašenim u Hemofarmu. Ovo svojevring process’ was accompanied by an e-mail camsno interno „usaglašavanje“ ispratila je i imejl paign for all the employees, but also launching kampanja za sve zaposlene, ali i lansiranje of the funny comic with an important topic – how duhovitog stripa sa važnom temom – kako se to refrain from exchange of business sensitive uzdržati od razmene poslovno osetljivih inforinformation. This comic is only the beginning of a macija. Ovaj strip je samo početak niza sličnih series of similar formats, which easily educate the formata, koji na pitak način edukuju zapoemployees about topics significant for the busislene o suštinski značajnim temama od velike ness operations. važnosti za poslovanje. 87 Osim toga, realizovana je i harmonizacija lokalnih politika Hemofarmovih filijala sa postojećim Hemofarmovim i STADA politikama. Sve ove aktivnosti postavile su osnovu za dalji razvoj korporativne kulture, koja značajne reference pronalazi upravo u usklađenosti i usaglašenosti poslovanja. 88 Besides, local policies of Hemofarm’s subsidiaries were harmonized with the existing policies of Hemofarm and STADA. All these activities set the basis for further development of corporate culture, which finds the significant references exactly in compliance of business operations. 89 ONE STADA Šta je za nas jedinstvena STADA What ONE STADA means to us 103-1 103-2 103-3 203-1 413-1 Svako od nas postupa u najboljem interesu Each and every one of us acts in the best interests kompanije, a ne samo svoje poslovne jedinice of the company as a whole rather than our busiili funkcije, kako bismo izgradili jedinstvenu ness unit or function in order to build one succeuspešnu STADU. ssful STADA. Izgradnja stabilnog odnosa sa internim i Building stable relationship with internal and eksternim zainteresovanim stranama suštinexternal stakeholders is the essential acknowledska je potvrda lične i kolektivne odgovornosti gement of personal and collective responsibiu Hemofarmu, usmerene na razvoj i unaprelity in Hemofarm, focused on development and đenje globalnog društva. Zato svi zaposleni u improvement of the global society. Therefore, all kompaniji čine jedinstvenu STADA porodicu! the employees in the company make one STADA family! Materijalna tema, koja je u fokusu, prema strateškom pristupu poslovanju i vezana za The materiality topic in focus, according to straovu vrednost je: tegic approach to business, with regard to this value includes: • KORPORATIVNA DRUŠTVENA ODGOVORNOST i podrška lokalnim • CORPORATE SOCIAL RESPONSIBILITY and zajednicama support to local communities Briga o zdravlju ljudi kao suština društvene odgovornosti Caring for people’s health as the core of social responsibility U duhu nove korporativne ključne vrednosti In the spirit of the new key corporate value – ONE ONE STADA, Hemofarm i ostale kompanije STADA, Hemofarm and other companies operakoje posluju u okviru STADA Grupe nastoje ting within the STADA Group aim at sharing the da svuda u svetu dele iste vrednosti, kako bi same values everywhere in the world, in order to odnos prema zaposlenima, ključnim stejkholimprove the attitude to the employees, key stakederima, pacijentima i okruženju učinili boljim. holders, patients and the environment. Hemofarm Tome se priključuje i Hemofarm fondacija koja Foundation has joined in by advocating the care se zalaže za brigu o zdravlju ljudi, podršku of people’s health, support to the Serbian healthzdravstvenom sistemu Srbije i podizanje kvacare system, and improving the quality of life. In liteta života. U toku 2018. godine, fondacija the course of 2018, the Foundation completed 86 je realizovala 86 aktivnosti vrednosti od oko activities worth about half a million euros. pola miliona evra usmerenih na: unapređenje zdravlja pojedinaca, podršku zdravstvenom The largest number of activities, as many sistemu Srbije i podizanje kvaliteta života as 27 of them, were completed within the uopšte. Wholeheartedly for Health programme through donation and sponsorship programmes, aimed Najveći broj aktivnosti, čak 27, realizovan je u at reinforcing institutions, while 19 activities okviru programa Svim srcem za zdravlje kroz were implemented within the Wholeheartedly for Programe donacija i sponzorstava usmerenih Knowledge programme, and 3 activities within na institucionalno osnaživanje, dok je u okviru the Wholeheartedly for Culture programme. As programa Svim srcem za znanje implemenmany as 173 partnerships were created with key tirano 19 aktivnosti i Svim srcem za kulturu stakeholders – system institutions, international 3 aktivnosti. Ostvareno je i 173 partnerstva community, civil sector, media and distinguished sa ključnim stejkholderima institucijama individuals. sistema, međunarodnom zajednicom, civilnim sektorom, medijima i uglednim pojedincima. 92 Neki od najvažnijih projekata i aktivnosti u Some of the most important projects and activiprotekloj godini su: ties in the last year were: • Akademija Hemofarm fondacije u okviru • Hemofarm Foundation Academy – 127 propodrške programu edukacije medicingrammes of continuous medical education, skih radnika i farmaceuta: održano je attended by 11,934 medical professionals, 127 programa kontinuirane medicinske were organised to support the education edukacije koje je pohađalo 11.934 zdravprogramme for medical professionals and stvenih radnika. pharmacists. • Kampanja za prevenciju povišenog krvnog pritiska „Ne dozvoli da pukne“: • Don’t Let it Burst campaign for prevention pokrenuta je u cilju podizanja zdravof high blood pressure was initiated with stvene kulture i podsticanja ljudi na the aim of improving healthcare culture and redovne kontrole krvnog pritiska; u encouraging people to control their blood znak sećanja na one koji nisu uspeli da pressure regularly; in memory of those se izbore sa ovom bolešću, Hemofarm who did not manage to fight this disease, fondacija pustila je na početku Trke Hemofarm Foundation released 6,639 red zadovoljstva u okviru 31. Beogradskog balloons into the sky at the start of the maratona 6.639 crvenih balona u nebo; Fun Run at 31st Belgrade Marathon; on 22. aprila, u okviru preventivnog delo22nd April, as part of the preventive action vanja protiv hipertenzije, građani Srbije against hypertension, citizens of Serbia had su besplatno merili krvni pritisak, uz their blood pressure controlled for free, savete lekara u više od 90 zdravstveand received advice from doctors in over nih ustanova širom zemlje; „maskota“ 90 healthcare institutions countrywide; the projekta bila je crvena lopta kao simbol mascot of the project was a red ball as a za visok krvni pritisak, rađena po ugledu symbol of high blood pressure, designed na projekat „Red ball” američkog after the Red Ball project of the US artist umetnika Kurt Perschke-a; kampanju je Kurt Perschke; the campaign was also podržao i fudbalski klub Crvena Zvezda, supported by Red Star football club, whose čiji su fudbaleri pre utakmice izašli na footballers ran into the pitch before the teren u majicama sa nazivom kampanje, start of the game wearing T-shirts with the a 10 simboličnih crvenih lopti bilo je name of the campaign, and 10 symbolical upućeno publici na stadionu; merenje red balls were kicked towards the spectators krvnog pritiska organizovano je i u 11 at the stadium; blood pressure control was 93 gradova širom Srbije, dok je kampanja also organised in 11 cities around Serbia, završena donacijom 306 aparata za and the campaign was completed by a merenje krvnog pritiska 81 ustanovi donation of 306 blood pressure monitors to zdravstvenog sistema na teritoriji Srbije; 81 healthcare institutions in the territory of Zahvaljujući kampanji „Ne dozvoli da Serbia; the partnerships with stakeholders pukne” ostvarena su i potvrđena partner– the Ministry of Health of Serbia, Institute stva sa stejkholderima – Ministarstvom for Public Health Milan Jovanović – Batut , zdravlja Srbije, Institutom za javno Electronic Media Regulatory Body, and 6 TV zdravlje „Milan Jovanović – Batut“, channels with national coverage, were estaRegulatornim telom za elektronske blished and endorsed owing to Don’t Let medije i 6 TV kanala sa nacionalnom It Burst campaign. The campaign received pokrivenošću. kampanja je nagrađena 8 awards at national and international sa 8 priznanja na domaćim i stranim festivals. festivalima. • 6. jun – Nacionalni dan donora na ini• 6th June – National Donor Day following cijativu Hemofarm fondacije i aktivnosti the initiative of Hemofarm Foundation and sprovedenih u okviru kampanje o donithe activities carried out as part of the Most ranju i transplantaciji organa „Najvažniji Important Call in Life campaign on organ poziv u životu“, 2016. godine ustanovljen donation and transplantation, the National je Nacionalni dan donora a u julu 2018. je Donor Day was established in 2016, while usvojen i Zakon o presađivanju ljudskih the Law on Organ Transplantation was organa, što je ujedno i najveći uspeh ove adopted in July 2018, which was the greatest kampanje. success of this campaign. • Nastavljen je i godišnji Program stipendija, kojim je kroz različite programe • The annual Scholarship Programme was stipendiranja podržano 60 stipendista, uz continued as well, whereby 60 scholardodatnu podršku i pomoć deci preminuship holders were supported through lih radnika; uspešno je realizovan i drugi various programmes, and additional aid ciklus Mentorskog programa kao vid was provided for the children of deceased dodatne podrške stipendistima, sa ciljem company employees; the second cycle of podsticanja ličnog i profesionalnog the Mentoring Programme was succerazvoja i jačanja kapaciteta farmaceutssfully completed as a form of additional skih i medicinskih radnika i stručnjaka, support to scholarship holders, with the kao i kreiranje pozitivnog ambijenta za aim of encouraging personal and professizapošljavanje mladih u Srbiji; mentori u onal development and strengthening the okviru programa su eksperti Hemofarma capacities of pharmaceutical and medical iz sektora marketinga i prodaje, obezbeprofessionals and experts, as well as creating đenja i kontrole kvaliteta, istraživanja i positive environment for employment razvoja, kancelarije za projekte, oblasti of young people in Serbia; Hemofarm’s proizvodnje i dr. U okviru ovog programa experts from Marketing and Sales, Quality realizovano je ukupno 16 aktivnosti i Assurance and Quality Control, Research and to 2 treninga za mentore i mentije, 7 Development, Project Management Office, otvorenih predavanja, zajednički odlazak Production, and other divisions were the na kulturni događaj, kao i dve studijmentors in the Programme. Sixteen activities ske posete fabrici Hemofarma u Vršcu in total, specifically 2 trainings for mentors uz organizovana stručna predavanja and mentees, 7 open lectures, attending mentora – zaposlenih u Hemofarmu. U a cultural event together, and two study okviru programa pokrivene su sledeće visits to Hemofarm in Vršac with organized teme i oblasti: Lični i profesionalni razvoj; expert lectures of the mentors – Hemofarm’s Dobre komunikacione veštine – ključ employees, were carried out within this 94 za uspeh; Kako se uspešno predstaprogramme. The programme covered the viti poslodavcu; Aktivizam u zajednici; following topics and areas: Personal and Empatični lider: Kako se stvarno povezati professional development; Good commusa ljudima i postići više; Biotehnologija – nication skills – the key to success; How to tektonski poremećaj; kao i Atlas humanih successfully present yourself to employer; ćelija – Google mape ljudskog orgaActivism in the community; Emphatic leader: nizma. Organizovana su i dva redovna How to really liaise with people and achieve susreta mentorskih parova i generalnog more; Biotechnology – tectonic movement; direktora Ronalda Zeligera, kao i studijas well as the Atlas of Human Cells – a ska poseta Istraživačkoj stanici „Petnica” Google Map for the Human Body. Two kod Valjeva. Ovaj projekat predstavregular meetings of mentoring couples with lja pozitivan primer međusektorske the CEO Ronald Seeliger, as well as a study saradnje unutar kompanije. visit to Petnica Science Centre near Valjevo were also organized. This project is a positive U 2018. Hemofarm fondacija obeležila je 25 example of cross-divisional cooperation godina postojanja tokom kojih je realizowithin the company. vala čak 2.000 aktivnosti za koje je izdvojeno ukupno 12 miliona evra, u okviru kojih je doniIn 2018, Hemofarm Foundation marked 25 years ranjem medicinskih aparata i opreme podržala of its existence, during which time it accomplished i pomogla brojne ustanove zdravstvenog as many as 2,000 activities with earmarked EUR sistema, kliničko bolničke centre, porodilišta 12 million in total. Through donation of medical i domove zdravlja, ali i škole i vrtiće, ustanove devices and equipment, Hemofarm Foundation kulture, sportska udruženja i manifestacije. supported and aided numerous institutions of Pokrenuti su i realizovani brojni društveno the healthcare system, clinical and hospital cenznačajni infrastrukturni projekti a sprovedeno tres, maternity wards and health centres, as well je na stotine projekata u oblasti obrazovanja, as schools and kindergartens, cultural institukulture, zaštite životne sredine i sporta sa ciljem tions, sports associations and events. Numerous unapređenja kvaliteta života svih građana. projects of great importance for the society and Povodom značajnog jubileja, Hemofarm foninfrastructure were initiated and completed, dacija ustanovila je Nagradu za izuzetnost koju together with hundreds of projects in the field će, počev od 2018. godine, dodeljivati svake of education, culture, environmental protection, godine pojedincima, institucijama ili organizaand sport, with the aim of improving the quality of cijama za izuzetan doprinos u oblasti zdravlja, life of all citizens. On the occasion of this imporobrazovanja i kulture. Nagrada predstavlja tant jubilee, Hemofarm Foundation established konkretnu podršku za razvoj ideja i projekata the Excellence Award which would be awarded koji menjaju lice našeg društva na bolje, a prva every year, as of 2018, to individuals, institutions Nagrada za izuzetnost uručena je Vigoru Majić, or organisations for exceptional contribution in direktoru Naučno istraživačke stanice Petnica. the fields of health, education and culture. The Na dan obeležavanja jubileja lansiran je i novi, award represents a tangible support for develredizajnirani web sajt fondacije kao i novi blog opment of ideas and projects which change the na temu „Kako sačuvati srce društva“ za koji su face of our society for the better, and the first pisali istaknuti pojedinci, predstavnici međunaExcellence Award was presented to Vigor Majić, rodne zajednice i diplomatije. Director of Petnica Science Center. A new, redesigned internet site of Hemofarm Foundation, and a new blog on the topic: How to Preserve the Heart of Society were launched on the day of marking the jubilee. Among the bloggers were prominent individuals, representatives of international community and diplomacy. 95 Komparativna analiza održivog razvoja i uticaja Hemofarma (2016-2018) Comparative analysis of Hemofarm’s sustainable development and impact (2016-2018) 305-1 305-2 305-4 305-5 305-6 305-7 Tokom 2018. godine Hemofarm je oborio During 2018, Hemofarm broke a new production novi proizvodni rekord – 245 miliona pakovarecord – 245 million packs of finished products, nja gotovih proizvoda, što je za 1% više nego which is an increase of 1% compared to the preprethodne godine. Uprkos tome, utrošak vious year. Nevertheless, the consumption of all svih ključnih resursa je smanjen, što najbolje key resources was reduced, which best confirms potvrđuje veliki napredak kompanije u company’s great progress in managing sustaupravljanju održivim razvojem i potrošnjom inable development and energy consumption. energije. Takođe, navedeni parametri dokaz su Likewise, the mentioned parameters are the eviizuzetno visokog nivoa optimizacije svih proidence of an extremely high level of the optimizazvodnih i operativnih procesa, što je rezultiralo tion of all production and operational processes, i budžetskim uštedama u odnosu na planirane which resulted also in budget savings compared troškove. Ovako ustrojena proizvodnja, sa to planned costs. Such a customized production višestrukim uspesima koji su osnova daljeg with multiple successes that are the basis of furtrazvoja kompanije, najbolja su motivacija i za her company development is the best motivation Hemofarm i za STADA Grupu da se nastavi u for both Hemofarm and STADA Group to continue istom pravcu i da se razmotre nove mogućnoin the same direction and review new possibilities sti za još efikasniju proizvodnju, čiji je uticaj na for even more efficient production with exclusiokruženje isključivo pozitivan. vely positive impact on the environment. Utrošak resursa razlika 2016 2017 2018 Resources consumption diﬀerence Na smanjenje potrošnje Potrošnja el. energije (kWh) uticala je planska obustava Electricity consumption (kWh) 45.371.748 47.278.126 45.615.616 -3,6% proizvodnje u avgustu i sve bolje upravljanje potrošnjom energenata / Planned production suspension in August Potrošnja gasa (m3) and better management Gas consumption (m3) 6.135.542 6.830.641 6.452.489 -5,5% of energy consumption inﬂuenced the decrease in consumption. Voda iz javnog vodovoda (m3) Public water supply syst. (m3) 350.349 360.094 354.947 -1,4% Smanjenje utroška vode iz svih izvora, uprkos rastu proizvodnje, dokaz je vrhunske optimizacije Voda iz arteških bunara (m3) proizvodnih procesa / Artesian wells (m3) 71.916 116.970 81.416 -30,4% Reducing the consumption of water from all sources, despite the increase in production, is a proof of the quality optimization of the Ukupno potrošnja vode production process. Total water consumption 422.265 477.064 436.363 -8,5% 96 Potrošnja energenata po pakovanju gotovog proizvoda 2016 2017 2018 Consumption of energy sources per ﬁnished product pack ELEKTRIČNA ENERGIJA (kWh/pak) 0,16 0,16 0,15 () ELECTRICITY (kWh/pack) PRIRODNI GAS (m3/pak) 0,02 0,02 0,02 () NATURAL GAS (m3/pack) Napomena: Usled građevinskih radova i unapređivanja proizvodnih i poslovnih objekata od ukupnog utroška energenata u 2018. za ove namene je potrošeno oko 15% električne energije i prirodnog gasa. Note: Out of total energy consumption in 2018, about 15% of electricity and natural gas was consumed for construction works and upgrades of production and business facilities. PROIZVODNJA I PRODAJA 2016 2017 2018 PRODUCTION & SALES PROIZVODNJA (u milionima pakovanja) 221 244 245 () PRODUCTION ( in millions of packs) Napomena: Proizvodnja je porasla ukupno 1% (po obimu) u odnosu na 2017. Note: Production grew by a total of 1% (in volume) compared to 2017. PRODAJA (u milionima dinara) 26.979 26.263 30.036() SALES (in millions of RSD) Napomena: Hemofarm a.d. beleži rast prihoda od prodaje u 2018.godini za 14,36% u odnosu na 2017.godinu. U odnosu na 2017. godinu, rast beleži prodaja ka trećim licima u zemlji i inostranstvu. Na interkompanijskim tržištima na nivou STADA Grupe dolazi do blagog pada, dok je na interkompanijskim tržištima Hemofarm grupe došlo do porasta prihoda. Note: Hemofarm A.D. recorded increase in income from sales by 14.36% in 2018 compared to 2017. Sales to third parties in the country and abroad recorded growth compared to 2017. There was a slight decline in intercompany markets at the STADA Group level, while increase in revenues was recorded in Hemofarm Group intercompany markets. Emisije gasova sa efektom staklene bašte (Freoni) / 2016 2017 2018 GHG emissions (Freons) / (tCO2eq) FREON R404A 442,4 236,6 827,9 () FREON R134A 682,5 998,4 468,0 () FREON R507 360,2 1215,8 1035,7 () Emisija po pakovanju gotovog proizvoda 0,0000067 0,0000100 0,0000095() Emission per ﬁnished product pack Napomena: Uprkos povećanju proizvodnje za oko 1%, emisije gasova sa efektom staklene bašte po pakovanju gotovog proizvoda su manje za čak 5% Note: Despite the increase in production by approximately 1%, greenhouse gas emissions per pack of ﬁnished product were lower by as much as 5% Scope1 1) Izvor: prirodni gas 2) Izvor: rashladni ﬂuidi 3) Izvor: goriva,vozni park GHG emisije Source: natural gas Source: refrigerants Source: fuels, mobile combustion GHG emissions CO2 CH4 NOx R404a R134a R507 CO2 CH4 NOx Emisija, t_gas 12186,97 0,22 0,022 827,99 468,00 1035,70 688,78 0,05 0,04 Emission, t_gas Emisija, t_CO2eq 12186,97 6,08 5,76 Emission, t_CO2eq Emisija, t_CO2eq 12198,81 81% 2331,69 15% 515,05 3% Emission, t_CO2eq TOTAL SCOPE 1, tCO2eq: 15045.55 (-4.7%) Scope 2 CO2 [tons CO2eq.] Vršac Šabac Total emisije od kupljene električne energije/ emissions from purchased electricity 41.083,10 9.792,00 50.875,90 (t) generisano/ Upravljanje otpadom zbrinuto 2016 2017 2018 Waste management generated/ disposed of OPASAN 162,13 / 167,08 181,73 / 200,19 173,39() / 192,50* HAZARDOUS NEOPASAN 640,75 / 638,15 627,76 / 629,05 619,81() / 616,58** NONHAZARDOUS *navedena količina je zbrinuta u 2018, uzimajući u obzir i količine koje su prema planu i dinamici zbrinjavanja prebačene iz ranijih godina * the stated quantity was disposed of in 2017, taking into account also the quantities that were transferred from the previous years according to the plan and the dynamics of waste management; **zbrinjavanje preostale količine generisanog neopasnog otpada biće realizovano u skladu sa planom i dinamikom upravljanja otpadom **remaining quantities of generated non-hazardous waste will be disposed of in accordance with the waste management plan and scheduleNapomena: uprkos porastu proizvodnje, Hemofarm je u 2018. generisao manje otpada u odnosu na prethodnu godinu. Note: in spite of the increase in production, Hemofarm generated less waste in 2018 compared to the previous year. KRETANJE BROJA ZAPOSLENIH 2016 2017 2018 HEADCOUNT TREND Žene Female 1.237 1.160 1.235 () Muškarci Male 1.086 1.024 1.107 () Ukupno Total 2.323 2.184 2.342 () Broj povreda na radu Nr. of injuries at work 21 19 14 () Prema broju zaposlenih (%) Compared to nr. of employees (%) 0,90 0,85 0,60 () REZULTATI UPOTREBE RECIKLIRANOG KARTONA ZA PAKOVANJE PROIZVODA RESULTS OF USE OF RECYCLED CARDBOARD FOR PRODUCT PACKAGING 1t 2016 (615,2t) 2017 (931,5t) 2018 (1.024,7t) 2.584 MW 3.912 MW 4.304 MW Ušteda el. energije ili oko 26 dana potrošnje el. ili oko 40 dana potrošnje el. ili oko 44 dana potrošnje el. Electricity savings 4.200 kW energije u Hemofarmu energije u Hemofarmu energije u Hemofarmu or about 26 days of electric or about 40 days of electric or about 44 days of electric power consumption in power consumption in power consumption in Hemofarm Hemofarm Hemofarm 19.688.000 29.808.000 32.790.400 Ušteda vode (m3) ili oko 22 dana potrošnje ili oko 34 dana potrošnje ili oko 37 dana potrošnje Water savings (m3) 32.000 vode u Hemofarmu vode u Hemofarmu vode u Hemofarmu or about 22 days of water or about 34 days of water or about 37 days of water consumption in Hemofarm consumption in Hemofarm consumption in Hemofarm Sačuvana stabla (kom) Preserved trees (pcs.) 17 10.459 15.835 17.420 Za 74% se manje zagađuje vazduh / Air pollution reduced by 74% Novčana ušteda je do 11% / Financial savings of up to 11% Napomena: Prosečna mesečna potrošnja (za 30 dana) električne energije je oko 2,97 mil kWh ili oko 24 hiljade m3 gradske vode (ne računajući arteški bunar) odnosno 26.296 m3 vode (računajući oba izvora). Note: Average monthly consumption (for 30 days) of electric power is about 2,97 mil. kWh or approximately 24 thousand m3 of tap water (excluding artesian well), i.e. 26,296 m3 of water (including both sources). 98 O izveštaju i principima izveštavanja About report and reporting principles 102-41 102-48 102-49 102-50 102-51 102-52 102-53 102-54 102-56 201-2 201-4 205-3 206-1 304-1 304-2 304-3 304-4 306-3 307-1 308-2 402-1 406-1 407-1 408-1 409-1 411-1 413-2 414-2 415-1 418-1 419-1 Pod terminom „lokalno“ u kontekstu The term local in the context of Hemofarm and Hemofarma i ovog izveštaja, podrazumeva se this report means the territory of the Republic of teritorija Republike Srbije. Serbia. Pod pojmovima „menadžment“ i „upravljanje“ The term management and governance in this u ovom izveštaju se podrazumeva niži, srednji Report means junior, middle and senior managei viši menadžment kompanije, uključujući i ment of the company, including also the top-level najviša upravljačka tela – generalnog direkmanagement bodies – Chief Executive Officer and tora i SMT (senior menadžment tim), koji vrši SMT (Senior Management Team), which plays the ulogu u okviru upravljanja jednaku Upravnom management role equal to the Board of Directors. odboru. Climate change does not significantly aﬀect busiKlimatske promene ne utiču u značajnoj meri ness operation of the company. na poslovanje kompanije. Overall business operations of Hemofarm A.D. Celokupno poslovanje Hemofarma a.d. u 2018. in 2018 were completely aligned with applicable bilo je u potpunosti usaglašeno sa važećom legislation. Accordingly, not a single case of comzakonskom regulativom. Sa tim u vezi, nije plaints or fines related to company products was zabeležen ni jedan slučaj pritužbe ili kazne recorded. vezane za proizvode kompanije. Hemofarm A.D. has no reporting limitations, neiHemofarm a.d. nema nikakva ograničenja na ther within the organization nor outside of it. izveštavanje niti unutar organizacije niti izvan Also, with regard to the data presented in the nje. Takođe, u odnosu na podatke prezentoprevious reporting cycle (for 2017), there were no vane u prethodnom ciklusu izveštavanja (za subsequent adjustments of the previously stated 2017.) nije bilo nikakvih naknadnih korekcija figures. prethodno iznetih cifara. 99 Tokom 2018. godine, kao u i prethodnim In 2018, similarly to the previous reporting cycles, ciklusima izveštavanja, Hemofarm a.d. nije Hemofarm A.D. did not recive or grant any kind of primio niti pružio bilo koju vrstu materijalnih donations, either in kind or in money, to political ili finansijskih donacija političkim partijama, parties, politically active persons, or political and politički aktivnim licima ili političkim i državnim state institutions. ustanovama. In 2018, there were neither complaints filed nor Tokom 2018. godine nije bilo žalbi niti je proceedings instituted against the company on pokrenut ijedan postupak protiv kompanije the grounds of gender, national, religious or any po osnovu polne, nacionalne, verske ili nekog other type of discrimination or violation of human drugog vida diskriminacije ili povrede ljudskih rights. The company has not had either cases of prava. Kompanija do sada nije imala slučajeve work engagement of minors, or cases of violation radnog angažovanja maloletnih radnika, niti of labour rights of its employees, on any grounds slučajeve povrede radnih prava svojih zaposlewhatsoever, so far. nih, po bilo kom osnovu. Hemofarm A.D. did not record a single corruption Hemofarm a.d. u 2018. nije imao nijedan or monopoly-related incident or non-compliance zabeležen incident usled korupcije niti monoor conﬂict with legal regulations in 2018. polskog ponašanja. Takođe, kompanija nije imala nijedan slučaj neusaglašenosti niti protiNot a single case of a risky or crisis situation, which vrečnosti sa zakonskim propisima. inﬂicted damage to the company or the environment, or indirectly negatively aﬀected local comTokom dosadašnje poluvekovne istorije kommunities, was recorded over the course of half-apanije nije zabeležen nijedan slučaj rizične ili century long history of the company. krizne situacije koji je naneo štetu kompaniji ili okruženju, niti imao posredno negativan uticaj In 2018, as in the previous six reporting cycles, na lokalne zajednice. there were no official remarks, fines or restrictions imposed on Hemofarm A.D. as regards packaging Tokom 2018. godine, kao i u prethodnih šest and/or labelling of its products, sales of banned ciklusa izveštavanja, Hemofarm a.d. nije imao products, marketing communication, or violation nikakve zvanične primedbe, kazne ili restrikcije of privacy, and loss of consumer data. po pitanju pakovanja i/ili obeležavanja svojih proizvoda, prometa zabranjenih proizvoda, Business operations of Hemofarm A.D. do not marketinških komunikacija, kao ni povrede priexert negative impact either on the environment vatnosti i gubitka podataka potrošača. or biodiversity in the environment of manufacturing plants and business premises of the company Poslovanje Hemofarma a.d. nema negativan in which core activity is carried out. In that regard, uticaj na životnu sredinu niti biodiverzitet u there are no protected habitats or endangered okruženju proizvodnih pogona ni poslovnih proanimal and plant species, which are under special storija kompanije, u kojima se obavlja primarna protection, at the sites at which Hemofarm A.D. delatnost. Sa tim u vezi, na lokalitetima na operates. kojima posluje Hemofarm a.d. nema zaštićenih staništa niti ugroženih biljnih i životinjskih Not a single case of wastewater discharge from vrsta, koje su pod posebnom zaštitom. Hemofarm A.D. facilities was recorded neither over the course of 2018, nor in the period from 2012, Tokom 2018. kao i u periodu od 2012. kada je when the company started reporting on sustainakompanija započela izveštavanje o održivom ble development, to date. razvoju, nije zabeležen nijedan slučaj izlivanja otpadnih voda iz postrojenja u Hemofarmu a.d. Although Hemofarm A.D. does not exert negative impact on the environment, the company has Iako Hemofarm a.d. nema negativan uticaj been continuously striving to improve its business 100 na životnu sredinu, kompanija kontinuirano operations. One of such examples is the initiative nastoji da unapređuje svoje poslovanje. Jedan for reducing organic solvents in manufacturing od takvih primera jeste inicijativa za smanjenje process. organskih rastvarača u procesu proizvodnje. Hemofarm A.D. neither received any complaints Tokom 2018. godine, kao i u prethodnim cikluor protests, nor had any fine imposed for negative sima izveštavanja, Hemofarm a.d. nije imao impact on the environment and local community nikakve žalbe i pritužbe, kao ni kazne za negatiover the course of 2018 or during the previous van uticaj na životnu sredinu i lokalnu zajednicu. reporting cycles. Hemofarm A.D. does not exert Hemofarm a.d. nema negativan uticaj na staronegative impact on the indigenous population in sedelačko stanovništvo u sredinama u kojima the communities in which it performs its activity. obavlja svoju delatnost. There was not any recorded non-compliance of Tokom 2018. godine nije zabeležena nijedna Hemofarm A.D. products with the law in terms neusaglašenost proizvoda Hemofarma a.d. of safety and health protection over the course sa aspektima bezbednosti i zaštite zdravlja u of 2018. Occupational diseases or work-related skladu sa zakonom. Profesionalnih oboljenja i diseases in Hemofarm were not recorded in 2018. bolesti u vezi sa radom u Hemofarmu nije bilo ni u 2018. godini. Hemofarm confirms a comprehensive approach to risk management and preventive action Sveobuhvatan pristup upravljanju rizicima i also through active care for the environment. In preventivnom delovanju, Hemofarm potvrthe period from 2009 to date, the company has đuje i kroz aktivnu brigu o svom okruženju. U made more than 10 reference assessments and periodu od 2009. do danas, kompanija je uradila environmental impact studies, such as the enviviše od 10 referentnih procena i studija uticaja ronmental impact study in case of accidents and na životnu sredinu, poput studija uticaja na other adverse situations, environmental impact životnu sredinu u slučaju akcidentnih i drugih study for primary wastewater treatment plants, neželjenih situacija, studija uticaja na životnu etc. All of them confirm that Hemofarm A.D. has sredinu za primarne prečišćivače otpadnih no adverse environmental impact from any of its voda, i dr. Sve one potvrđuju da Hemofarm a.d. manufacturing or business premises, in any way. ni iz jednog svog proizvodnog ili poslovnog objekta, ni na koji način, nema štetan uticaj na Hemofarm oﬀers to its employees any potential okruženje. job and position related change, in writing, within the legally guaranteed 8-day deadline, during Svaku potencijalnu promenu koja je vezana za which they have the right to make their stateradno mesto i poslovnu poziciju, Hemofarm ment on the acceptance or non-acceptance of the nudi zaposlenom u pisanoj formu, uz zakonom change proposal. zagarantovan rok od 8 dana, u okviru koga ima pravo da se izjasni – prihvati ili ne prihvati dati Each employee receives feedback on their perforpredlog za promenu. mance and level of meeting business expectations in the form of an annual evaluation, within Svaki zaposleni dobija povratnu informaciju o which the objectives and priorities for further svom učinku i stepenu zadovoljenja poslovnih work are set, all within responsibilities and duties očekivanja u vidu godišnje evaluacije, u okviru defined by the labour contract, and in accordance čega se postavljaju i ciljevi i prioriteti za dalji rad, with the rights and obligations stipulated by the a u okviru odgovornosti i poslovnih dužnosti collective bargaining agreement that applies to definisanih Ugovorom o radu, te usklađenih sa all employess. pravima i obavezama propisanim Kolektivnim ugovorom koji važi za sve zaposlene. In accordance with the type of activity performed by Hemofarm, all its products and services U skladu sa vrstom delatnosti koju obavlja are subject to constant inspection and verificaHemofarm, svi njegovi proizvodi i usluge tion of the eﬀects on human health, according to 101 podložni su konstantnoj proveri i potvrdi pharmaceutical standards and legal framework. uticaja na zdravlje ljudi, prema farmaceutskim In this regard, Hemofarm R&D, QA and QC divistandardima i zakonskom okviru. Sa tim u sions have a special responsibility in verifying the vezi, Hemofarmovi sektori R&D, QA i QC imaju compliance of each product and absence of any posebnu odgovornost u potvrđivanju ispravpossible negative impact. nosti svakog proizvoda i odsustvu svakog potencijalnog negativnog uticaja. In addition to their expertise and professionalism, Hemofarm employees have also invested approxiPored svoje stručnosti i profesionalizma, zapomately 786 hours of volunteer work dedicated to sleni u Hemofarmu su kroz Mentorski program the development of future young colleagues and Hemofarm fondacije investirali i oko 786 sati experts through the Mentoring Programme of volonterskog rada, posvećenih razvoju budućih Hemofarm Foundation. mladih kolega i stručnjaka. Annual Sustainable Development Report of Godišnji Izveštaj o održivom razvoju Hemofarm A.D. provides all stakeholders with Hemofarma a.d. pruža svim zainteresovanim information on the progress that the company stranama informacije o napretku koji komcontinuously achieves following the global trends, panija kontinuirano ostvaruje prateći svetske trying to remain a reliable partner in all relationstrendove, nastojeći da ostane pouzdan partner hips and a stable support of the national healthu svim odnosima i stabilan oslonac domaćeg care system. zdravstvenog sistema. The methodology-related rules and principles of U pripremi i izradi ovog godišnjeg Izveštaja o the GRI (Global Reporting Initiative) standards održivom razvoju kompanije Hemofarm a.d., have been used as the basis for the developkoji obuhvata period od 1. januara do 31. ment and preparation of this Annual Sustainable decembra 2018. godine, kao osnova, korišćena Development Report of Hemofarm A.D. which su metodološka pravila i principi GRI (Global covers the period from January 1st to December Reporting Initiative) standarda. 31st, 2018. Prethodno publikovani Izveštaj odnosi se na The previously published Report relates to the 2017. godinu i izdat je u julu 2018. Ovaj izveštaj year 2017, and was released in July 2018. This ne obuhvata Hemomont, Hemofarm d.o.o. Report does not include Hemomont, Hemofarm Banja Luka, STADA Hemofarm S.R.L., Ivančić i d.o.o. Banja Luka, STADA Hemofarm S.R.L., Ivančić sinovi, Velexfarm, kao ni druga zavisna društva i sinovi, Velexfarm, as well as other subsidiaries in u zemlji i inostranstvu. Serbia and abroad. Global Reporting Initiative neprofitna je orgaThe Global Reporting Initiative is a non-profit organizacija koja se zalaže za uspostavljanje održive nization that advocates for the establishment of a globalne ekonomije, postavljajući smernice sustainable global economy, setting out guidelines za sastavljanje Izveštaja o održivom razvoju. for the preparation of Sustainable Development Navedene smernice priznate su širom sveta i Report. The specified guidelines are acknowledged prihvatile su ih sve vodeće kompanije. worldwide, and accepted by all leading companies. 102 MATRICA MATERIJALNOSTI / MATERIALITY MATRIX Polazna osnova za pripremu ovog Izveštaja je The starting point for the preparation of this Report Hemofarmova Matrica materijalnosti (prezenis the Hemofarm Materiality Matrix (presented at tovana na početku Izveštaja), koja predstavlja the beginning of the Report), which represents a uporedni pregled najvažnijih tema za poslovanje comparative overview of the most important busiiz ugla kompanije, s jedne, i ključnih zainteresovaness topics from the perspective of the company, on nih strana, s druge strane. one part, and key stakeholders, on the other part. Teme su rangirane prema uticaju i značaju iz ugla Topics are ranked according to the impact and kompanije (horizontalna osa) i pozicionirane significance from company’s standpoint (horizonprema ocenama dobijenim od zainteresovanih tal axis) and positioned according to assessments strana (na vertikalnoj osi). obtained from stakeholders (vertical axis). Analizom GRI indikatora povezani su indikatori Indicators and topics are connected by the analysis i teme, čime Matrica materijalnosti daje osnov of GRI indicators, whereby the Materiality Matrix za buduće izveštavanje, ali i unapređenje poslogives the basis for future reporting as well as busivanja. Osim toga, kompanija je obradila i teme ness improvement. In addition, the company prokoje nisu bile najviše rangirane a smatraju se cessed also topics that were not among the topbitnim za ukupni razvoj lokalnih zajednica u ranked ones, but are considered essential for the kojima Hemofarm posluje, što prevazilazi zahteve overall development of local communities in which osnovnog nivoa izveštavanja po GRI standardu. Hemofarm operates, which exceeds the requirements of the basic reporting level according to the S obzirom na to da Izveštaj o održivom razvoju GRI standard. obuhvata teme koje su od značaja za kompaniju i zainteresovane strane, Izveštaj može predstavGiven that the Sustainable Development Report ljati osnov za procenu i odluke organa upravljanja encompasses topics of relevance to the company i zainteresovanih strana. Primena GRI smernica and stakeholders, the Report can be the basis for the omogućava kompaniji da transparentno izvesti o estimates and decisions of the management bodies učinku u četiri ključne oblasti održivog poslovanja and stakeholders. The application of GRI guidelines ekonomskoj, ekološkoj, socijalnoj i upravljačkoj. enables the company to transparently report on the Pored profila kompanije, kao i broja indikatora, performance in four key areas of sustainable opertemelj izveštaja zasniva se na principima koji ations: economic, environmental, social, and manslede. agement. In addition to the company profile, as well as the number of indicators, the report is grounded on the following principles. 103 MATERIJALNOST / MATERIALITY Izveštaj obuhvata sve one teme koje su važne The Report encompasses all the topics which are zainteresovanim stranama. U Izveštaj su ukljurelevant for the stakeholders. The Report includes čene sve teme koje se odnose na ekonomiju, all economic, environmental, social and manageekologiju, na socijalne i upravljačke aktivment-related topics and activities, as well as the nosti, ali i na aktivnosti koje su imale uticaja activities which had inﬂuence on the company, na kompaniju, odnosno na aktivnosti koje bi that is, activities which would have a possible potencijalno uticale na mišljenje zainteresovaeﬀect on the opinion of stakeholders. nih strana. The process of prioritizing the topics in 2018 Proces određivanja prioritetnih tema u Report involved an active dialogue with key stakeIzveštaju za 2018. godinu podrazumevao je holders through workshops and online surveys, aktivan dijalog za ključnim zainteresovanim creating the Materiality Matrix in accordance stranama putem radionica i onlajn anketa, with GRI guidelines, needs and interests of all kreirajući Matricu materijalnosti, u skladu sa stakeholders, as well as strategic priorities of the GRI smernicama, potrebama i interesima svih company. zainteresovanih strana, kao i strateškim prioritetima kompanije. INKLUZIVNOST / INCLUSIVITY Jedan od ciljeva Hemofarma i izveštavanja One of Hemofarm’s and sustainability reporting o održivom razvoju jeste da se, stvaranjem goals is to improve mutual relations and raise uslova za efikasan dijalog sa svim zainteresothe general level of satisfaction with company vanim stranama, unaprede međusobni odnosi operations by creating conditions for an efficient i podigne opšti nivo zadovoljstva poslovanjem dialogue with all stakeholders. Apart from the kompanije. Izveštaj, osim dijaloga sa ključnim dialogue with key stakeholders, the Report also zainteresovanim stranama, obuhvata i interna includes internal survey on employees’ attitudes, istraživanja stavova zaposlenih, potom annual survey among the expert public physigodišnja istraživanja stručne javnosti – lekara i cians and pharmacists, wholesalers, and private farmaceuta, veledrogerija i privatnih apoteka pharmacies, and market research, jointly showi istraživanja tržišta, što sve zajedno pokazuje ing in which way the company operations have na koji način poslovanje kompanije utiče na an impact on the environment. okolinu. The company is looking forward to receiving any U kompaniji se rado očekuju sve povratne feedback from the readers of this Report concerninformacije koje će čitateljke i čitaoci ovog ing its quality and content, because Hemofarm is izveštaja imati na njegov kvalitet i sadržaj, ready to review any feedback so that the quality jer u Hemofarmu postoji spremnost da se of future reports would be enhanced. The e-mail razmotre sve povratne informacije, kako bi address for sending suggestions, impressions, budući izveštaji bili kvalitetniji. Mejl za sugeand any feedback is svakodobro@hemofarm.com. stije, utiske i sve povratne informacije je svakodobro@hemofarm.com. 104 ODRŽIVOST / SUSTAINABILITY Princip održivosti poslovanja predstavlja The principle of operation sustainability reprenačin na koji kompanija posmatra svoj dugosents the way in which the company perceives its ročni uticaj na okruženje i prezentuje svoje long-term environmental impact, and presents its aktivnosti na nacionalnom, regionalnom i activities at the national, regional and global level. globalnom nivou. POTPUNOST / COMPLETENESS U Izveštaju su izložene informacije i podaci The Report provides information and data until zaključno sa 31. decembrom 2018. godine. December 31st 2018, inclusive. Comparative data Prikazani su i uporedni podaci, gde god je to from previous years were also shown, wherever bilo moguće, za prethodne godine. Finansijski possible. Financial and economic indicators are i ekonomski pokazatelji preuzeti su iz finantaken over from Hemofarm A.D. 2018 Financial sijskog izveštaja za Hemofarm a.d. za 2018. Statements, pertaining to the company activgodinu, a odnose se na aktivnosti kompanije u ities in Serbia, excluding related legal entites Srbiji, izuzimajući povezana pravna lica u Crnoj in Montenegro, Bosnia and Herzegovina, and Gori, Bosni i Hercegovini i Rumuniji. Romania. URAVNOTEŽENOST / BALANCE Uravnoteženost zahteva predstavljanje kako Balance requires the presentation of both posipozitivnih, tako i negativnih aspekata i uticaja tive and negative aspects and eﬀects of the comkompanije na održivost, čime se pruža nepripany on sustainability, thus providing impartial strasna i objektivna slika njenog učinka. and objective presentation of its results. Objective Objektivna slika učinka kompanije tokom presentation of the company results in 2018, in 2018. godine, kada je reč o ekonomskoj, ekoeconomic, environmental and social segment, is loškoj i društvenoj dimenziji, zasniva se na based on responses to 36 general and 83 speodgovorima na 36 opštih i 83 specifična indicific indicators of GRI methodology, which preskatora GRI metodologije, koji prezentuju sve ent all relevant information, regardless of their informacije od značaja, bez obzira na njihove characteristics. karakteristike. UPOREDIVOST / COMPARABILITY Uporedivost znači prikazivanje podataka Comparability means presenting data in a conna dosledan i kontinuiran način, kako bi se sistent and continuous manner, so as to provide pružila mogućnost poređenja sa GRI standaran option of comparison with GRI standards dima i drugim kompanijama. Budući da je reč and other companies. Since this is the seventh o sedmom Izveštaju o održivom razvoju koji Sustainable Development Report published by publikuje Hemofarm a.d. moguće je poređeHemofarm A.D., it is possible to compare it with nje sa prethodnih šest izveštaja. the previous six reports. 105 TAČNOST / ACCURACY Tačnost podrazumeva pružanje adekvatnih Accuracy implies providing information of approkvalitativnih i kvantitativnih informacija, kao priate quality and quantity, while constantly i stalno unapređivanje sistema za prikupljaimproving the system of data collection and analnje i analizu podataka. Gde nije bilo moguće ysis. Where source data could not be collected, prikupiti izvorne podatke, vršene su kalkulacalculations were performed with explanations cije uz objašnjenje metodologije obračuna. regarding the calculation methodology. BLAGOVREMENOST / TIMELINESS Blagovremenost označava doslednost u Timeliness means consistency in reporting freučestalosti izveštavanja i dužini perioda quency and length of reporting period in order to izveštavanja, čime se osigurava redovna secure availability of information on regular basis, dostupnost informacijama i mogućnost donoand possibility to make adequate and timely decišenja adekvatnih i pravovremenih odluka u sions regarding the company and its operations. vezi sa kompanijom i njenim poslovanjem. JASNOĆA /CLARITY Jasnoća u stvari predstavlja prezentovanje Clarity is actually presenting information in a informacija na pregledan, jednostavan i transparent, simple and clear manner, thus ensurjasan način, čime se osigurava pristupačnost ing the accessibility to information. Availability informacijama. Dostupnost i razumljivost and intelligibility of information on the part of all svim zainteresovanim stranama bili su glavni stakeholders were the major landmarks which orijentiri kojima se težilo prilikom izrade were strived to be reached during the preparaIzveštaja za 2018. godinu. tion of the 2018 Report. POUZDANOST / RELIABILITY Pouzdanost podrazumeva prikupljanje, Reliability means collecting, recording, compilbeleženje, sastavljanje, analiziranje i objaving, analysing, and publishing information in a ljivanje informacija na način koji se može way which can be subjected to inspection and podvrgnuti proveri i koji potkrepljuje kvalitet which can substantiate quality and materiality of i materijalnost informacije. information. Oslanjajući se na standarde i zahteve GRI Relying on standards and requirements of the metodologije, priznate u svetu, verifikaciju globally recognized GRI methodology, this Report ovog izveštaja sprovela je revizorska kuća was verified by the auditing company Ernst & Ernst & Young d.o.o. Beograd. Young d.o.o. Beograd. 106 GRI indeks / GRI index 102-55 Broj strane / GRI Standardi Teme Page number(s) GRI Standard Disclosure and/or URL(s) GRI 101: Osnova 2016 / Opšta obelodanjivanja GRI 101: Foundation 2016 / General Disclosures Profil kompanije / Organizational profile Naziv organizacije 102-1 24 Name of the organization Aktivnosti, brendovi, proizvodi i usluge 102-2 24 Activities, brands, products, and services Lokacija sedišta 102-3 24 Location of headquarters Lokacija na kojoj kompanija posluje 102-4 24 Location of operations Vlasništvo i pravna forma 102-5 24 Ownership and legal form GRI 102: Opšta Tržišta na kojima kompanija posluje obelodanjivanja 2016 102-6 Markets served 24 GRI 102: General Veličina organizacije Disclosures 2016 102-7 24 Scale of the organization Informacije o zaposlenima i ostalim radnicima 102-8 24 Information on employees and other workers Lanac nabavke 102-9 33, 86 Supply chain Značajne izmene organizacije i lanca nabavke 102-10 24 Significant changes to the organization and its supply chain Princip ili pristup predostrožnosti 102-11 86 Precautionary Principle or approach Eksterne inicijative 102-12 24 External initiatives Članstvo u udruženjima 102-13 24 Membership of associations Strategija / Strategy Izjava višeg donosioca odluka 102-14 10 Statement from senior decision-maker Etika i integritet / Ethics and integrity Vrednosti, principi, standardi i norme ponašanja 30 102-16 Values, principles, standards, and norms of behavior Princip ili pristup predostrožnosti 102-17 24, 86 Mehanizmi davanja saveta i izražavanje brige vezano za etiku 107 Upravljanje / Governance GRI Standardi Upravljačka struktura GRI Standard 102-18 Governance structure 24 Revidiranje ekonomskih, ekoloških i društvenih tema 102-31 21 Review of economic, environmental, and social topics Uloga najvišeg upravljačkog tela u izveštavanju 102-32 o održivom razvoju 24 Highest governance body’s role in sustainability reporting Uključivanje zainteresovanih strana / Stakeholder engagement Spisak grupa zainteresovanih strana 102-40 18 List of stakeholder groups Kolektivni ugovori 102-41 99 Location of operations Identifikovanje i selekcija zainteresovanih strana 102-42 18 Ownership and legal form Pristup uključivanju zainteresovanih strana 102-43 18 Approach to stakeholder engagement GRI 102: Opšta Ključne teme i brige pokrenute tokom angažovanja 18 102-44 Key topics and concerns raised obelodanjivanja 2016 GRI 102: General Praksa izveštavanja / Reporting practice Disclosures 2016 Subjekti uključeni u konsolidovane finansijske izveštaje 24 102-45 Entities included in the consolidated financial statements Definisanje sadržaja izveštaja i ograničenja teme 102-46 7 Defining report content and topic Boundaries Spisak materijalnih tema 102-47 21 List of material topics Revidiranje podataka 102-48 99 Restatements of information Izmene u izveštavanju 102-49 99 Changes in reporting Period izveštavanja 102-50 99 Reporting period Datum prethodnog izveštavanja 102-51 99 Date of most recent report Ciklus izveštavanja 99 102-52 Reporting cycle Kontakt osoba za pitanja vezano za izveštaj 102-53 99 Contact point for questions regarding the report Zahtevi izveštavanja u skladu sa GRI standardima 102-54 99 Claims of reporting in accordance with the GRI Standards Indeks GRI sadržaja 102-55 107 GRI content index Eksterna revizija 102-56 99 External assurance 108 Pristup menadžmenta / Management Approach Objašnjenje materijalne teme i ograničenja 103-1 33, 47, 65, 91 Explanation of the material topic and its Boundary GRI 103: Pristup menadžmenta Pristup menadžmenta GRI 103: 103-2 33, 47, 65, 91 The management approach and its components Management Approach Evaluacija pristupa menadžmenta 103-3 33, 47, 65, 91 Evaluation of the management approach GRI Standardi Obelodanjivanje materijalnih tema GRI Standard Material Topics Disclosure 99 200 serija (ekonomske teme) 200 series (Economic topics) Ekonomske performanse / Economic Performance Generisana i distribuirana direktna ekonomska vrednost 201-1 47 Direct economic value generated and distributed GRI 201: Ekonomske Finansijske implikacije i ostali rizici i mogućnosti nastali usled klimatskih promena 99 performanse 2016 201-2 Financial implications and other risks and opportunities GRI 201: Economic due to climate change Performance 2016 Definisan plan beneficija i drugi penzijski planovi 47 201-3 Location of headquarters Finansijska pomoć vlade 99 201-4 Financial assistance received from government Prisutnost na tržištu / Market Presence Odnos standarde početne zarade po polu sa lokalnom GRI 202: Prisutnost minimalnom zaradom 65 202-1 na tržištu 2016 Ratios of standard entry level wage by gender compared to local minimum wage GRI 202: Market Presence 2016 Udeo višeg rukovodstva koje je angažovano iz lokalne zajednice 24 202-2 Proportion of senior management hired from the local community Indirektni ekonomski uticaji / Indirect Economic Impacts GRI 203: Indirektni Vlasništvo i pravna forma 203-1 91 ekonomski uticaji 2016 Ownership and legal form GRI 203: Indirect Tržišta na kojima kompanija posluje 47 203-2 Economic Impacts 2016 Markets served Prakse nabavke / Procurement Practices GRI 204: Prakse nabavke 2016 Veličina organizacije 204-1 33 GRI 204: Procurement Scale of the organization Practices 2016 109 Borba protiv korupcije / Anti-corruption Procena rizika poslovnih operacija vezano za korupciju 86 205-1 Operations assessed for risks related to corruption GRI 205: Borba protiv Komunikacija i obuka vezano za politike i postupke korupcije 2016 borbe protiv korupcije 205-2 86 GRI 205: Borba protiv Communication and training about anti-corruption korupcije 2016 policies and procedures Potvrđeni incidenti korupcije i preduzete mere 205-3 99 Confirmed incidents of corruption and actions taken Antikonkurentsko ponašanje / Anti-competitive Behavior GRI 206: Antikonkurentsko Zakonske mere za antikonkurentsko ponašanje, ponašanje 2016 antitrustovske i monopolske prakse GRI 206: 206-1 99 Legal actions for anti-competitive behavior, Anti-competitive anti-trust, and monopoly practices Behavior 2016 300 serija (teme vezano za zaštitu životne sredine) 300 series (Environmental topics) Materijali / Materials Generisana i distribuirana direktna ekonomska vrednost 33 301-1 GRI 301: Materials used by weight or volume Materijali 2016 Korišćeni reciklirani ulazni materijali 301-2 47 GRI 301: Recycled input materials used Materials 2016 Reciklirani proizvodi i njihova ambalaža 301-3 65 Reclaimed products and their packaging materials Energija / Energy Potrošnja energije unutar organizacije 302-1 47 Energy consumption within the organization Snaga energije GRI 302: 302-3 47 Energy intensity Energija 2016 GRI 302: Smanjenje potrošnje energije 302-4 47 Energy 2016 Reduction of energy consumption Smanjenje energetskih zahteva proizvoda i usluga 302-5 47 Reductions in energy requirements of products and services Voda / Water Interakcije sa vodom kao zajedničkim resursom 47 303-1 GRI 303: Vode i Interactions with water as a shared resource otpadne vode 2018 Upravljanje ispuštanjem vode – povezani uticaji GRI 303: Water 303-2 47 Management of water discharge-related impacts and Effluents 2018 Povlačenje vode 303-3 47 Water withdrawal 110 303-4 Ispuštanje vode Water discharge 47 303-5 Trošenje vode Water consumption 47 Biološka raznolikost / Biodiversity Operative lokacije koje su u vlasništvu, iznajmljene, kojima se upravlja ili su u blizini zaštićenih područja i područja visoke vrednosti biološke raznovrsnosti 304-1 izvan zaštićenih područja 99 Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high GRI 304: biodiversity value outside protected areas Biološka raznolikost 2016 Značajan uticaj aktivnosti, proizvoda i GRI 304: usluga na biološku raznovrsnost 99 304-2 Biodiversity 2016 Significant impacts of activities, products, and services on biodiversity Zaštićena ili obnovljena staništa 304-3 99 Habitats protected or restored Vrste na crvenoj listi IUCN i vrste na nacionalnoj listi za očuvanje sa staništima u područjima 304-4 pod uticajem poslovnih operacija 99 IUCN Red List species and national conservation list species with habitats in areas affected by operations Emisije / Emissions Direktne (Opseg 1) emisije gasova staklene bašte 47, 96 305-1 Direct (Scope 1) GHG emissions Energetske indirektne (Opseg 2) emisije gasova staklene bašte 305-2 47, 96 Energy indirect (Scope 2) GHG emissions GRI 305: Intezitet emisija gasova staklene bašte 305-4 47, 96 Emisije 2016 GHG emissions intensity GRI 305: Redukcija emisije gasova staklene bašte Emissions 2016 305-5 47, 96 Reduction of GHG emissions Emisije supstanci koje oštećuju ozonski omotač (ODS) 305-6 47, 96 Emissions of ozone-depleting substances (ODS) Emisije azotnih oksida (NOX), sumpornih oksida (SOX) 305-7 i druge značajne emisije u vazduh 47, 96 Nitrogen oxides (NOX), sulfur oxides (SOX), and other significant air emissions Otpadne vode i otpad / Effluents and Waste Ispuštanje vode po kvalitetu i odredištu 306-1 47 Water discharge by quality and destination GRI 306: Otpadne Otpad po vrsti i načinu uklanjanja vode i otpad 2016. 306-2 47 Waste by type and disposal method GRI 306: Effluents and Waste 2016 Značajna izlivanja 306-3 99 Significant spills 111 Transport opasnog otpada 306-4 47 Transport of hazardous waste Vodena tela pogođena izlivanjem odnosno isticanjem vode 306-5 47 Water bodies affected by water discharges and/or runoff Usaglašenost sa životnom sredinom / Environmental Compliance GRI 307: Usaglašenost sa životnom sredinom Neusaglašenost sa zakonima i propisima o zaštiti životne sredine 99 2016 307-1 Non-compliance with environmental laws and regulations GRI 307: Environmental Compliance 2016 Procena dobavljača u odnosu na životnu sredinu / Supplier Environmental Assessment GRI 308: Skrining novih dobavljača upotrebom kriterijuma zaštite životne sredine 33 Procena dobavljača 308-1 u odnosu na životnu New suppliers that were screened using environmental criteria sredinu 2016 GRI 308: Negativni uticaj lanca snabdevanja i preduzetih 308-2 mera na životnu sredinu Supplier 99 Negative environmental impacts in the supply chain Environmental and actions taken Assessment 2016 400 serija (Socijalne teme) 400 series (Social topics) Zaposlenje / Employment Broj novozaposlenih i fluktuacija zaposlenih 65 401-1 New employee hires and employee turnover GRI 401: Beneficije za stalno zaposlene koje se ne dodeljuju Zaposlenje 2016 privremeno zaposlenima ili zaposlenima 401-2 sa pola radnog vremena 65 GRI 401: Employment 2016 Benefits provided to full-time employees that are not provided to temporary or part-time employees Roditeljsko odsustvo 401-3 65 Parental leave Radni/upravljački odnosi / Labor/Management Relations GRI 402: Radni/upravljački Minimalni otkazni rok u pogledu operativnih promena 402-1 odnosi 2016 Minimum notice periods regarding operational changes 99 GRI 402: Labor/Management Relations 2016 112 Zdravlje i bezbednost na radu / Occupational Health and Safety Sistem upravljanja zdravljem i bezbednošću na radu 47 403-1 Occupational health and safety management system Utvrđivanje opasnosti, procena rizika i istraga incidenta 403-2 47 Hazard identification, risk assessment, and incident investigation Usluge zaštite zdravlja na radu 403-3 47 Occupational health services Učestvovanje, konsultovanje i komunikacija sa GRI 403: Zdravlje i radnicima vezano za zdravlje i bezbednost na radu bezbednost na 403-4 47 Worker participation, consultation, and communication radu 2018 on occupational health and safety GRI 403: Occupational Obuka radnika vezano za zdravlje i bezbednost na radu Health and 403-5 47 Worker training on occupational health and safety Safety 2018 Unapređenje zdravlja radnika 403-6 47 Promotion of worker health Prevencija i ublažavanje uticaja zdravlja i bezbednosti 403-7 na radu koji su direktno povezani sa poslovnim odnosima 47 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships Radnici obuhvaćeni sistemom upravljanja zdravlje i 403-8 bezbednošću na radu 47 Workers covered by an occupational health and safety management system Povrede vezano za rad 47 403-9 Work-related injuries Loše zdravlje vezano za rad 403-10 47 Work-related ill health Obuka i obrazovanje / Training and Education Prosečan broj sati obuke po zaposlenom 404-1 65 Average hours of training per year per employee Programi za unapređenje veština zaposlenih i GRI 404: Obuka i programi pomoći za tranziciju obrazovanje 2016 404-2 Programs for upgrading employee skills and 65 GRI 404: Training transition assistance programs and Education 2016 Procenat zaposlenih koji imaju redovnu ocenu 404-3 učinka i razvoja karijere 65 Percentage of employees receiving regular performance and career development reviews Raznovrsnost i jednake mogućnosti / Diversity and Equal Opportunity GRI 405: Raznovrsnost upravljačkih tela i zaposlenih Raznovrsnost i jednake 405-1 65 Diversity of governance bodies and employees mogućnosti 2016 GRI 405: Odnos osnovne zarade i naknade žena i muškaraca Diversity and Equal 405-2 65 Ratio of basic salary and remuneration of women to men Opportunity 2016 113 Nediskriminacija / Non-discrimination GRI 406: Nediskriminacija 2016 Sistem upravljanja zdravljem i bezbednošću na radu 406-1 99 GRI 406: Occupational health and safety management system Non-discrimination 2016 Sloboda udruživanja i kolektivno pregovaranje / Freedom of Association and Collective Bargaining GRI 407: Sloboda udruživanja i kolektivno Poslovanje i dobavljači kod kojih može biti ugroženo pregovaranje 2016 pravo na slobodu udruživanja i kolektivno pregovaranje 407-1 99 GRI 407: Freedom of Operations and suppliers in which the right to freedom Association and of association and collective bargaining may be at risk Collective Bargaining 2016 Dečiji rad / Child Labor GRI 408: Dečiji rad 2016 Značajan rizik dečijeg rada u poslovanju i kod dobavljača 408-1 99 GRI 408: Operations and suppliers at significant risk Child Labor 2016 for incidents of child labor Prinudni ili obavezni rad / Forced or Compulsory Labor GRI 409: Prinudni ili Značajan rizik od prisilnog ili prinudnog rada u obavezni rad 2016 409-1 poslovanju i kod dobavljača 99 GRI 409: Forced or Operations and suppliers at significant risk for incidents Compulsory Labor 2016 of forced or compulsory labor Sigurnosne prakse / Security Practices GRI 410: Sigurnosne Osoblje obezbeđenja koje je obučeno u pogledu prakse 2016 politika ljudskih prava ili procedura 410-1 65 GRI 410: Security Security personnel trained in human rights policies or procedures Practices 2016 Prava autohtonih naroda / Rights of Indigenous Peoples GRI 411: Prava autohtonih naroda 2016 Slučajevi kršenja prava autohtonih naroda 99 411-1 GRI 411: Incidents of violations involving rights of indigenous peoples Rights of Indigenous Peoples 2016 114 Procene ljudskih prava / Human Rights Assessment Poslovanje koje je predmet pregleda ljudskih prava ili procene uticaja 65 412-1 Operations that have been subject to human rights reviews or GRI 412: Procene impact assessments ljudskih prava 2016 Obuka zaposlenih o politikama ili postupcima ljudskih prava GRI 412: Human Rights 412-2 65 Employee training on human rights policies or procedures Assessment 2016 Značajni sporazumi i ugovori o investiranju koji uključuju odredbe vezano za ljudska prava ili koji su prošli skrining 412-3 vezano za ljudska prava 65 Significant investment agreements and contracts that include human rights clauses or that underwent human rights screening Lokalne zajednice / Local Communities Angažovanje lokalne zajednice, procena uticaja i 413-1 razvojni programi 91 GRI 413: Lokalne Operations with local community engagement, zajednice 2016 impact assessments, and development programs GRI 413: Local Communities 2016 Poslovanje sa značajnim stvarnim i potencijalnim 413-2 negativnim uticajem na lokalne zajednice 99 Operations with significant actual and potential negative impacts on local communities Procena dobavljača u pogledu uticaja na društvo / Supplier Social Assessment GRI 414: Procena Novi dobavljači na kojima je izvršen skrining koristeći 33 414-1 društvene kriterijume dobavljača u pogledu uticaja na društvo 2016 New suppliers that were screened using social criteria GRI 414: Supplier Negativni uticaji na društvo u lancu snabdevanja i Social Assessment 2016 414-2 preduzete mere 99 Negative social impacts in the supply chain and actions taken Javna politika / Public Policy GRI 415: Javna politika 2016 Politički doprinosi 99 GRI 415: 415-1 Political contributions Public Policy 2016 Zdravlje i bezbednost kupaca / Customer Health and Safety Procena uticaja kategorija proizvoda i usluga 416-1 na zdravlje i bezbednost 65 GRI 416: Zdravlje i Assessment of the health and safety impacts of bezbednost kupaca 2016 product and service categories GRI 416: Customer Health and Safety 2016 Slučajevi neusaglašenosti vezano za uticaj proizvoda i 416-2 usluga na zdravlje i bezbednost 65 Incidents of non-compliance concerning the health and safety impacts of products and services 115 Marketing i obeležavanje / Marketing and Labeling Zahtevi vezano za informacije i obeležavanje proizvoda i usluga 65 417-1 Requirements for product and service information and labeling GRI 417: Marketing i obeležavanje 2016 Slučajevi neusaglašenosti vezano za informacije i GRI 417: Marketing obeležavanje proizvoda i usluga and Labeling 2016 417-2 65 Incidents of non-compliance concerning product and service information and labeling Slučajevi neusaglašenosti vezano za marketinško komuniciranje 417-3 65 Incidents of non-compliance concerning marketing communications Privatnost korisnika / Customer Privacy GRI 418: Privatnost Potkrepljene žalbe vezano za kršenje privatnosti korisnika korisnika 2016 418-1 i gubitak podataka o korisniku 99 GRI 418: Customer Substantiated complaints concerning breaches of customer Privacy 2016 privacy and losses of customer data Socioekonomska usaglašenost / Socioeconomic Compliance GRI 419: Socioekonomska Neusaglašenost sa zakonima i propisima u društvenoj usaglašenost 2016 419-1 i ekonomskoj oblasti 99 GRI 419: Non-compliance with laws and regulations in the social Socioeconomic and economic area Compliance 2016 116 117 118 119 120 121 122 123 124 Beleške / Notes 125
